<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005121.pub2" GROUP_ID="MUSKEL" ID="961604102615190226" MERGED_FROM="" MODIFIED="2008-11-12 20:56:08 +0100" MODIFIED_BY="Elizabeth Tanjong Ghogomu" REVIEW_NO="C107-R" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.0">
<COVER_SHEET MODIFIED="2008-11-12 14:51:55 -0500" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-10-21 12:50:40 -0400" MODIFIED_BY="Elizabeth Tanjong Ghogomu">Anakinra for rheumatoid arthritis</TITLE>
<CONTACT>
<PERSON ID="29B8AAE582E26AA20188057136EFA963" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Marty</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Mertens</LAST_NAME>
<SUFFIX/>
<POSITION>Resident, Internal Medicine</POSITION>
<EMAIL_1>mtm7575@yahoo.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>University of Minnesota</ORGANISATION>
<ADDRESS_1>596 Grand Ave., Apt 1</ADDRESS_1>
<ADDRESS_2/>
<CITY>Saint Paul</CITY>
<ZIP>Minnesota</ZIP>
<REGION>55102</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>1 608 358 2307</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2008-11-12 14:51:03 -0500" MODIFIED_BY="Elizabeth Tanjong Ghogomu">
<PERSON ID="29B8AAE582E26AA20188057136EFA963" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Marty</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Mertens</LAST_NAME>
<SUFFIX/>
<POSITION>Resident, Internal Medicine</POSITION>
<EMAIL_1>mtm7575@yahoo.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>University of Minnesota</ORGANISATION>
<ADDRESS_1>596 Grand Ave., Apt 1</ADDRESS_1>
<ADDRESS_2/>
<CITY>Saint Paul</CITY>
<ZIP>Minnesota</ZIP>
<REGION>55102</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>1 608 358 2307</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="15590F7882E26AA2010AB3F26EA8D870" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Jasvinder</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Singh</LAST_NAME>
<SUFFIX>MD, MPH</SUFFIX>
<POSITION>Staff Physician</POSITION>
<EMAIL_1>jasvinder.md@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Medicine</DEPARTMENT>
<ORGANISATION>Minneapolis VA Medical Center</ORGANISATION>
<ADDRESS_1>1 Veterans Drive</ADDRESS_1>
<ADDRESS_2>Rheumatology (111R)</ADDRESS_2>
<CITY>Minneapolis</CITY>
<ZIP>55417</ZIP>
<REGION>MN</REGION>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1>612-467-4190</PHONE_1>
<PHONE_2>612-467-4195</PHONE_2>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-11-12 14:51:55 -0500" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="6" MONTH="2" YEAR="2008"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="6" MONTH="2" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="12" MONTH="11" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2008"/>
</DATES>
<WHATS_NEW MODIFIED="2008-10-16 19:07:22 -0400" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-10-16 19:07:22 -0400" MODIFIED_BY="[Empty name]">
<DATE DAY="18" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
<P>CMSG ID: C107-R</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-11-11 22:23:05 -0500" MODIFIED_BY="[Empty name]"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Minneapolis VA Medical Center</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>NIH CTSA Award 1 KL2 RR024151-01 (Mayo Clinic Center for Clinical and Translational Research)</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>National Institute of Health</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-11-12 14:07:24 -0500" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-11-12 14:07:24 -0500" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-08-06 19:55:10 -0400" MODIFIED_BY="[Empty name]">Anakinra for Rheumatoid Arthritis</TITLE>
<SUMMARY_BODY MODIFIED="2008-11-12 14:07:24 -0500" MODIFIED_BY="[Empty name]">
<P>This summary of a Cochrane review presents what we know from research about the effect of Anakrina on rheumatoid arthritis (RA).</P>
<P>
<B>
<BR/>The review shows that in people with RA, </B>
</P>
<P>Taking Anakrina for 6 months may improve RA symptoms such as pain, function, and stiffness.</P>
<P>
<BR/>
<B>What are RA and Anakrina?</B>
</P>
<P>When you have rheumatoid arthritis, your immune system, which normally fights infection, attacks the lining of your joints. This makes your joints swollen, stiff and painful. The small joints of your hands and feet are usually affected first. There is no cure for RA at present, so the treatments aim to relieve pain and stiffness and improve your ability to move.  </P>
<P>Anakinra is an interleukin-1 receptor antagonist which is a drug that blocks the inflammatory protein interleukin-1. The drug is used to slow the progression of moderate to severe active RA in patients over age 18 who have not responded to one or more of  the disease-modifying anti-rheumatic drugs (DMARD).  Anakrina can be used with other RA drugs.</P>
<P>
<BR/>
<B>Best estimate of what happens to people with RA who take Anakrina:</B>
</P>
<P>23 out of 100 people experienced improvement of RA symptoms such as pain, function, and stiffness when taking a placebo</P>
<P>38 out of 100 people experienced improvement of RA symptoms such as pain, function, and stiffness when taking Anakrina<BR/>
</P>
<P>15 more people out of 100 experienced improvement of RA symptoms after taking Anakrina for 6 months compared with taking a placebo. </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-11-11 22:27:16 -0500" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2008-11-09 20:22:59 -0500" MODIFIED_BY="[Empty name]">
<P>In the past decade, a novel class of therapies directed against specific cytokines implicated in the disease process of rheumatoid arthritis (RA), called the 'Biologics' have greatly improved and expanded treatment for RA. Anakinra is an interleukin-1 receptor antagonist that is currently FDA-approved for moderate-severe RA that has been unresponsive to initial disease-modifying anti-rheumatic drugs (DMARD) therapy.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2008-10-21 20:31:32 -0400" MODIFIED_BY="[Empty name]">
<P>To evaluate the clinical effectiveness and safety of anakinra in adult patients with rheumatoid arthritis.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-11-09 20:24:31 -0500" MODIFIED_BY="[Empty name]">
<P>We searched the following electronic databases: the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library </I>Issue 1, 2008), MEDLINE (1950 to Week 4 2008) , EMBASE (1980 to Week 5 2008), CINAHL (1982 to November 2007) and reference lists of articles.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2008-10-21 20:31:43 -0400" MODIFIED_BY="[Empty name]">
<P>Randomized controlled trials comparing anakinra alone or in combination with DMARDs or biologics to placebo or other DMARDs or biologics in patients &gt;18 years old with rheumatoid arthritis.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2008-11-09 20:24:43 -0500" MODIFIED_BY="[Empty name]">
<P>Two review authors independently assessed trial quality and extracted data. We contacted study authors for additional information. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2008-11-10 18:58:53 -0500" MODIFIED_BY="[Empty name]">
<P>Five trials involving 2876 patients, 781 randomized to placebo and 2065 to anakinra, were included. There was a significant improvement in number of participants achieving ACR20 (38% versus 23%) who were treated with anakinra 50 to 150 mg daily versus placebo after 24 weeks. This 15% increase in patients achieving ACR20 with anakinra versus placebo is felt to be a clinically meaningful, though modest, outcome. Other efficacy data - including ACR50 (18% versus 7%), ACR70 (7% versus 2%), HAQ, visual analog score (VAS), Larsen radiographic scores, and change in erythrocyte sedimentation rate (ESR) - all demonstrated significant improvement with anakinra 50 to 150 mg daily versus placebo as well. There were no statistically significant differences noted in most safety outcomes with treatment with anakinra versus placebo - including number of withdrawals, deaths, adverse events (total and serious), and infections (total and serious). Injection site reactions were significantly increased, occurring in 1235/1729 (71%) versus 204/729 (28%) of patients treated with anakinra versus placebo, respectively. The incidence of serious infections was clinically higher, but not statistically different, in the anakinra (25/1366 patients, 1.8%) versus placebo group (3/534 patients, 0.6%).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2008-11-11 22:27:16 -0500" MODIFIED_BY="[Empty name]">
<P>Anakinra is a relatively safe and modestly efficacious biologic therapy for rheumatoid arthritis. Although head to head comparison trials have not been carried out, the amount of improvement is notably less when compared to studies using other biologic therapies. More studies are needed to evaluate safety and efficacy, especially in comparison to other therapies, and adverse event data for the long-term use of Anakinra has yet to be assessed.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-11-12 14:07:02 -0500" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2008-11-09 20:25:27 -0500" MODIFIED_BY="[Empty name]">
<P>Rheumatoid arthritis (RA) is the most common inflammatory arthritis in adults, affecting 0.5 to 1% of the population worldwide. It is a chronic systemic inflammatory disease with a particular predilection to the joint synovium. The clinical hallmark of RA is polyarticular synovial inflammation of peripheral joints - typically in the hands (MCP, PIPs), causing pain, stiffness, and - for many - some degree of irreversible joint damage and disability. In addition, there is also a significant systemic inflammatory state present that may lead to a number of other extra-articular effects, including coronary artery disease, pulmonary fibrosis, osteoporosis, and vasculitis (<LINK REF="REF-O_x0027_Dell-2004" TYPE="REFERENCE">O'Dell 2004</LINK>). RA is associated with a high degree of disability, leading to an estimated 50% of affected patients toward work disability within 10 years. In addition, there is an estimated 2.5-fold increase in mortality rate, with life expectancy shortened by an average of three to seven years (<LINK REF="REF-Lipsky-2005" TYPE="REFERENCE">Lipsky 2005</LINK>).</P>
<P>The exact cause of RA remains unclear. It is likely a multi-factorial disease in which there are a number of genetic and environmental influences (<LINK REF="REF-Lipsky-2005" TYPE="REFERENCE">Lipsky 2005</LINK>). There is significant evidence that the activation of T-cells and macrophages with the consequent release of a number of inflammatory cytokines play a key role in the initiation and maintenance of both the systemic and local synovial inflammation present in RA (<LINK REF="REF-Lipsky-2005" TYPE="REFERENCE">Lipsky 2005</LINK>). In particular, tumor necrosis factor (TNF), interleukin-1 (IL-1), and IL-6 are considered the pivotal inflammatory mediators, though a large number of other cytokines are also likely contributing to its pathogenesis.</P>
<P>IL-1 has been demonstrated in a number of in vitro and animal models to play a role in the pathogenesis of the inflammation and joint destruction seen in rheumatoid arthritis. This includes direct stimulation of cartilage degradation processes and inhibition of cartilage matrix synthesis. Animal models that express overproduction of IL-1 have demonstrated cartilage and joint changes that are similar histopathologically to rheumatoid arthritis (<LINK REF="REF-Abramson-2002" TYPE="REFERENCE">Abramson 2002</LINK>). IL-1 has also been demonstrated to be a stimulatory cytokine for both osteoclast precursor differentiation and osteoclast activity, likely indicating a further role in the osteopenia and joint destruction seen with rheumatoid arthritis (<LINK REF="REF-Gravallese-2002" TYPE="REFERENCE">Gravallese 2002</LINK>).</P>
<P>The American College of Rheumatology (ACR) guidelines for the effective management of patients with RA require a multidisciplinary approach coordinated with a rheumatologist. The objectives of treatment are to control joint inflammation and to reduce joint damage, minimize loss of function, improve quality of life and reduce pain, and treat extra-articular complications (<LINK REF="REF-ACR-2002" TYPE="REFERENCE">ACR 2002</LINK>). Medical therapy for RA falls into two categories: symptomatic therapy and disease-modifying anti-rheumatic drugs (DMARDs).</P>
<P>Symptomatic treatment for patients with RA may be achieved with the use of analgesics, most commonly non-steroidal anti-inflammatory drugs (NSAIDs). NSAIDs may reduce early morning stiffness and pain and improve quality of life, though have no effect on long-term outcomes of RA. Corticosteroids are also commonly used to acutely reduce inflammation with active disease. They are primarily used in short courses for flares or during the initiation of DMARD therapy and may be used for long-term therapy, though this may be associated with significant side effects. Local therapies - typically with corticosteroid injections to affected joints - have also been found to be beneficial. Other options for symptomatic improvement in RA may also include resting acutely inflamed joints, local application of heat/cold, and regular exercises to help strengthen muscles and improve range of motion in affected joints (<LINK REF="REF-ACR-2002" TYPE="REFERENCE">ACR 2002</LINK>).</P>
<P>Disease-modifying anti-rheumatic drugs (DMARDs) are the main-stay for therapy of rheumatoid arthritis. They are a group of medications designed to inhibit specific mediators of inflammation and have been found to significantly reduce and prevent damage to joints (radiographic and clinical) and improve/maintain function of joints in patients with RA. ACR guidelines recommend initiation of DMARD therapy within three months of the diagnosis of rheumatoid arthritis. Medications in this class include methotrexate, sulfasalazine, leflunamide, and azathioprine. In the last decade, a new class of DMARDs - called the 'biologics' has been developed for the treatment of rheumatoid arthritis. These medications act as selective inhibitors to specific cytokines - including TNF-a (etanercept, infliximab, adalimumab), CTLA-4 - a T-cell co-stimulator (abatacept), and IL-1 (anakinra). These medications have been found to further suppress inflammation and reduce joint damage in RA patients previously unresponsive to standard DMARD therapy (<LINK REF="REF-ACR-2002" TYPE="REFERENCE">ACR 2002</LINK>).</P>
<P>Anakinra (tradename: kineret) is a recombinant form of a human interleukin-1 receptor antagonist (IL-1ra) and is the first biologic agent designed specifically to modify the biological immune response of IL-1. It has been found in a number of studies to significantly improve clinical signs of RA and was FDA approved in 2001 for moderately-severe RA with at least one failed DMARD therapy (<LINK REF="REF-FDA-2003" TYPE="REFERENCE">FDA 2003</LINK>). It is administered as a daily subcutaneous injection and adverse effects primarily include injection-site reactions, recurrent infections - notably pulmonary infections with history of asthma/COPD - and possible risk of malignancy (<LINK REF="REF-ACR-2002" TYPE="REFERENCE">ACR 2002</LINK>).</P>
</BACKGROUND>
<OBJECTIVES>
<P>The aim of this review was to provide a systematic evaluation of the clinical effectiveness of Anakinra in adult patients (18 years and older) who have not responded to conventional DMARD treatments.</P>
<P>This review addressed the following questions:<BR/>1. What is the clinical effectiveness of Anakinra for the treatment of RA in terms of:<BR/>a. relieving symptoms?<BR/>b. delaying disease progression?<BR/>2. What are the risks (frequency and severity of adverse events) associated with Anakinra treatment in these patients?</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-11-11 22:38:44 -0500" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2008-11-09 20:25:47 -0500" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2008-10-21 20:35:12 -0400" MODIFIED_BY="[Empty name]">
<P>All randomized controlled trials (RCTs) comparing anakinra alone or in combination with DMARDs or biologics to placebo or other DMARDs or biologics in patients with rheumatoid arthritis were considered.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Adults aged 18 years and above meeting the ACR 1987 revised criteria for rheumatoid arthritis (<LINK REF="REF-Arnett-1988" TYPE="REFERENCE">Arnett 1988</LINK>). </P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Anakinra alone or in combination with other drugs.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-11-09 20:25:47 -0500" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-11-09 20:25:34 -0500" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="5">Efficacy</HEADING>
<P>a. An ACR20 response rate to treatment with anakinra as defined by the American College of Rheumatology (ACR) (<LINK REF="REF-Felson-1995" TYPE="REFERENCE">Felson 1995</LINK>).<BR/>The variables included in this definition are:</P>
<UL>
<LI>tender joint count;</LI>
</UL>
<UL>
<LI>swollen joint count;</LI>
</UL>
<UL>
<LI>patient's assessment of pain (VAS or Likert scale);</LI>
</UL>
<UL>
<LI>patient and physician assessment of disease activity (VAS or Likert scale);</LI>
</UL>
<UL>
<LI>patient assessment of functional ability (HAQ, AIMS, MACTAR);</LI>
</UL>
<UL>
<LI>inflammatory markers, such as erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP).</LI>
</UL>
<P>An ACR20 response is defined as a 20 per cent improvement in tender and swollen joint counts and the same level of improvement in three of the five following variables: patient/physician global assessments, pain scores, HAQ score, and laboratory acute phase reactants.</P>
<P>b. Improvement in Disease Activity Score (DAS)/DAS28 score<BR/>The DAS is a composite index that includes a combination of the values of tender and swollen joint counts, patient's global assessment of disease activity, and ESR value (<LINK REF="REF-van-der-Heijde-1993" TYPE="REFERENCE">van der Heijde 1993</LINK>). A DAS28 score is used when a 28 joint count is used as the index (<LINK REF="REF-Prevoo-1995" TYPE="REFERENCE">Prevoo 1995</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Safety</HEADING>
<P>a. Adverse events, including allergic reactions, injection site reactions</P>
<P>b. Serious adverse events, including serious infections, as defined by the individual studies</P>
<P>c. Withdrawals due to lack of efficacy</P>
<P>d. Withdrawals due to adverse events</P>
<P>e. Total Withdrawals</P>
<P>f. Number of Deaths</P>
</SUBSECTION>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-11-09 20:25:47 -0500" MODIFIED_BY="[Empty name]">
<P>1. An ACR50 and 70 response criteria: as defined by 50% and 70% improvements, respectively, in the criteria as outlined above under ACR20.</P>
<P>2. Proportion achieving the European League Against Rheumatism (EULAR) Response: EULAR criteria defines responses (good, moderate and none)<BR/>according to relative changes in the Disease Activity Score (DAS) (<LINK REF="REF-van-Gestel-1996" TYPE="REFERENCE">van Gestel 1996</LINK>):<BR/>
</P>
<UL>
<LI>A 'good' response is defined as a decrease in DAS or DAS 28 &gt; 1.2 from baseline with a final DAS &lt; 2.4 (or DAS 28 &lt; 3.2) (<LINK REF="REF-Fransen-2005" TYPE="REFERENCE">Fransen 2005</LINK>; <LINK REF="REF-van-Gestel-1996" TYPE="REFERENCE">van Gestel 1996</LINK>)</LI>
<LI>A 'none' response is defined as a decrease in DAS or DAS 28 &lt; 0.6 or a decrease &gt;0.6 and &lt; 1.2 with a final DAS &gt; 3.7 (or DAS 28 &gt; 5.1) (<LINK REF="REF-Fransen-2005" TYPE="REFERENCE">Fransen 2005</LINK>; <LINK REF="REF-van-Gestel-1996" TYPE="REFERENCE">van Gestel 1996</LINK>)</LI>
<LI>Any other scores are regarded as moderate response.</LI>
</UL>
<P>Low disease activity as defined by DAS score &lt; 2.4 or DAS28 &lt; 3.2 (<LINK REF="REF-Fransen-2005" TYPE="REFERENCE">Fransen 2005</LINK>; <LINK REF="REF-van-Gestel-1996" TYPE="REFERENCE">van Gestel 1996</LINK>)</P>
<P>Disease remission as defined by DAS &lt; 1.6 or DAS28 &lt; 2.6 (<LINK REF="REF-Fransen-2005" TYPE="REFERENCE">Fransen 2005</LINK>; <LINK REF="REF-Prevoo-1996" TYPE="REFERENCE">Prevoo 1996</LINK>)</P>
<P>3. Radiographic progression, as measured by the Sharp, modified Sharp or Larsen methods (<LINK REF="REF-Larsen-1977" TYPE="REFERENCE">Larsen 1977</LINK>; <LINK REF="REF-Sharp-1971" TYPE="REFERENCE">Sharp 1971</LINK>; <LINK REF="REF-van-der-Heijde-1989" TYPE="REFERENCE">van der Heijde 1989</LINK>)</P>
<P>4. Recently revised ACR criteria (<LINK REF="REF-Felson-2007" TYPE="REFERENCE">Felson 2007</LINK>):<BR/>e.g. Nominal measure of improvement such as ACR Step: 0 if ACR20 = 0, 1 if ACR20 but not ACR50, 2 if ACR50 but not ACR70, 3 if ACR70</P>
<P>5. Health-related quality of life (HRQoL) as measured by the Short Form (SF)-36 or other instruments: (<LINK REF="REF-Kosinski-2000" TYPE="REFERENCE">Kosinski 2000</LINK>; <LINK REF="REF-Tugwell-2000" TYPE="REFERENCE">Tugwell 2000</LINK>)<BR/>
</P>
<UL>
<LI>Change in SF-36 Physical and Mental Component Summary (PCS and MCS) scores</LI>
<LI>Change in SF-36 subscale scores</LI>
<LI>Proportion achieving the population norms for PCS and MCS (Mean of 50)</LI>
<LI>Proportion achieving the Minimal Clinical Important Change (MCID) in SF-36 PCS and MCS - defined as a change of 2.5 to 5 on each summary score (<LINK REF="REF-Kosinski-2000" TYPE="REFERENCE">Kosinski 2000</LINK>; <LINK REF="REF-Samsa-1999" TYPE="REFERENCE">Samsa 1999</LINK>; <LINK REF="REF-Tugwell-2000" TYPE="REFERENCE">Tugwell 2000</LINK>)</LI>
</UL>
<P>
<BR/>6. Function Change, as measured by Composite Function scales: Stanford Health Assessment Questionnaire (HAQ), modified HAQ or others.<BR/>- HAQ is a self-report questionnaire aimed for assessment of effect of disease on 8 basic categories of functions (dressing, standing, eating, walking, toileting, reach, grip, and instrumental activities) (<LINK REF="REF-Fries-1980" TYPE="REFERENCE">Fries 1980</LINK>).<BR/>- mHAQ is the modified and simplified version of this scale utilizing the above categories (<LINK REF="REF-Pincus-1983" TYPE="REFERENCE">Pincus 1983</LINK>).<BR/>
</P>
<UL>
<LI>Proportion achieving a Minimal Clinical Important Change (MCID) in HAQ (defined as change &#8805; 0.22) (<LINK REF="REF-Wells-1993" TYPE="REFERENCE">Wells 1993</LINK>) or in a similar functional assessment</LI>
<LI>Proportion achieving HAQ of 0</LI>
<LI>Proportion achieving the population norm for HAQ (0.25) (<LINK REF="REF-Krishnan-2004" TYPE="REFERENCE">Krishnan 2004</LINK>)</LI>
</UL>
<P>
<BR/>7. Pain Visual Analog Scale (VAS) scores<BR/>- pain VAS score is a validated measure of pain (0 to 10cm, 0 to 100mm or a similar scale).</P>
<P>8. Inflammatory Markers: Erythrocyte Sedimentation Rate (ESR) in mm/hr and C-reactive Protein (CRP) in mg/dl.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-11-11 22:29:17 -0500" MODIFIED_BY="[Empty name]">
<P>
<I>See</I>: Cochrane Musculoskeletal Group methods used in reviews.</P>
<P>We searched the following electronic bibliographic databases: Cochrane Central Register of Controlled Trials (CENTRAL (<I>The Cochrane Library </I>Issue 1, 2008) <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>, MEDLINE (1950 to January Week 4 2008) <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> and EMBASE (1980 to 2008) <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK> and CINAHL (1982 to November 2007) <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>.</P>
<P>We also reviewed the reference lists of identified publications, including previous meta-analyses, to identify any additional studies or citations or both.</P>
<P>No language restrictions were applied and translations were obtained when necessary. If information was missing, further information was sought from the authors or industry. Data from studies with multiple publications were extracted and reported as a single study.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-11-11 22:38:44 -0500" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Selection of studies</HEADING>
<P>Two review authors independently applied the following inclusion/exclusion criteria to all potential studies. Any disagreements were resolved by discussion; referring to a third party if necessary. Review authors were not blinded to any features of the report including authorship. However inclusion/exclusion decisions were made prior to detailed scrutiny of the results.</P>
<P>For details of screening process for articles identified from the above search, please refer to <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data extraction strategy</HEADING>
<P>Two review authors independently extracted data using a pre-designed data extraction form. Disagreements were resolved by discussion; consulting with a third party if there was still disagreement.</P>
<P>We extracted the following data.</P>
<OL>
<LI>Details of the study population and baseline characteristics of the intervention and control groups, with particular reference to disease characteristics and previous treatment history.</LI>
<LI>Details of the intervention, including dose, mode of administration, frequency of administration, duration of treatment, and co-administered medications.</LI>
<LI>Details of withdrawal rates across the groups, frequency of loss to follow-up.</LI>
<LI>Details of individual outcomes measured through tools as described above:</LI>
</OL>
<UL>
<LI>Changes in disease activity (e.g. ACR improvement criteria, DAS/DAS28 scores, pain scales, radiographic scores, inflammatory markers)</LI>
<LI>Changes in quality of life (e.g. HRQoL scores - SF-36)</LI>
<LI>Changes in function (e.g. HAQ or mHAQ scores)</LI>
<LI>Adverse events (serious, total, and injection site reactions)</LI>
<LI>Infections (serious and total)</LI>
<LI>Number of deaths</LI>
</UL>
<P>Results were extracted, where possible, for the intention-to-treat population, as raw numbers, plus any summary measures with standard deviations, confidence intervals and P values where given.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quality assessment strategy</HEADING>
<P>Two review authors independently undertook quality assessments using a structured form. Disagreements were resolved by discussion, with reference to a third party if there remained a disagreement. The information on quality assessment is presented in table form and summarized within the text of the report. The validity of included studies was assessed by looking at the method of randomization, the concealment of allocation, the comparability of baseline characteristics between the different arms, blinding, withdrawals and losses to follow-up for each patient. Each criteria was assessed and graded as 'yes', 'no', or 'unclear'.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Methods of analysis/synthesis</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Clinical relevance tables</HEADING>
<P>Clinical relevance tables were compiled under additional tables to improve the readability of the review. For dichotomous outcomes, the absolute risk difference was calculated between anakinra and control arms, using the risk difference (RD) statistic in RevMan. We calculated the numbers needed to treat to benefit (NNTB) for ACR20, ACR50 and ACR70 by taking the inverse of absolute risk difference i.e. NNTB = 1/absolute risk difference.</P>
<P>The tables summarizing continuous outcomes are also presented. The mean difference (MD) statistic in RevMan was calculated by weighting the absolute change by the group size, in cases where trials used the same scale. Relative per cent change from baseline was calculated as the absolute benefit divided by the baseline mean of the respective group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Heterogeneity</HEADING>
<P>In addition to reviewing forest plots, heterogeneity of the data was formally tested using the Chi-square with a P-value &lt; 0.10 indicating significant heterogeneity. The I<SUP>2 </SUP>statistic was also assessed (<LINK REF="REF-Higgins-2004" TYPE="REFERENCE">Higgins 2004</LINK>). A value greater than 50% indicates substantial heterogeneity. In the case of substantial heterogeneity, we explored the data further. We performed sub-group analyses, in an attempt to explore the cause of the heterogeneity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Data synthesis</HEADING>
<P>In the absence of significant heterogeneity - defined by an I<SUP>2 </SUP>statistic &lt; 50%, a fixed-effect model was used. However, if significant heterogeneity was demonstrated, a random-effects model was used for analysis. Where available, the analyses were based on intention-to-treat data from the individual studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Publication bias</HEADING>
<P>We constructed a funnel plot to assess the possibility of publication bias. A funnel plot is a scatter plot with sample size along the y-axis and the treatment effect along the x-axis. An asymmetric appearance of this plot in either x-axis likely indicates a level of publication bias in the literature.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sub-group analysis</HEADING>
<P>The following sub-group analyses were planned to explore possible effect size differences:<BR/>1. Intervention - variable dosage or duration of treatment<BR/>2. Characteristics of participants - severity of baseline disease; age; disease duration; sex; disease with or without peripheral joint involvement.<BR/>3. Patients in whom anakinra is being prescribed in combination with MTX (or other DMARDs)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sensitivity analysis</HEADING>
<P>The following sensitivity analyses were planned to explore effect size differences and the robustness of conclusions:</P>
<UL>
<LI>Effect of study quality - defined as adequate allocation concealment and outcome assessor blinding.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Grading of the evidence</HEADING>
<P>In addition, a further ranking based on the level of evidence was performed in the manner described by Tugwell and approved by the CMSG editorial team (<LINK REF="REF-Tugwell-2004" TYPE="REFERENCE">Tugwell 2004</LINK>). A simplified ranking scale was used to grade the strength of scientific evidence for the trial intervention. The scale is as follows, in decreasing order:</P>
<P>Platinum: A published systematic review that has at least two individual controlled trials each satisfying the following:<BR/>Sample sizes of at least 50 per group - if these do not find a statistically significant difference, they are adequately powered for a 20% relative difference in the relevant outcome.<BR/>Blinding of patients and assessors for outcomes.<BR/>Handling of withdrawals &gt; 80% follow-up (imputations based on methods such as Last Observation Carried Forward (LOCF) are acceptable).<BR/>Concealment of treatment allocation.</P>
<P>Gold: At least one randomized clinical trial meeting all of the following criteria for the major outcome(s) as reported:<BR/>Sample sizes of at least 50 per group - if these do not find a statistically significant difference, they are adequately powered for a 20% relative difference in the relevant outcome.<BR/>Blinding of patients and assessors for outcomes.<BR/>Handling of withdrawals &gt; 80% follow-up (imputations based on methods such as LOCF are acceptable).<BR/>Concealment of treatment allocation.</P>
<P>Silver: A randomized trial that does not meet the above criteria. Silver ranking would also include evidence from at least one study of non-randomized cohorts that did and did not receive the therapy, or evidence from at least one high quality case-control study. A randomized trial with a 'head-to-head' comparison of agents would be considered silver level ranking unless a reference was provided to a comparison of one of the agents to placebo showing at least a 20% relative difference.</P>
<P>Bronze: The bronze ranking is given to evidence if at least one high quality case series without controls (including simple before/after studies in which patients act as their own control) or if the conclusion is derived from expert opinion based on clinical experience without reference to any of the foregoing (for example, argument from physiology, bench research or first principles).<BR/>
</P>
</SUBSECTION>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-11-12 14:07:02 -0500" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2008-11-09 20:29:19 -0500" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Bresnihan-1998" TYPE="STUDY">Bresnihan 1998</LINK> was a randomized, double-blind, placebo-controlled trial involving 472 participants among 41 centers in 11 countries in Europe. It randomized participants into four groups: placebo (n = 119) and 30 mg (n = 119), 75 mg (n = 115), and 150 mg (n = 115) of recombinant IL-1 receptor antagonist. Four patients (two placebo, two anakinra) did not receive doses of the study drug and were not included in analysis. Doses were given as subcutaneous injections daily for 24 weeks. Patients included in the study had to meet all of the following criteria: (1) a diagnosis of rheumatoid arthritis based on the ACR Classification criteria with duration of &gt; 6 months and &lt; 8 years; (2) active disease - determined by presence of &gt; 10 swollen joints and three of the following four: &gt; 10 tender joints, rheumatologists' grading of RA as severe-very severe, CRP &gt; 1.5 mg/dl, or patient with severe-very severe RA. NSAIDs and oral steroids (&lt; 10 mg prednisolone daily) were allowed, though any DMARD therapy had to be discontinued at least six weeks prior to study enrollment. Exclusion criteria included intraarticular or systemic corticosteroids within six weeks prior to the study or treatment failure (toxicity or lack of efficacy) with three or more DMARDs after at least 3 months of continuous administration. The study was sponsored by Amgen, Inc.</P>
<P>
<LINK REF="STD-Cohen-2002" TYPE="STUDY">Cohen 2002</LINK> was a randomized, double-blind, placebo-controlled trial involving 36 centers in the U.S, Canada and Australia that was originally designed as a 12-week trial involving 105 participants randomized to placebo and 0.1 mg/kg, 0.4 mg/kg, 2.0 mg/kg of anakinra given subcutaneous daily. An amendment was made to this original protocol so that the double-blind treatment was extended from 12 to 24 weeks and additional subcutaneous daily doses of 0.04 mg/kg and 1.0 mg/kg of anakinra were added in the study. An additional 314 participants were randomized into this 24 week treatment protocol. Three participants from the original 12 week study re-consented to remain blinded in their treatment group for the 24 week study. A total of 419 participants were evaluated at 12 weeks and 317 were evaluated at 24 weeks. For the 24 week analysis, the number of patients in each were as follows: placebo (n = 48), 0.04 mg/kg (n = 63), 0.1 mg/kg (n = 46), 0.4 mg/kg (n = 55), 1.0 mg/kg (n = 59), 2.0 mg/kg (n = 46).</P>
<P>Inclusion criteria for this study were as follows: (1) diagnosis of rheumatoid arthritis by ACR criteria for &gt; 6 months and &lt; 12 years; (2) active disease - defined as &gt; 6 swollen joints and two of the following three criteria: &gt; 9 tender joints, AM stiffness &gt; 45 minutes, or CRP &gt; 1.5 mg/dl; and (3) treatment with methotrexate for at least six consecutive months and on a stable dose for &gt; 3 months prior to the study. NSAIDs and oral steroids (&lt; 10 mg/day prednisone) were allowed and had to be stable for four weeks prior to the study. Exclusion criteria included the following: receiving systemic/intraarticular steroids within four weeks of the study, receiving penicillamine, oral or parenteral gold, azathioprine, or cyclosporine within 12 weeks of the study, receiving hydroxychloroquine or sulfasalazine within eight weeks of the study. The study was sponsored by Amgen, Inc.</P>
<P>
<LINK REF="STD-Cohen-2004" TYPE="STUDY">Cohen 2004</LINK> was a multi-center double-blind, placebo-controlled trial involving 506 participants who were randomized to placebo (n = 251) or anakinra 100 mg (n = 250) subcutaneous daily for 24 weeks. Five randomized patients (two placebo, three anakinra) did not receive any doses and were not included in analysis. Inclusion criteria were the following for this study: (1) diagnosis of rheumatoid arthritis by ACR criteria for &gt; 24 weeks; (2) presence of radiographic erosions in hands, feet, or wrists; (3) active disease, defined by &gt; 5 swollen joints, &gt; 8 tender joints, and one of the following two criteria: CRP &gt; 15 ml/L or ESR &gt; 28 mm/hr. All patients were also required to be treated with a stable dose of methotrexate for at least 24 consecutive weeks, and were provided folic acid 1 mg daily. All other DMARD therapy was withdrawn for at least 60 days prior to study inclusion. NSAIDs and oral steroids (&lt; 10 mg/day prednisone) were allowed and required to be stable for at least four weeks prior to the study. Exclusion criteria included the following: other autoimmune diseases, treatment with intraarticular/systemic steroids within four weeks of the study, treatment with other DMARDs within 60 days of the study, the use of narcotic analgesics for pain. The study was sponsored by Amgen, Inc.</P>
<P>
<LINK REF="STD-Fleischman-2003" TYPE="STUDY">Fleischman 2003</LINK> was a double-blind, placebo-controlled trial involving 169 centers in the U.S, Canada, Europe, and Australia involving 1414 participants randomized to placebo (n = 283) or anakinra 100 mg (n = 1116) subcutaneous daily for six months. Fifteen randomized patients (1 placebo, 14 anakinra) did not receive any study drug doses and were not included in analysis. Inclusion criteria were the following: (1) diagnosis of rheumatoid arthritis for &gt; 3 months; (2) active disease: defined as &gt; 3 swollen and &gt; 3 tender joints or &gt; 45 minutes of AM stiffness. NSAIDs and steroids were allowed as long as doses were stable for &gt; 1 month. DMARDs were allowed as long as doses were stable for &gt; 2 months. The use of TNF-inhibitors was not allowed during the study. Exclusion criteria included recent diagnosis of a malignancy (other than basal cell of skin and in situ cervical CA) in the last 5 years. The study was sponsored by Amgen, Inc.</P>
<P>
<LINK REF="STD-Genovese-2004" TYPE="STUDY">Genovese 2004</LINK> was a multi-center double-blind, placebo-controlled trial involving 41 centers in the U.S and 244 participants randomized into the following groups: placebo + etanercept 25 mg biweekly (n = 80), anakinra 100 mg daily + etanercept 25 mg weekly (with placebo for other biweekly etanercept dose) (n = 81), and anakinra 100 mg daily + etanercept 25 mg biweekly. (n = 81). Two patients (both placebo) did not receive any study drug doses and were not included in analysis. Treatment duration was 24 weeks. Inclusion criteria were the following: (1) diagnosis of rheumatoid arthritis for &gt; 6 months; (2) active disease, defined as following: &gt; 5 swollen joints, &gt; 8 tender joints, and two of the following 3: &gt; 45 minutes of AM stiffness, CRP &gt; 1.5 mg/dl, or ESR &gt; 28 mm/hr.</P>
<P>All participants required treatment with methotrexate for at least &gt;16 weeks prior to the study, with stable doses (10 to 25 mg/wk) for &gt; 8 weeks. NSAIDs and corticosteroids were allowed as long as doses remained stable. Exclusion criteria included use of other DMARD therapy other than MTX in previous four weeks or intraarticular/systemic steroids within four weeks of the study. The study was sponsored by Amgen, Inc.</P>
<P>Please refer to the table <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> for overview of included studies above.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-11-11 22:40:03 -0500" MODIFIED_BY="[Empty name]">
<P>
<LINK REF="STD-Bresnihan-1998" TYPE="STUDY">Bresnihan 1998</LINK> had blinding reported for both assessors and patients. Method of randomization was not reported. There was 73.3% follow-up through the entire study. The study did not have full intention-to-treat analysis, since safety analysis was done only for those who received at least one dose of IL-1Ra. Missing data for efficacy outcomes was also excluded in their final analysis, resulting in four patients not included for ACR20 data, 129 patients not included for Larsen scores, 26 patients not included for ESR, and 12 patients not included for CRP outcomes.</P>
<P>
<LINK REF="STD-Cohen-2002" TYPE="STUDY">Cohen 2002</LINK> was reported as a double-blind study, though blinding was only described for the patients. Method of randomization was not reported. As stated above, the study was originally set as a 12 week study, though was amended to a 24 week study with the recruitment of additional patients. However, only three patients from the original 12 week study re-consented to the 24 week study and it was unclear about the methodology of maintaining blinding and randomization with the amended study. The small number of participants re-consenting for the longer study also poses a significant bias for the 24 week group. Full intention-to-treat analysis was performed on analysis of results. For the patients consenting to the 24 week trial, there was a 21.0% withdrawal rate. However, if the patients from the original 12 week trial who refused to consent for the full 24 week study extension were included, only 45.3% of the original study participants followed up for the full 24 weeks.</P>
<P>
<LINK REF="STD-Cohen-2004" TYPE="STUDY">Cohen 2004</LINK> had blinding reported for both patients and assessors. Method of randomization was not reported. The study did not have full intention-to-treat analysis as results were analyzed for only those who received at least one dose of the study drug (5 patients were not included in analysis because of this). Unfortunately, the number of total withdrawals was not reported in this study - with only reporting of withdrawals secondary to adverse events being reported.</P>
<P>
<LINK REF="STD-Fleischman-2003" TYPE="STUDY">Fleischman 2003</LINK> had blinding reported for patients, health-care providers, and the sponsor. Method of randomization was not reported. The study did not have full intention-to-treat analysis with results analyzed for only those who received at least one dose of the study drug (15 patients not included because of this). There was 78.1% follow-up through the entire study.</P>
<P>
<LINK REF="STD-Genovese-2004" TYPE="STUDY">Genovese 2004</LINK> was reported as double-blinded study, though full blinding was only reported for the patients. For the assessors, blinding was described by having the patients wear clothing over potential injection-site reactions. Method of randomization was not reported. Treatment allocation was not reported in this study. The study did not have full intention-to-treat analysis as results were analyzed for only those who received at least one dose each of anakinra/placebo and etanercept/placebo (two patients not included because of this). There was 83.6% follow-up through the entire study.</P>
<P>Overall, this systematic review achieved a rating of Silver, based upon the CMSG rating described above. Only one study had &lt; 20% withdrawals (<LINK REF="STD-Genovese-2004" TYPE="STUDY">Genovese 2004</LINK>) though this study did not provide method of treatment allocation.</P>
<SUBSECTION>
<HEADING LEVEL="3">Excluded studies</HEADING>
<P>
<BR/>Please refer to the table <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> for listing of studies excluded for not meeting inclusion criteria listed above for this systematic review.</P>
<P>
<LINK REF="STD-Drevlow-1996" TYPE="STUDY">Drevlow 1996</LINK> was a randomized, double-blinded placebo controlled trial that initially met inclusion criteria for the systematic review though was not included in the final review. It was a small trial including 23 participants randomized to placebo (n = 4), 125 mcg/m<SUP>2</SUP>/day (n = 3), 250 mcg/m<SUP>2</SUP>/day (n = 3), 500 mcg/m<SUP>2</SUP>/day (n = 3), 1000 mcg/m<SUP>2</SUP>/day (n = 8) of recombinant human IL-1 receptor-1 antagonist (rHuIL-1R1) given subcutaneous daily for 28 days. Unfortunately, data was only expressed as number of individuals achieving the primary outcome of &gt; 40% improvement in # swollen joints. No numerical data for assessment was provided by this study.</P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-11-12 14:07:02 -0500" MODIFIED_BY="[Empty name]">
<P>Five trials (<LINK REF="STD-Bresnihan-1998" TYPE="STUDY">Bresnihan 1998</LINK>; <LINK REF="STD-Cohen-2002" TYPE="STUDY">Cohen 2002</LINK>; <LINK REF="STD-Cohen-2004" TYPE="STUDY">Cohen 2004</LINK>; <LINK REF="STD-Fleischman-2003" TYPE="STUDY">Fleischman 2003</LINK>; <LINK REF="STD-Genovese-2004" TYPE="STUDY">Genovese 2004</LINK>), representing a total of 3055 patients, were included in this review. <LINK REF="STD-Bresnihan-1998" TYPE="STUDY">Bresnihan 1998</LINK>, <LINK REF="STD-Cohen-2004" TYPE="STUDY">Cohen 2004</LINK>, and <LINK REF="STD-Genovese-2004" TYPE="STUDY">Genovese 2004</LINK> followed patients for 24 weeks and <LINK REF="STD-Fleischman-2003" TYPE="STUDY">Fleischman 2003</LINK> followed patients for six months. <LINK REF="STD-Cohen-2002" TYPE="STUDY">Cohen 2002</LINK> was initially a 12 week study though additional participants were recruited for an extension into a 24 week study. For correlation with the other studies in this review, only the 24 week data from the <LINK REF="STD-Cohen-2002" TYPE="STUDY">Cohen 2002</LINK> study was utilized in the systematic review, excluding the 102 participants in the 12 week group. <LINK REF="STD-Bresnihan-1998" TYPE="STUDY">Bresnihan 1998</LINK> and <LINK REF="STD-Fleischman-2003" TYPE="STUDY">Fleischman 2003</LINK> compared anakinra with placebo. <LINK REF="STD-Cohen-2002" TYPE="STUDY">Cohen 2002</LINK> and <LINK REF="STD-Cohen-2004" TYPE="STUDY">Cohen 2004</LINK> compared anakinra + MTX and placebo + MTX. <LINK REF="STD-Genovese-2004" TYPE="STUDY">Genovese 2004</LINK> had the following comparisons: anakinra + etanercept biweekly + MTX, anakinra + etanercept once weekly + MTX, and placebo + etanercept biweekly + MTX. The 81 participants in the anakinra + etanercept once weekly + MTX were excluded in the systematic review as this group was not placebo controlled. Therefore, a total of 2872 participants - divided among 788 randomized to placebo and 2084 to anakinra - were included in this systematic review. Of these, data were not presented for 26 randomized patients (7 placebo, 19 anakinra) who did not receive any treatments in their respective studies, leaving us with 2846 patients for analysis in this systematic review - 2065 in anakinra and 781 in placebo.</P>
<P>The <LINK REF="STD-Cohen-2002" TYPE="STUDY">Cohen 2002</LINK> study did not report standard deviations or errors when describing its continuous data results and was unable to be contacted by the time of this publication, therefore we were unable to utilize these data.</P>
<P>
<LINK REF="STD-Cohen-2004" TYPE="STUDY">Cohen 2004</LINK>, <LINK REF="STD-Fleischman-2003" TYPE="STUDY">Fleischman 2003</LINK>, and <LINK REF="STD-Genovese-2004" TYPE="STUDY">Genovese 2004</LINK> used anakinra 100 mg daily dosing. <LINK REF="STD-Bresnihan-1998" TYPE="STUDY">Bresnihan 1998</LINK> used doses of 30 mg, 75 mg, and 150 mg daily of anakinra. <LINK REF="STD-Cohen-2002" TYPE="STUDY">Cohen 2002</LINK> used the following doses: 0.04 mg/kg, 0.1 mg/kg, 0.4 mg/kg, 1.0 mg/kg, and 2.0 mg/kg daily which was correlated to approximate doses of 3 mg, 7.5 mg, 30 mg, 75 mg, and 150 mg for this review given average adult weight of 75 kg.</P>
<P>Due to the large variability in doses utilized by the trials, two groups were created to assist with analysis: data from doses &lt; 50 mg/day of Anakinra and data from doses 50 to 150 mg/day of Anakinra. This was a clinical decision based upon the fact that the recommended daily dose for Anakinra is 100 mg daily. Given proximity of 24 weeks and 6 months, the data of <LINK REF="STD-Fleischman-2003" TYPE="STUDY">Fleischman 2003</LINK> was pooled with the other studies for analysis. For studies with multiple dosing arms of anakinra, dichotomous data were combined into the stated ranges (&lt; 50 mg/day versus 50 to 150 mg/day) while continuous outcome data were analyzed separately to avoid double counting of the placebo groups, as recommended.</P>
<P>With inclusion of all five studies, there was significant heterogeneity for ACR20 (the primary outcome) with an I<SUP>2 </SUP>statistic of 80.7%. This was thought to be primarily secondary to the <LINK REF="STD-Genovese-2004" TYPE="STUDY">Genovese 2004</LINK> study based upon its clinical design and our analysis of the collected data. <LINK REF="STD-Genovese-2004" TYPE="STUDY">Genovese 2004</LINK> compared anakinra to placebo in the setting of etanercept, another biologic medication. This was a significant variation from the other studies included in this review and is not a standard therapy in current clinical practice. Therefore, this study was separated in our meta-analysis. After removal of the <LINK REF="STD-Genovese-2004" TYPE="STUDY">Genovese 2004</LINK> study, heterogeneity was noted to be 0% for the primary outcome and &lt; 50% for majority of the secondary efficacy outcomes.</P>
<P>Due to the small number of studies for the primary outcome, ACR20, a funnel plot for evaluation of publication bias was not interpretable.</P>
<P>Subgroup analysis was performed separating studies that utilized anakinra versus placebo (<LINK REF="STD-Bresnihan-1998" TYPE="STUDY">Bresnihan 1998</LINK>; <LINK REF="STD-Fleischman-2003" TYPE="STUDY">Fleischman 2003</LINK>) and studies that utilized anakinra versus placebo in the setting of methotrexate therapy (<LINK REF="STD-Cohen-2002" TYPE="STUDY">Cohen 2002</LINK>; <LINK REF="STD-Cohen-2004" TYPE="STUDY">Cohen 2004</LINK>). The other subgroup analyses proposed in the methods section could not be performed due to lack of these group-level data in the included studies.</P>
<SUBSECTION>
<HEADING LEVEL="3">Efficacy Results</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Primary Outcomes:</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">ACR20</HEADING>
<P>There was a significantly greater improvement with anakinra doses 50 to 150 mg/day with 38% of anakinra versus 23% placebo treated patients achieving ACR20 at 24 weeks, (RR 1.61;95% CI 1.32 to 1.98). The absolute treatment benefit for anakinra 50 to 150 mg/day was 15% with NNTB of 8 for ACR20 after 24 weeks. There was also a significantly greater improvement with anakinra doses &lt; 50 mg/day with a RR of 1.38 (95% CI 1.01 to 1.89), 33% of anakinra versus 26% achieving ACR20 at 24 weeks. The <LINK REF="STD-Genovese-2004" TYPE="STUDY">Genovese 2004</LINK> study demonstrated no benefit with addition of anakinra to etanercept therapy for the number achieving ACR20 at 24 weeks with a RR of 0.91 (95% CI 0.73 to 1.15). For anakinra 50 to 150 mg daily, there was also notable significant improvement in the sub-groups of anakinra versus placebo (without MTX) (RR 1.42; 95% CI 1.01 to 2.00) and anakinra + MTX versus placebo + MTX (RR 1.73; 95% CI 1.34 to 2.23) for achieving ACR 20 after 24 weeks at anakinra doses of 50 to 150 mg/day.</P>
<P>None of the studies reported data on DAS/DAS28 scores, a co-primary outcome for this review.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary Outcomes:</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">ACR50</HEADING>
<P>Significantly more improvement was noted with anakinra doses 50 to 150 mg/day with 18% of Anakinra versus 7% placebo treated patients achieving ACR50 after 24 weeks of therapy (RR 2.51; 95% CI 1.56 to 4.03). The absolute treatment benefit for anakinra 50 to 150 mg/day was 11% and NNTB was 9 for ACR50 after 24 weeks. Only one study (<LINK REF="STD-Cohen-2002" TYPE="STUDY">Cohen 2002</LINK>) examined anakinra doses &lt; 50 mg/day for ACR50 responses and there was no significant improvement noted (RR 3.37; 95% CI 0.82 to 13.77). The <LINK REF="STD-Genovese-2004" TYPE="STUDY">Genovese 2004</LINK> study demonstrated no additional benefit with addition of anakinra to etanercept therapy for the number achieving ACR50 after 24 weeks (RR 0.75; 95% CI 0.49 to 1.14). The two studies that evaluated anakinra + MTX versus placebo + MTX were the only studies that provided ACR50 data (<LINK REF="STD-Cohen-2002" TYPE="STUDY">Cohen 2002</LINK>; <LINK REF="STD-Cohen-2004" TYPE="STUDY">Cohen 2004</LINK>), so no sub-group analysis could be performed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">ACR70</HEADING>
<P>There was a significantly greater improvement with anakinra doses 50 to 150 mg/day for achieving ACR70 at 24 weeks (RR 3.71; 95% CI 1.44 to 9.57), achieved by 7% of anakinra versus 2% of placebo treated patients. The absolute treatment benefit for anakinra 50 to 150 mg/day was 5% and NNTB was 22 for ACR70 after 24 weeks. Only one study (<LINK REF="STD-Cohen-2002" TYPE="STUDY">Cohen 2002</LINK>) evaluated anakinra doses &lt; 50 mg/day for ACR70 and there was no significant improvement noted at 24 weeks compared to placebo (RR 4.45; 95% CI 0.26 to 76.62). The <LINK REF="STD-Genovese-2004" TYPE="STUDY">Genovese 2004</LINK> study also demonstrated no additional improvement with addition of anakinra to etanercept therapy for achieving ACR70 after 24 weeks (RR 0.64; 95% CI 0.32 to 1.28). The two studies that evaluated anakinra + MTX versus placebo + MTX were the only studies that provided ACR70 data, so no sub-group analysis could be performed.</P>
<P>Clinical Relevance Table detailing ACR20, ACR50 and ACR70 is provided in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
<P>Data from individual studies for ACR20, ACR50, and ACR70 outcome data is provided in <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Functional Scales (HAQ, pain VAS)</HEADING>
<P>There was significant improvement noted with both VAS and HAQ scores with anakinra doses 50 to 150 mg/day at 24 weeks of treatment. HAQ scores were significantly better with anakinra with a MD of -0.19 (95% CI -0.30 to -0.09). Only one study (<LINK REF="STD-Bresnihan-1998" TYPE="STUDY">Bresnihan 1998</LINK>) measured pain VAS scores as outcome data and this noted a significant improvement with a WMD of -0.10 (95% CI -0.15 to -0.04) for anakinra 50 to 150 mg/day after 24 weeks. <LINK REF="STD-Bresnihan-1998" TYPE="STUDY">Bresnihan 1998</LINK> was the only study to evaluate both HAQ and VAS scores for anakinra doses &lt; 50 mg/day. This study found a significant improvement in HAQ scores (WMD -0.20; 95% CI -0.33 to -0.07) but no significant improvement in VAS scores (WMD -0.08; 95% CI -0.16 to 0).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Radiographic scales (Larsen scores)</HEADING>
<P>Only one study utilized standard radiographic scales for outcome data (<LINK REF="STD-Bresnihan-1998" TYPE="STUDY">Bresnihan 1998</LINK>) and there was significant improvement noted in Larsen radiographic scores with both anakinra 50 to 150 mg/day doses (WMD -2.45; 95% CI -4.53 to -0.36) and anakinra &lt; 50 mg/day (WMD -2.8; 95% CI -5.47 to -0.13), compared to placebo.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Inflammatory markers</HEADING>
<P>There was significant improvement in change in ESR (WMD -10.04; 95% CI -12.75 to -7.33) with anakinra doses 50 to 150 mg/day after 24 weeks of treatment, compared to placebo. Only one study (<LINK REF="STD-Bresnihan-1998" TYPE="STUDY">Bresnihan 1998</LINK>) evaluated change in CRP and there was no significant improvement noted with anakinra doses 50 to 150 mg/day after 24 weeks of treatment (WMD -0.60; 95% CI -1.26 to 0.06). <LINK REF="STD-Bresnihan-1998" TYPE="STUDY">Bresnihan 1998</LINK> was also the only study to evaluate change in ESR and CRP levels for anakinra doses &lt; 50 mg/day and significant improvement was noted for both change in ESR [WMD -10.0 (95% CI -15.67 to -4.33)] and change in CRP levels (WMD -0.90; 95% CI -1.64 to -0.16) after 24 weeks as compared to placebo.</P>
<P>The following secondary efficacy outcomes listed in the methods section were not reported in the included studies: low disease activity or remission as defined by DAS/DAS28 scores, radiographic Sharp/modified Sharp scores, HRQoL/SF-36 scores for PCS/MCS, or % achieving MCID for PCS/MCS or population norms, and % achieving MCID, population norm, or a score of 0 on mHAQ/HAQ. None of the studies described new revised ACR response criteria, since most studies preceded the description of these revised response criteria.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Safety Results</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Withdrawals</HEADING>
<P>There was no difference in the total number of withdrawals for anakinra 50 to 150 mg/day versus placebo. After 24 weeks, there were 22% withdrawals in the anakinra 50 to 150 mg/day group versus 22% withdrawals in the placebo group (RR 1.04; 95% CI 0.86 to 1.27). In the anakinra versus placebo (without MTX) subgroup, there was no significant difference in the total number of withdrawals (RR 1.01; 95% CI 0.82 to 1.25). In the anakinra + MTX versus placebo + MTX subgroup, there was also no significant difference in the total number of withdrawals [RR 1.29 (95% CI 0.74 to 2.26)]. For anakinra &lt; 50 mg/day versus placebo, there was also no difference in the total number of withdrawals after 24 weeks (RR 0.85; 95% CI 0.62 to 1.18). However, <LINK REF="STD-Genovese-2004" TYPE="STUDY">Genovese 2004</LINK> reported a significant increase in the total number of withdrawals in the anakinra group versus control (RR 2.96; 95% CI 1.13 to 7.77).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Deaths</HEADING>
<P>Mortality was only presented by one study, <LINK REF="STD-Fleischman-2003" TYPE="STUDY">Fleischman 2003</LINK>, and there was no significant difference in the number of deaths - 0.3% each for the anakinra 50 to 150 mg/day and placebo groups [RR 1.01 (95% CI 0.11 to 9.04)].</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Adverse Events</HEADING>
<P>Adverse events were presented by the studies, <LINK REF="STD-Cohen-2004" TYPE="STUDY">Cohen 2004</LINK> and <LINK REF="STD-Fleischman-2003" TYPE="STUDY">Fleischman 2003</LINK>, though specific definitions for adverse events were not provided in either study. Total number of adverse events was not significantly increased in anakinra 50 to 150 mg/day treated patients, occurring in 92% versus 87% of anakinra versus placebo treated patients, after 24 weeks (RR 1.05; 95% CI 0.94 to 1.17). In the anakinra versus placebo (without MTX) subgroup, there was no significant difference in total adverse events (RR 1.00; 95% CI 0.96 to 1.04). However, in the anakinra + MTX versus placebo + MTX subgroup, there was a significant difference in the total adverse events (RR 1.11; 95% CI 1.03 to 1.20). Injection site reactions occurred significantly higher in the anakinra 50 to 150 mg/day (71%) versus placebo (28%) groups (RR 2.45; 95% CI 2.17 to 2.77) and were significantly higher in both subgroups.</P>
<P>Serious adverse events were presented in the <LINK REF="STD-Fleischman-2003" TYPE="STUDY">Fleischman 2003</LINK> and <LINK REF="STD-Cohen-2004" TYPE="STUDY">Cohen 2004</LINK> studies. Definition for serious adverse events were not provided by <LINK REF="STD-Fleischman-2003" TYPE="STUDY">Fleischman 2003</LINK> though <LINK REF="STD-Cohen-2004" TYPE="STUDY">Cohen 2004</LINK> defined these as adverse events that required hospitalization, resulted in persistent disability, or were life-threatening in nature. In the analysis of serious adverse events, there was no significant difference between anakinra 50 to 150 mg/day versus placebo groups (7% versus 6%, RR 1.04; 95% CI 0.70 to 1.56). Malignancy data was reported in the <LINK REF="STD-Fleischman-2003" TYPE="STUDY">Fleischman 2003</LINK> study - noting five malignancies (1.8%) in the placebo group versus four malignancies (0.4%) in the anakinra group. The <LINK REF="STD-Cohen-2002" TYPE="STUDY">Cohen 2002</LINK> study reported one malignancy each in anakinra (0.8%; 1/131) and placebo group (1.4%; 1/74).</P>
<P>The <LINK REF="STD-Genovese-2004" TYPE="STUDY">Genovese 2004</LINK> study demonstrated no difference in the total number of adverse events (RR 1.04; 95% CI 0.95 to 1.14) though there was a significant increase in the number of serious adverse events (RR 5.93; 95% CI 1.37 to 25.64) when anakinra was compared to control. Only one malignancy was reported in the anakinra + etanercept group (1.3%) in this study, versus none in the etanercept + placebo group (0%). There was a significant increase in injection site reactions with anakinra versus control (RR 1.76; 95% CI 1.30 to 2.38).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Infections</HEADING>
<P>The total number of infections was not significantly different between anakinra 50 to 150 mg/day and placebo treated patients after 24 weeks, occurring in 40% and 35% patients respectively (RR 1.08; 95% CI 0.80 to 1.45). Data on the number of serious infections were provided in the studies by <LINK REF="STD-Cohen-2004" TYPE="STUDY">Cohen 2004</LINK> and <LINK REF="STD-Fleischman-2003" TYPE="STUDY">Fleischman 2003</LINK>. Definitions for serious infections were not specified by either study. There was no significant difference between patients receiving anakinra 50 to 150 mg/day versus placebo, occurring in 1.8% versus 0.6% of patients (RR 3.15; 95% CI 0.81 to 12.20).</P>
<P>The types of serious infections were not presented in the <LINK REF="STD-Cohen-2004" TYPE="STUDY">Cohen 2004</LINK> study. In the <LINK REF="STD-Fleischman-2003" TYPE="STUDY">Fleischman 2003</LINK> study, of the 24 'serious' infections reported, 23 occurred in anakinra group (n = 1116) and 1 in placebo (n = 283). The most common were pneumonia in 10 patients and cellulitis in three patients. There was no difference in the total number of infections or serious infections within each subgroup of anakinra + placebo (without MTX) and anakinra + MTX versus placebo + MTX.</P>
<P>The <LINK REF="STD-Genovese-2004" TYPE="STUDY">Genovese 2004</LINK> study demonstrated no significant difference in either total infections (RR 1.17; 95% CI 0.82 to 1.67) or serious infections (RR 12.84; 95% CI 0.74 to 224.23) after 24 weeks of therapy as well. There were six serious infections in the anakinra + etanercept group, of which they were clarified to two with serious pneumonia and two with serious cellulitis. No opportunistic infections were reported in this study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Other</HEADING>
<P>None of the included studies reported opportunistic infections (including tuberculosis etc.), congestive heart failure or demyelinating syndromes.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-11-11 22:49:59 -0500" MODIFIED_BY="[Empty name]">
<P>This review had several limitations. Foremost, there was a significant variability among the included studies with the specific outcomes measured, limiting the power of our systematic review. For example, <LINK REF="STD-Fleischman-2003" TYPE="STUDY">Fleischman 2003</LINK> only included safety outcomes in its study and <LINK REF="STD-Bresnihan-1998" TYPE="STUDY">Bresnihan 1998</LINK> did not include ACR50 or ACR70 data. Also, there was significant variability in the doses of anakinra used in <LINK REF="STD-Bresnihan-1998" TYPE="STUDY">Bresnihan 1998</LINK> and <LINK REF="STD-Cohen-2002" TYPE="STUDY">Cohen 2002</LINK> from the current standard dose of 100 mg daily. We divided the pooled data to those utilizing &lt; 50 mg/day and 50 to 150 mg/day of anakinra based on clinical relevance to allow for data analysis. However, we were unable to examine for possible differences between individual doses of anakinra due to the limited number of studies. The lack of reporting of standard deviation/error data in the <LINK REF="STD-Cohen-2002" TYPE="STUDY">Cohen 2002</LINK> study prevented inclusion in analysis of continuous outcomes, further limiting the power of these outcomes in our systematic review.</P>
<P>With the removal of the <LINK REF="STD-Genovese-2004" TYPE="STUDY">Genovese 2004</LINK> study, significant heterogeneity remained with change in HAQ score, the total number of adverse events, and total number of infections. Explanations likely include the small number of studies involved as well as possible differing definitions for adverse events and infections within each of these studies. Only <LINK REF="STD-Genovese-2004" TYPE="STUDY">Genovese 2004</LINK> specified a specific definition for adverse events of the included studies. Another explanation may be that one of the included studies, <LINK REF="STD-Fleischman-2003" TYPE="STUDY">Fleischman 2003</LINK>, had a sample size much larger than other studies, thus likely impacting the overall outcomes far greater than other smaller studies.</P>
<P>While the studies were adequate as randomized controlled trials, the method of randomization was not reported in any study and a number did not report full blinding. None of the studies except for <LINK REF="STD-Cohen-2002" TYPE="STUDY">Cohen 2002</LINK> described a true intention-to-treat analysis. All studies except for <LINK REF="STD-Cohen-2002" TYPE="STUDY">Cohen 2002</LINK> excluded patients from analysis if they did not receive at least one dose of a study drug (excluding a total of 30 patients). <LINK REF="STD-Bresnihan-1998" TYPE="STUDY">Bresnihan 1998</LINK> did not include patients with missing data for respective outcomes. This introduces significant bias, especially for Larsen scores, since 129 patients were excluded from the analysis.</P>
<P>This review systematically analyzed the efficacy and safety data from five randomized-controlled trials of anakinra, involving 2876 participants, divided among 781 randomized to placebo and 2065 to anakinra. At 24 weeks of therapy, there was a significant improvement in the number of participants achieving ACR20 (the primary outcome for this review) who were treated with anakinra 50 to 150 mg daily versus placebo (38% versus 23%). The absolute treatment benefit was 15% with a NNTB of 8 for treatment with anakinra versus placebo. Other efficacy data - including ACR50, ACR70, HAQ, VAS, Larsen radiographic scores, and change in ESR - all demonstrated significant improvement with anakinra 50 to150 mg daily versus placebo as well. In subgroup analysis, improvement was noted for both studies comparing anakinra/placebo and anakinra/placebo + MTX in ACR20 outcomes as well. The two studies that utilized doses &lt; 50 mg/day demonstrated significant improvements in ACR20, HAQ, Larsen score, and inflammatory markers in anakinra versus placebo. The <LINK REF="STD-Genovese-2004" TYPE="STUDY">Genovese 2004</LINK> study demonstrated no significant improvement in any outcome data (ACR20, ACR50, or ACR70) in its evaluation of anakinra + etanercept + MTX versus placebo + etanercept + MTX.</P>
<P>When compared to other Cochrane reviews of biologic therapies for rheumatoid arthritis - specifically etanercept, infliximab, and adalimumab, the absolute benefit of treatment versus placebo for the proportion achieving ACR20, ACR50, and ACR70 was notably lower. With etanercept 25 mg biweekly, there was a 49%, 39%, and 14% absolute treatment benefit over placebo for ACR20, ACR50, and ACR70, respectively, after six months (<LINK REF="REF-Blumenauer-2003" TYPE="REFERENCE">Blumenauer 2003</LINK>). With adalimumab 40 mg every other week, there were ranges of 18 to 53%, 18 to 47%, and 10 to 22% absolute treatment benefits over placebo for ACR20, ACR50, and ACR70 after 24 weeks (heterogeneity prevented pooling of RCTs for adalimumab) (<LINK REF="REF-Navarro_x002d_Sarabia-2005" TYPE="REFERENCE">Navarro-Sarabia 2005</LINK>). With infliximab 3 mg/kg IV every eight weeks, there was a 33%, 21%, and 8% absolute treatment benefit over placebo for ACR20, ACR50, and ACR70, respectively, after six months (<LINK REF="REF-Blumenauer-2002" TYPE="REFERENCE">Blumenauer 2002</LINK>). In comparison, the absolute treatment benefits with anakinra 50 to 150 mg daily after 6 months were 15%, 11%, and 5% over placebo for ACR20, ACR50, and ACR70 respectively. For each of these outcomes, there was a notably lower level of improvement than the above biologics.</P>
<P>The analysis of safety data for anakinra revealed no statistically significant differences between anakinra versus placebo groups for the total number of withdrawals, deaths, adverse events (total and serious), and infections (total and serious). While the difference between serious infection rates between anakinra and placebo - 1.8% versus 0.6% - was not statistically significantly different, the relative difference of 3.15 may be clinically significant. This may be secondary to the lack of power of the included studies where larger populations may demonstrate statistical significance. Larger registry-based post-marketing study would likely be helpful to clarify this risk as well. Opportunistic infections were not reported in any of the included studies. Injection site reactions were noted to be significantly increased in patients treated with anakinra versus placebo - occurring in 71% versus 28% of patients respectively, with a number needed to harm of 2.3.</P>
<P>On subgroup analysis, the total number of adverse events was significantly increased with the anakinra/placebo + MTX group, raising some clinical concern for the use of these medications together. Malignancy rates were generally rare and without notable difference between anakinra and placebo groups of the included studies. However, post-marketing analysis would likely be more helpful to evaluate the risk of malignancy or other rare serious adverse events that may be associated with anakinra.</P>
<P>The <LINK REF="STD-Genovese-2004" TYPE="STUDY">Genovese 2004</LINK> study did demonstrate significant increases in the number of withdrawals, injection site reactions, and serious adverse events, likely indicating the poor tolerability and increased risks associated with combining biologic therapies. With the observation of a lack of significant improvement in clinical outcomes noted in this study, we conclude that the use of a combination of biologic medications with anakinra should be avoided in treatment of rheumatoid arthritis.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2008-11-09 20:31:48 -0500" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2008-11-09 20:31:48 -0500" MODIFIED_BY="[Empty name]">
<P>Anakinra is currently FDA approved for the treatment of rheumatoid arthritis that is unresponsive to initial DMARD therapy. This review demonstrated significant improvement in the primary outcome of ACR20, as well as a number of other efficacy outcomes - including ACR50, ACR70, HAQ scores, VAS scores, and ESR - in those treated with anakinra versus placebo. When compared to other biologics for RA - specifically adalimumab, infliximab, and etanercept - the absolute treatment benefit seen versus placebo in ACR20, ACR50, ACR70 was notably larger than the treatment benefit with anakinra. There was no statistically significant increase in the number of adverse events (total or serious) or infections (total or serious) with anakinra versus placebo. Injection site reactions were significantly more common with anakinra versus placebo. The relative increase in serious infections was statistically insignificant, but may be clinically significant. There was no significant difference in number of withdrawals between anakinra versus placebo.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2008-10-21 21:46:03 -0400" MODIFIED_BY="[Empty name]">
<P>Limited data are available for safety of anakinra and post-marketing surveillance studies are needed to better inform patients and physicians. Studies comparing anakinra to other traditional DMARDs or other biologics may also be helpful to inform physicians about relative efficacies of these agents for treatment of RA.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We thank Louise Falzon for her support with electronic searches.<BR/>We thank Rod MacDonald for his efforts in assisting with this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2008-11-11 22:50:26 -0500" MODIFIED_BY="[Empty name]">
<P>All review authors contributed to the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-11-11 22:55:20 -0500" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2008-11-11 22:54:43 -0500" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2008-11-09 20:43:10 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Bresnihan-1998" MODIFIED="2008-10-21 22:19:04 -0400" MODIFIED_BY="[Empty name]" NAME="Bresnihan 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-10-21 21:58:34 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, et al</AU>
<TI>Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>1998</YR>
<VL>41</VL>
<NO>12</NO>
<PG>2196-204</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohen-2002" MODIFIED="2008-10-21 22:19:10 -0400" MODIFIED_BY="[Empty name]" NAME="Cohen 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-10-21 21:58:47 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, et al</AU>
<TI>Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>2002</YR>
<VL>46</VL>
<NO>3</NO>
<PG>614-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohen-2004" MODIFIED="2008-10-21 22:19:15 -0400" MODIFIED_BY="[Empty name]" NAME="Cohen 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-10-21 21:59:03 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cohen SB, Moreland LW, Cush JJ, Greenwald MW, Block S, Shergy WJ, et al</AU>
<TI>A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2004</YR>
<VL>63</VL>
<NO>9</NO>
<PG>1062-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fleischman-2003" MODIFIED="2008-11-09 20:38:42 -0500" MODIFIED_BY="[Empty name]" NAME="Fleischman 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-11-09 20:38:42 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fleischmann RM, Schechtman J, Bennet R, Handel ML, Burmeister GR, Tesser J, et al</AU>
<TI>Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>2003</YR>
<VL>48</VL>
<NO>4</NO>
<PG>927-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Genovese-2004" MODIFIED="2008-11-09 20:43:10 -0500" MODIFIED_BY="[Empty name]" NAME="Genovese 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-11-09 20:43:10 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Genovese MC, Cohen S , Moreland L, Lium D, Robbins S, Newmark R, et al</AU>
<TI>Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>2004</YR>
<VL>50</VL>
<NO>5</NO>
<PG>1412-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-11-11 22:54:43 -0500" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-AMGEN-FDA-2001" MODIFIED="2008-11-11 22:52:06 -0500" MODIFIED_BY="[Empty name]" NAME="AMGEN FDA 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-11-11 22:52:06 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;from Reinte, 2004&lt;/p&gt;" NOTES_MODIFIED="2008-11-11 22:52:06 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Amgen, Inc</AU>
<TI>Anakinra FDA briefing information</TI>
<SO>www.fda.gov/ohrms/dockets/ac/01/briefing/3779bI.htm</SO>
<YR>8/21/2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bresnihan-2001" MODIFIED="2008-10-21 22:13:11 -0400" MODIFIED_BY="[Empty name]" NAME="Bresnihan 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-10-21 22:00:04 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Excluded as Review&lt;/p&gt;" NOTES_MODIFIED="2008-10-21 22:00:04 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bresnihan B</AU>
<TI>The safety and efficacy of interleukin-1 receptor antagonist in the treatment of rheumatoid arthritis</TI>
<SO>Seminars in Arthritis &amp; Rheumatism</SO>
<YR>2001</YR>
<VL>30</VL>
<NO>5 Suppl 2</NO>
<PG>17-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bresnihan-2002" MODIFIED="2008-11-11 22:52:27 -0500" MODIFIED_BY="[Empty name]" NAME="Bresnihan 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-11-11 22:52:27 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Excluded as review&lt;/p&gt;" NOTES_MODIFIED="2008-11-11 22:52:27 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bresnihan B</AU>
<TI>Effects of anakinra on clinical and radiological outcomes in rheumatoid arthritis</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2002</YR>
<VL>61</VL>
<NO>Suppl 2</NO>
<PG>ii74 - 7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bresnihan-2002b" MODIFIED="2008-11-09 20:36:50 -0500" MODIFIED_BY="[Empty name]" NAME="Bresnihan 2002b" YEAR="2002">
<REFERENCE MODIFIED="2008-11-09 20:36:50 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Excluded as Review&lt;/p&gt;" NOTES_MODIFIED="2008-11-09 20:36:50 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bresnihan B</AU>
<TI>Anakinra as a new therapeutic option in rheumatoid arthritis: clinical results and perspectives</TI>
<SO>Clinical &amp; Experimental Rheumatology</SO>
<YR>2002</YR>
<VL>20</VL>
<NO>5 Suppl 27</NO>
<PG>S32 - 4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bresnihan-2004" MODIFIED="2008-10-21 22:13:43 -0400" MODIFIED_BY="[Empty name]" NAME="Bresnihan 2004" YEAR="">
<REFERENCE MODIFIED="2008-10-21 22:00:41 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Excluded - no placebo arm with extension of Bresnihan 1998&lt;/p&gt;" NOTES_MODIFIED="2008-10-21 22:00:41 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bresnihan B, Newmark R, Robbins S, Genant HK, Bresnihan B, Newmark R, et al</AU>
<TI>Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-controlled trial</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>2004</YR>
<VL>31</VL>
<NO>6</NO>
<PG>1103-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Burls-2004" MODIFIED="2008-11-09 20:46:18 -0500" MODIFIED_BY="[Empty name]" NAME="Burls 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-11-09 20:46:18 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Excluded as editorial&lt;/p&gt;" NOTES_MODIFIED="2008-11-09 20:46:18 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burls A, Jobanputra P</AU>
<TI>The trials of anakinra</TI>
<SO>Lancet</SO>
<YR>2004</YR>
<VL>364</VL>
<PG>827-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Calabrese-2002" MODIFIED="2008-11-09 20:37:06 -0500" MODIFIED_BY="[Empty name]" NAME="Calabrese 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-11-09 20:37:06 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;from Riente, 2004&lt;/p&gt;" NOTES_MODIFIED="2008-11-09 20:37:06 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Calabrese LH</AU>
<TI>Anakinra treatment of patient with rheumatoid arthritis</TI>
<SO>Annals of Pharmacotherapy</SO>
<YR>2002</YR>
<VL>36</VL>
<PG>1204-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Campion-1996" MODIFIED="2008-11-09 20:37:24 -0500" MODIFIED_BY="[Empty name]" NAME="Campion 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-11-09 20:37:24 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Excluded as no placebo arm&lt;/p&gt;" NOTES_MODIFIED="2008-11-09 20:37:24 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Campion GV, Lebsack ME, Lookabaugh J, Gordon G, Catalano M</AU>
<TI>Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>1996</YR>
<VL>39</VL>
<NO>7</NO>
<PG>1092-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Choy-2005" MODIFIED="2008-11-09 20:37:36 -0500" MODIFIED_BY="[Empty name]" NAME="Choy 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-11-09 20:37:36 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Excluded as meta-analysis (broad)&lt;/p&gt;" NOTES_MODIFIED="2008-11-09 20:37:36 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Choy EHS, Smith C, Dore CJ, Scott DL</AU>
<TI>A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal</TI>
<SO>Rheumatology</SO>
<YR>2005</YR>
<VL>44</VL>
<NO>11</NO>
<PG>1414 - 21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohen-2003" MODIFIED="2008-10-21 22:13:54 -0400" MODIFIED_BY="[Empty name]" NAME="Cohen 2003" YEAR="2003">
<REFERENCE NOTES="&lt;p&gt;Excluded as duplicate study of Cohen 2002&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cohen, S. B., J. M. Woolley, Chan W, Anakinra 960180 Study G</AU>
<TI>Interleukin 1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis</TI>
<SO>Journal of Rheumatology</SO>
<YR>2003</YR>
<VL>30</VL>
<NO>2</NO>
<PG>225-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cohen-2004b" MODIFIED="2008-11-09 20:38:08 -0500" MODIFIED_BY="[Empty name]" NAME="Cohen 2004b" YEAR="2004">
<REFERENCE MODIFIED="2008-11-09 20:38:08 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Excluded as Review&lt;/p&gt;" NOTES_MODIFIED="2008-11-09 20:38:08 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cohen SB, Strand V, Aguilar D, Ofman JJ</AU>
<TI>Patient- versus physician-reported outcomes in rheumatoid arthritis patients treated with recombinant interleukin-1 receptor antagonist (anakinra) therapy</TI>
<SO>Rheumatology</SO>
<YR>2004</YR>
<VL>43</VL>
<NO>6</NO>
<PG>704-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-La-Mata-2007" MODIFIED="2008-11-09 20:38:30 -0500" MODIFIED_BY="[Empty name]" NAME="De La Mata 2007" YEAR="2007">
<REFERENCE MODIFIED="2008-11-09 20:38:30 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Excluded = systematic review of Anakinra&lt;/p&gt;" NOTES_MODIFIED="2008-11-09 20:38:30 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De La Mata Llord J, Crespo RG, Manzano JM</AU>
<TI>Treatment of rheumatoid arthritis with anakinra: A systematic review</TI>
<SO>Reumatologia Clinica</SO>
<YR>2007</YR>
<VL>3</VL>
<NO>4</NO>
<PG>153-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dinarello-2005" MODIFIED="2008-11-09 20:39:23 -0500" MODIFIED_BY="[Empty name]" NAME="Dinarello 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-11-09 20:39:23 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Excluded as review&lt;/p&gt;" NOTES_MODIFIED="2008-11-09 20:39:23 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dinarello CA</AU>
<TI>The many worlds of reducing interleukin-1</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>2005</YR>
<VL>52</VL>
<NO>7</NO>
<PG>1960-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dougados-1992" MODIFIED="2008-10-21 22:08:30 -0400" MODIFIED_BY="[Empty name]" NAME="Dougados 1992" YEAR="1992">
<REFERENCE MODIFIED="2008-10-21 22:02:18 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Excluded - not recombinant IL-1 antagonist&lt;/p&gt;" NOTES_MODIFIED="2008-10-21 22:02:18 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dougados M, Combe B, Beveridge T, Bourdeix I, Lallemand A, Amor B, et al</AU>
<TI>IX 207-887 in rheumatoid arthritis</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>1992</YR>
<VL>35</VL>
<NO>9</NO>
<PG>999-1006</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Drevlow-1996" MODIFIED="2008-10-21 22:02:51 -0400" MODIFIED_BY="[Empty name]" NAME="Drevlow 1996" YEAR="1996">
<REFERENCE MODIFIED="2008-10-21 22:02:51 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Drevlow BE, Lovis R, Haag MA, Sinacore JM, Jacobs C, Blosche C, et al</AU>
<TI>Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>1996</YR>
<VL>39</VL>
<NO>2</NO>
<PG>257-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fleischmann-2002" MODIFIED="2008-11-11 22:52:52 -0500" MODIFIED_BY="[Empty name]" NAME="Fleischmann 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-11-11 22:52:52 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Excluded as review&lt;/p&gt;" NOTES_MODIFIED="2008-11-11 22:52:52 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fleishmann RM</AU>
<TI>Safety of anakinra, a recombinant interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis and comparison to anti-TNF-alpha agents</TI>
<SO>Clinical &amp; Experimental Rheumatology</SO>
<YR>2002</YR>
<VL>20</VL>
<NO>5 Suppl 27</NO>
<PG>S35-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fleischmann-2006" MODIFIED="2008-11-11 22:53:37 -0500" MODIFIED_BY="[Empty name]" NAME="Fleischmann 2006" YEAR="2006">
<REFERENCE MODIFIED="2008-11-11 22:53:37 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Excluded as open label followup study&lt;/p&gt;" NOTES_MODIFIED="2008-11-11 22:53:37 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fleischmann RM, Tesser J, et al</AU>
<TI>Safety of extended treatment with anakinra in patients with rheumatoid arthritis</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2006</YR>
<VL>65</VL>
<NO>8</NO>
<PG>1006-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garces-2001" MODIFIED="2008-10-21 22:08:18 -0400" MODIFIED_BY="[Empty name]" NAME="Garces 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-10-21 22:03:28 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Excluded - review of Anakinra treatment for RA&lt;/p&gt;" NOTES_MODIFIED="2008-10-21 22:03:28 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garces K</AU>
<TI>Anakinra: interleukin-1 receptor antagonist therapy for rheumatoid arthritis</TI>
<SO>Issues in Emerging Health Technologies</SO>
<YR>2001</YR>
<VL>16</VL>
<PG>1-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garrood-2001" MODIFIED="2008-11-09 20:40:03 -0500" MODIFIED_BY="[Empty name]" NAME="Garrood 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-11-09 20:40:03 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Excluded as Review&lt;/p&gt;" NOTES_MODIFIED="2008-11-09 20:40:03 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garrood T, Scott DL</AU>
<TI>Combination therapy with disease modifying anti-rheumatic drugs in rheumatoid arthritis</TI>
<SO>Biodrugs</SO>
<YR>2001</YR>
<VL>15</VL>
<NO>8</NO>
<PG>543-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Genant-2001" MODIFIED="2008-10-21 22:08:07 -0400" MODIFIED_BY="[Empty name]" NAME="Genant 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Excluded as post-hoc analysis of Jiang et. al&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Genant, H. K</AU>
<TI>Interleukin-1 receptor antagonist treatment of rheumatoid arthritis patients: radiologic progression and correlation of Genant/Sharp and Larsen scoring methods</TI>
<SO>Seminars in Arthritis &amp; Rheumatism</SO>
<YR>2001</YR>
<VL>30</VL>
<NO>5, suppl 2</NO>
<PG>26-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haraoui-2003" MODIFIED="2008-10-21 22:08:01 -0400" MODIFIED_BY="[Empty name]" NAME="Haraoui 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-10-21 22:04:06 -0400" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haraoui B, Keystone EC.</AU>
<TI>Anakinra, a new pharmacotherapeutic approach to treating rheumatoid arthritis</TI>
<SO>Today's Therapeutic Trends</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>1</NO>
<PG>49-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jiang-2000" MODIFIED="2008-11-11 22:54:11 -0500" MODIFIED_BY="[Empty name]" NAME="Jiang 2000" YEAR="2000">
<REFERENCE MODIFIED="2008-11-11 22:54:11 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Excluded as post-hoc re-evaluation of Bresnihan, 1998&lt;/p&gt;" NOTES_MODIFIED="2008-11-11 22:54:11 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jiang Y, Genant HK, Watt I, Cobby M, Bresnihan B, Aitchison R, McCabe D</AU>
<TI>A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>2000</YR>
<VL>43</VL>
<NO>5</NO>
<PG>1001-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jones-2003" MODIFIED="2008-11-09 20:40:19 -0500" MODIFIED_BY="[Empty name]" NAME="Jones 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-11-09 20:40:19 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Excluded as review (only 1 anakinra)&lt;/p&gt;" NOTES_MODIFIED="2008-11-09 20:40:19 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jones G, Halbert J, Crotty M, Shanahan EM, Batterham M, Ahern M</AU>
<TI>The effect of treatment on radiological progression in rheumatoid arthritis: a systematic review of randomized placebo-controlled trials</TI>
<SO>Rheumatology</SO>
<YR>2003</YR>
<VL>42</VL>
<NO>1</NO>
<PG>6-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Loft-2003" MODIFIED="2008-11-09 20:41:16 -0500" MODIFIED_BY="[Empty name]" NAME="Loft 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-11-09 20:41:16 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Excluded as review&lt;/p&gt;" NOTES_MODIFIED="2008-11-09 20:41:16 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Loft AG, Tarp U, Thomsen BS, Loft AGR, Tarp U, Thomsen BS</AU>
<TI>[Anakinra in the treatment of rheumatoid arthritis]</TI>
<SO>Ugeskrift for Laeger</SO>
<YR>2003</YR>
<VL>165</VL>
<NO>39</NO>
<PG>3720-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-National-Horizon-2001" MODIFIED="2008-10-21 22:07:39 -0400" MODIFIED_BY="[Empty name]" NAME="National Horizon 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Excluded as review&lt;/p&gt;" PRIMARY="NO" TYPE="OTHER">
<AU>National Horizon Scanning Centre</AU>
<TI>Anakinra for rheumatoid arthritis - horizon scanning review</TI>
<SO>Birmingham: National Horizon Scanning Centre</SO>
<YR>2001</YR>
<VL>4</VL>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nixon-2007" MODIFIED="2008-11-09 20:41:06 -0500" MODIFIED_BY="[Empty name]" NAME="Nixon 2007" YEAR="2007">
<REFERENCE MODIFIED="2008-11-09 20:41:06 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nixon R, Bansback N, Brennan A</AU>
<TI>The efficacy of inhibiting tumour necrosis factor alpha and interleukin 1 in patients with rheumatoid arthritis: a meta-analysis and adjusted indirect comparisons</TI>
<SO>Rheumatology</SO>
<YR>2007</YR>
<VL>46</VL>
<NO>7</NO>
<PG>1140-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nuki-2002" MODIFIED="2008-11-09 20:40:51 -0500" MODIFIED_BY="[Empty name]" NAME="Nuki 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-11-09 20:40:51 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Excluded as follow-up of Bresnihan 1998 with no placebo arm&lt;/p&gt;" NOTES_MODIFIED="2008-11-09 20:40:51 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nuki G, Bresnihan B, Bear MB, McCabe D, European Group Of Clinical I, Nuki G, et al</AU>
<TI>Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>2002</YR>
<VL>46</VL>
<NO>11</NO>
<PG>2838-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Paget-2002" MODIFIED="2008-10-21 22:07:12 -0400" MODIFIED_BY="[Empty name]" NAME="Paget 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paget SA</AU>
<TI>Efficacy of anakinra in bone: comparison to other biologics</TI>
<SO>Advances in Therapy</SO>
<YR>2002</YR>
<VL>19</VL>
<NO>1</NO>
<PG>27-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rau-1998" MODIFIED="2008-10-21 22:06:52 -0400" MODIFIED_BY="[Empty name]" NAME="Rau 1998" YEAR="1998">
<REFERENCE MODIFIED="2008-10-21 22:06:21 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Excluded - same study as Bresnihan 1998&lt;/p&gt;" NOTES_MODIFIED="2008-10-21 22:06:21 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rau R, Sander O, Musikic P</AU>
<TI>[Treatment of chronic polyarthritis with a human recombinant interleukin 1 receptor antagonist]</TI>
<SO>Zeitschrift fur Rheumatologie</SO>
<YR>1998</YR>
<VL>57</VL>
<NO>5</NO>
<PG>312-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rau-2003" MODIFIED="2008-11-11 22:54:43 -0500" MODIFIED_BY="[Empty name]" NAME="Rau 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-11-11 22:54:43 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Excluded as Case report&lt;/p&gt;" NOTES_MODIFIED="2008-11-11 22:54:43 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rau R, Sander O, Wassenberg S</AU>
<TI>Erosion healing in rheumatoid arthritis after anakinra treatment</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2003</YR>
<VL>62</VL>
<NO>7</NO>
<PG>671-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Riente-2004" MODIFIED="2008-10-21 22:14:50 -0400" MODIFIED_BY="[Empty name]" NAME="Riente 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-10-21 22:14:50 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Excluded as review&lt;/p&gt;" NOTES_MODIFIED="2008-10-21 22:14:50 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Riente, L</AU>
<TI>The safety of interleukin-1 receptor antagonist (anakinra) in the treatment of rheumatoid arthritis. [Italian]</TI>
<SO>Reumatismo</SO>
<YR>2004</YR>
<VL>56</VL>
<NO>1, suppl 1</NO>
<PG>74-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schiff-2004" MODIFIED="2008-10-21 22:15:17 -0400" MODIFIED_BY="[Empty name]" NAME="Schiff 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-10-21 22:15:17 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Excluded as duplicate study to Fleischmann 2003&lt;/p&gt;" NOTES_MODIFIED="2008-10-21 22:15:17 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schiff MH, DiVittorio G, Tesser J, Fleischmann R, Schechtman J, Hartman S, et al</AU>
<TI>The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditions</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>2004</YR>
<VL>50</VL>
<NO>6</NO>
<PG>1752-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schwetz-2002" MODIFIED="2008-10-21 22:15:45 -0400" MODIFIED_BY="[Empty name]" NAME="Schwetz 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-10-21 22:15:45 -0400" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Excluded as not with Anakinra&lt;/p&gt;" NOTES_MODIFIED="2008-10-21 22:15:45 -0400" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schwetz BA</AU>
<TI>From the Food and Drug Administration</TI>
<SO>JAMA</SO>
<YR>2002</YR>
<VL>287</VL>
<NO>1</NO>
<PG>33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Strand-2002" MODIFIED="2008-11-09 20:45:36 -0500" MODIFIED_BY="[Empty name]" NAME="Strand 2002" YEAR="2002">
<REFERENCE MODIFIED="2008-11-09 20:45:36 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Excluded as review&lt;/p&gt;" NOTES_MODIFIED="2008-11-09 20:45:36 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Strand V, Landewe R, Van der Heijde D</AU>
<TI>Using estimated yearly progression rates to compare radiographic data across recent randomised controlled trials in rheumatoid arthritis</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2002</YR>
<VL>61</VL>
<NO>Suppl 2</NO>
<PG>ii64-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Strand-2004" MODIFIED="2008-11-09 20:45:24 -0500" MODIFIED_BY="[Empty name]" NAME="Strand 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-11-09 20:45:24 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Excluded - review of DMARD therapy on radiographic changes&lt;/p&gt;" NOTES_MODIFIED="2008-11-09 20:45:24 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Strand V</AU>
<TI>Longer term benefits of treating rheumatoid arthritis: Assessment of radiographic damage and physical function in clinical trials</TI>
<SO>Clinical and Experimental Rheumatology</SO>
<YR>2004</YR>
<VL>22</VL>
<NO>5 Suppl 35</NO>
<PG>S57-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tesser-2004" MODIFIED="2008-11-09 20:42:11 -0500" MODIFIED_BY="[Empty name]" NAME="Tesser 2004" YEAR="2004">
<REFERENCE MODIFIED="2008-11-09 20:42:11 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Excluded as equivalent study to Fleischman, 2003&lt;/p&gt;" NOTES_MODIFIED="2008-11-09 20:42:11 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tesser J, Fleischmann R, Dore R, Bennett R, Solinger A, Joh T, Modafferi D, Schechtman J</AU>
<TI>Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis</TI>
<SO>Journal of Rheumatology</SO>
<YR>2004</YR>
<VL>31</VL>
<NO>4</NO>
<PG>649-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tomoo-2005" MODIFIED="2008-11-09 20:48:14 -0500" MODIFIED_BY="[Empty name]" NAME="Tomoo 2005" YEAR="2005">
<REFERENCE MODIFIED="2008-11-09 20:48:14 -0500" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tomoo T, Sumida T, et al</AU>
<TI>"[Anakinra for therapy of rheumatoid arthritis]</TI>
<SO>Nippon Rinsho - Japanese Journal of Clinical Medicine</SO>
<YR>2005</YR>
<VL>63</VL>
<NO>Suppl 1</NO>
<PG>534-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Watt-2001" MODIFIED="2008-11-09 20:49:21 -0500" MODIFIED_BY="[Empty name]" NAME="Watt 2001" YEAR="2001">
<REFERENCE MODIFIED="2008-11-09 20:49:21 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Excluded as Editorial document on Bresnihan 1998&lt;/p&gt;" NOTES_MODIFIED="2008-11-09 20:49:21 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Watt I, Cobby M</AU>
<TI>Treatment of rheumatoid arthritis patients with interleukin-1 receptor antagonist: radiologic assessment</TI>
<SO>Seminars in Arthritis &amp; Rheumatism</SO>
<YR>2001</YR>
<VL>30</VL>
<NO>5 suppl 2</NO>
<PG>21-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zundorf-2003" MODIFIED="2008-11-09 20:42:40 -0500" MODIFIED_BY="[Empty name]" NAME="Zundorf 2003" YEAR="2003">
<REFERENCE MODIFIED="2008-11-09 20:42:40 -0500" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Excluded - as review of Biologics&lt;/p&gt;" NOTES_MODIFIED="2008-11-09 20:42:40 -0500" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zundorf I, Dingermann T, Zundorf I, Dingermann T</AU>
<TI>[Kineret, Enbrel, Remicade and company. Recombinant drugs in rheumatoid arthritis]</TI>
<SO>Pharmazie in Unserer Zeit</SO>
<YR>2003</YR>
<VL>32</VL>
<NO>5</NO>
<PG>376-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-11-11 22:55:20 -0500" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-11-11 22:55:20 -0500" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Abramson-2002" MODIFIED="2008-10-29 05:56:06 -0400" MODIFIED_BY="[Empty name]" NAME="Abramson 2002" TYPE="JOURNAL_ARTICLE">
<AU>Abramson SB, Amin A</AU>
<TI>Blocking the effects of IL-1 in rheumatoid arthritis protects bone and cartilage</TI>
<SO>Rheumatology</SO>
<YR>2002</YR>
<VL>41</VL>
<PG>972-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ACR-2002" MODIFIED="2008-10-29 05:56:06 -0400" MODIFIED_BY="[Empty name]" NAME="ACR 2002" TYPE="JOURNAL_ARTICLE">
<AU>American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines</AU>
<TI>Guidelines for the management of rheumatoid arthritis: 2002 update</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>2002</YR>
<VL>46</VL>
<NO>2</NO>
<PG>328-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Arnett-1988" MODIFIED="2008-10-29 05:56:06 -0400" MODIFIED_BY="[Empty name]" NAME="Arnett 1988" TYPE="JOURNAL_ARTICLE">
<AU>Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al</AU>
<TI>The American Rheumatism Association revised criteria for the classification of rheumatoid arthritis</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1988</YR>
<VL>31</VL>
<PG>315-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Blumenauer-2002" MODIFIED="2008-11-09 20:34:36 -0500" MODIFIED_BY="[Empty name]" NAME="Blumenauer 2002" TYPE="COCHRANE_REVIEW">
<AU>Blumenauer B, Judd M, Wells G, Burls A, Cranney A, Hochberg M, et al</AU>
<TI>Infliximab for the treatment of rheumatoid arthritis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2008-10-21 19:17:14 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-21 19:17:14 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003785  "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Blumenauer-2003" MODIFIED="2008-11-09 20:50:05 -0500" MODIFIED_BY="[Empty name]" NAME="Blumenauer 2003" TYPE="COCHRANE_REVIEW">
<AU>Blumenauer B, Judd M, Cranney A, Burls A, Coyle D, Hochberg M, et al</AU>
<TI>Etanercept for the treatment of rheumatoid arthritis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2008-10-21 19:18:12 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-21 19:18:12 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004525"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-FDA-2003" MODIFIED="2008-10-29 05:56:06 -0400" MODIFIED_BY="[Empty name]" NAME="FDA 2003" TYPE="COMPUTER_PROGRAM">
<AU>FDA website</AU>
<TI>Product approval information: Anakinra</TI>
<YR>2003</YR>
<PB>www.fda.gov</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Felson-1995" MODIFIED="2008-11-09 20:35:27 -0500" MODIFIED_BY="[Empty name]" NAME="Felson 1995" TYPE="JOURNAL_ARTICLE">
<AU>Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al</AU>
<TI>American college of rheumatology preliminary definition of improvement in rheumatoid arthritis</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>1995</YR>
<VL>38</VL>
<NO>6</NO>
<PG>727-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Felson-2007" MODIFIED="2008-11-09 20:35:42 -0500" MODIFIED_BY="[Empty name]" NAME="Felson 2007" TYPE="JOURNAL_ARTICLE">
<AU>Felson, American College of Rheumatology Committee to Reevaluate Improvement Criteria</AU>
<TI>A Proposed Revision to the ACR20: The Hybrid Measure of American College of Rheumatology Response</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>2007</YR>
<VL>57</VL>
<NO>2</NO>
<PG>193-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fransen-2005" MODIFIED="2008-10-29 05:56:06 -0400" MODIFIED_BY="[Empty name]" NAME="Fransen 2005" TYPE="JOURNAL_ARTICLE">
<AU>Fransen J, van Riel PLCM</AU>
<TI>The disease activity score and the EULAR response criteria</TI>
<SO>Clinical and Experimental Rheumatology</SO>
<YR>2005</YR>
<VL>23</VL>
<NO>S39</NO>
<PG>S93-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fries-1980" MODIFIED="2008-10-29 05:56:06 -0400" MODIFIED_BY="[Empty name]" NAME="Fries 1980" TYPE="JOURNAL_ARTICLE">
<AU>Fries JF, Spitz PW, Kraines RG, Holman HR</AU>
<TI>Measurement of patient outcome in arthritis</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>1980</YR>
<VL>23</VL>
<PG>137-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gravallese-2002" MODIFIED="2008-10-29 05:56:06 -0400" MODIFIED_BY="[Empty name]" NAME="Gravallese 2002" TYPE="JOURNAL_ARTICLE">
<AU>Gravallese EM</AU>
<TI>Bone destruction in arthritis</TI>
<SO>Annals of Rheumatic Disease</SO>
<YR>2002</YR>
<VL>61</VL>
<NO>Suppl ii</NO>
<PG>ii84-86</PG>
<IDENTIFIERS MODIFIED="2008-10-11 19:02:31 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-11 19:02:31 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1136/ard.61.suppl_2.ii84"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2004" MODIFIED="2008-11-09 20:50:40 -0500" MODIFIED_BY="[Empty name]" NAME="Higgins 2004" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG</AU>
<TI>Controlling the risk of spurious findings from meta-regression</TI>
<SO>Statistics in Medicine</SO>
<YR>2004</YR>
<VL>23</VL>
<PG>1663-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kosinski-2000" MODIFIED="2008-10-29 05:56:06 -0400" MODIFIED_BY="[Empty name]" NAME="Kosinski 2000" TYPE="JOURNAL_ARTICLE">
<AU>Kosinski M, Zhao SZ, Dedhiya S, Osterhaus JT, Ware JE</AU>
<TI>Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>2000</YR>
<VL>43</VL>
<PG>1478-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Krishnan-2004" MODIFIED="2008-10-29 05:56:06 -0400" MODIFIED_BY="[Empty name]" NAME="Krishnan 2004" TYPE="JOURNAL_ARTICLE">
<AU>Krishnan E, Sokka T, Häkkinen A, Hubert H, Hannonen P</AU>
<TI>Normative values for the Health Assessment Questionnaire Disability Index: benchmarking disability in the general population</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>2004</YR>
<VL>50</VL>
<PG>953-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Larsen-1977" MODIFIED="2008-10-29 05:56:06 -0400" MODIFIED_BY="[Empty name]" NAME="Larsen 1977" TYPE="JOURNAL_ARTICLE">
<AU>Larsen A, Dale K, Eek M</AU>
<TI>Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films</TI>
<SO>Acta Radiologic Diagnosis (Stockholm)</SO>
<YR>1977</YR>
<VL>18</VL>
<NO>4</NO>
<PG>481&#8211;91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lipsky-2005" MODIFIED="2008-10-29 05:56:06 -0400" MODIFIED_BY="[Empty name]" NAME="Lipsky 2005" TYPE="BOOK">
<AU>Lipsky RE</AU>
<TI>Rheumatoid arthritis</TI>
<SO>Harrison's Principles of Internal Medicine</SO>
<YR>2005</YR>
<EN>16</EN>
<ED>Kasper DL, Fauci AS, Longo DL, Braunwald E, Hauser SL, Jameson JL</ED>
<PB>McGraw-Hill</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Navarro_x002d_Sarabia-2005" MODIFIED="2008-10-29 05:56:06 -0400" MODIFIED_BY="[Empty name]" NAME="Navarro-Sarabia 2005" TYPE="COCHRANE_REVIEW">
<AU>Navarro-Sarabia F, Ariza-Ariza R, Hernandez-Cruz B, Villanueva I</AU>
<TI>Adalimumab for treating rheumatoid arthritis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2008-10-21 19:19:18 -0400" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-21 19:19:18 -0400" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005113.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Dell-2004" MODIFIED="2008-10-29 05:56:06 -0400" MODIFIED_BY="[Empty name]" NAME="O'Dell 2004" TYPE="BOOK">
<AU>O'Dell JR</AU>
<TI>Rheumatoid arthritis</TI>
<SO>Current Rheumatology Diagnosis and Treatment</SO>
<YR>2004</YR>
<VL>1</VL>
<EN>Imboden J, Hellman DB, Stone JH.</EN>
<PB>McGraw-Hill</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pincus-1983" MODIFIED="2008-11-09 20:51:05 -0500" MODIFIED_BY="[Empty name]" NAME="Pincus 1983" TYPE="JOURNAL_ARTICLE">
<AU>Pincus T, Summey JA, Soraci SA, Jr, Wallston KA, Hummon NP</AU>
<TI>Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>1983</YR>
<VL>26</VL>
<PG>1346-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Prevoo-1995" MODIFIED="2008-10-29 05:56:06 -0400" MODIFIED_BY="[Empty name]" NAME="Prevoo 1995" TYPE="JOURNAL_ARTICLE">
<AU>Prevoo MLL, Van't Hof MA, Kuper HH, Van Leeuwen MA, Van de Putte LBA, Van Riel PLCM</AU>
<TI>Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>1995</YR>
<VL>38</VL>
<PG>44-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Prevoo-1996" MODIFIED="2008-10-29 05:56:06 -0400" MODIFIED_BY="[Empty name]" NAME="Prevoo 1996" TYPE="JOURNAL_ARTICLE">
<AU>Prevoo MLL, Van Gestel AM, Van't Hof MA, Van Rijswijk MH, Van de Putte LBA, Van Riel PLCM</AU>
<TI>Remission in a prospective study of patients with rheumatoid arthritis</TI>
<SO>British Journal of Rheumatology</SO>
<YR>1996</YR>
<VL>35</VL>
<PG>1101-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Samsa-1999" MODIFIED="2008-10-29 05:56:06 -0400" MODIFIED_BY="[Empty name]" NAME="Samsa 1999" TYPE="JOURNAL_ARTICLE">
<AU>Samsa G, Edelman D, Rothman ML, Williams GR, Lipscomb J, Matchar D</AU>
<TI>Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II</TI>
<SO>Pharmacoeconomics</SO>
<YR>1999</YR>
<VL>15</VL>
<PG>141-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sharp-1971" MODIFIED="2008-11-09 20:51:29 -0500" MODIFIED_BY="[Empty name]" NAME="Sharp 1971" TYPE="JOURNAL_ARTICLE">
<AU>Sharp JT, Lidsky MD, Collins LC, Moreland J</AU>
<TI>Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>1971</YR>
<VL>14</VL>
<NO>6</NO>
<PG>706&#8211;20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tugwell-2000" MODIFIED="2008-10-29 05:56:06 -0400" MODIFIED_BY="[Empty name]" NAME="Tugwell 2000" TYPE="JOURNAL_ARTICLE">
<AU>Tugwell P, Wells G, Strand V, Maetzel A, Bombardier C, Crawford B, et al</AU>
<TI>Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigator Group</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>2000</YR>
<VL>43</VL>
<PG>506-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tugwell-2004" MODIFIED="2008-10-29 05:56:06 -0400" MODIFIED_BY="[Empty name]" NAME="Tugwell 2004" TYPE="BOOK">
<AU>Tugwell P, Shea B, Boers M, Brooks P, Simon L, Strand V et al. (editors)</AU>
<SO>Evidence-based Rheumatology</SO>
<YR>2004</YR>
<PB>BMJ Books</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-der-Heijde-1989" MODIFIED="2008-10-29 05:56:06 -0400" MODIFIED_BY="[Empty name]" NAME="van der Heijde 1989" TYPE="JOURNAL_ARTICLE">
<AU>van der Heijde DMFM, van Riel PL, Nuver-Zwart IH, Gribnau FW, Van de Puttte LB</AU>
<TI>Effects of hydroxychloroquine and sulfasalazine on progression of joint damage in rheumatoid arthritis</TI>
<SO>Lancet</SO>
<YR>1989</YR>
<VL>1</VL>
<PG>1036-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-der-Heijde-1993" MODIFIED="2008-11-09 20:44:21 -0500" MODIFIED_BY="[Empty name]" NAME="van der Heijde 1993" TYPE="JOURNAL_ARTICLE">
<AU>van der Heijde DM, van 't Hof M, van Riel PL, van de Putte LB</AU>
<TI>Development of a disease activity score based on judgment in clinical practice by rheumatologists</TI>
<SO>Journal of Rheumatology</SO>
<YR>1993</YR>
<VL>20</VL>
<NO>3</NO>
<PG>579-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-Gestel-1996" MODIFIED="2008-10-29 05:56:06 -0400" MODIFIED_BY="[Empty name]" NAME="van Gestel 1996" TYPE="JOURNAL_ARTICLE">
<AU>van Gestel AM, Prevoo ML, van't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL</AU>
<TI>Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria</TI>
<SO>Arthritis &amp; Rheumatism</SO>
<YR>1996</YR>
<VL>39</VL>
<NO>1</NO>
<PG>34-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wells-1993" MODIFIED="2008-11-11 22:55:20 -0500" MODIFIED_BY="[Empty name]" NAME="Wells 1993" TYPE="JOURNAL_ARTICLE">
<AU>Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA</AU>
<TI>Minimum important difference between patients with rheumatoid arthritis: the patient's perspective</TI>
<SO>Journal of Rheumatology</SO>
<YR>1993</YR>
<VL>20</VL>
<PG>557</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-11-11 22:50:58 -0500" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-11-09 20:32:00 -0500" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2008-11-09 20:31:50 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bresnihan-1998">
<CHAR_METHODS MODIFIED="2008-10-21 21:46:54 -0400" MODIFIED_BY="[Empty name]">
<P>A randomized, placebo-controlled, double blinded trial comparing anakinra to placebo.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-10-21 21:47:23 -0400" MODIFIED_BY="[Empty name]">
<P>472 patients with rheumatoid arthritis with active disease where all DMARDs were discontinued 6 weeks prior, allowing only NSAIDs and/or steroids</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-09 20:31:50 -0500" MODIFIED_BY="[Empty name]">
<P>placebo (n = 119) and IL-1 receptor antagonist 30 mg daily (n = 119), 75 mg daily (n = 115), 150 mg daily (n = 115) for 24 weeks. 4 excluded from analysis after not receiving any doses of study drug.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Outcome Data: ACR20, change in HAQ, change in CRP, change in ESR, change in Larsen score, change in pain VAS scale; Safety Data: withdrawals, injection site reactions</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>excluded missing data; only partial intention-to-treat analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-09 20:31:52 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cohen-2002">
<CHAR_METHODS MODIFIED="2008-10-21 21:48:27 -0400" MODIFIED_BY="[Empty name]">
<P>A randomized, double blinded, placebo-controlled trial comparing anakinra to placebo in the setting of methotrexate therapy; Originally set up as a 12 week trial with 105 participants, though extended as a 24 week trial involving 317 participants (314 new participants and 3 recruited from original 12 week trial).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-09 20:31:50 -0500" MODIFIED_BY="[Empty name]">
<P>419 patients with active rheumatoid arthritis and on methotrexate for at least 6 months while off other DMARDs for at least 2 months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-09 20:31:52 -0500" MODIFIED_BY="[Empty name]">
<P>placebo (n = 48) and anakinra 0.04 mg/kg/day (n = 63), 0.1 mg/kg/day (n = 46), 0.4 mg/kg/day (n = 55), 1.0 mg/kg/day (n = 59), and 2.0 mg/kg/day (n = 46) for 24 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-21 21:49:09 -0400" MODIFIED_BY="[Empty name]">
<P>Outcome data: ACR20, ACR50, ACR70. Change in HAQ score, change in CRP, and change in ESR data was also collected, though no standard deviations were given with these continuous data. Safety data: withdrawals, injection site reactions</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Only 3 reconsented from original 12 week trial for full, extended 24 week trial. Results were missing standard deviation data from all continuous data. Data analyzed with full intention-to-treat analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-09 20:31:52 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cohen-2004">
<CHAR_METHODS MODIFIED="2008-10-21 21:50:03 -0400" MODIFIED_BY="[Empty name]">
<P>A randomized, double-blinded, placebo-controlled trial comparing anakinra to placebo in the setting of methotrexate therapy.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>506 patients with active rheumatoid arthritis, including erosive disease on X-ray, and on methotrexate for at least 24 weeks and other DMARDs discontinued at least 60 days prior to the study.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-09 20:31:52 -0500" MODIFIED_BY="[Empty name]">
<P>placebo + methotrexate + folic acid (n = 251) vs. anakinra 100 mg daily + methotrexate + folic acid (n = 250). 5 excluded from analysis after not receiving any doses of study drug.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-21 21:50:27 -0400" MODIFIED_BY="[Empty name]">
<P>Outcome Data: ACR20, ACR50, ACR70, change in HAQ, change in ESR; Safety Data: infections, serious infections, adverse events, serious adverse events, injection site reactions</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>no withdrawal data provided; only partial intention-to-treat analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-09 20:31:52 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fleischman-2003">
<CHAR_METHODS MODIFIED="2008-10-21 21:50:50 -0400" MODIFIED_BY="[Empty name]">
<P>A randomized, double-blinded, placebo-controlled trial comparing anakinra to placebo.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>1414 patients with active rheumatoid arthritis and any DMARD therapy except for TNF-inhibitors that had been stable for 2 months.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-09 20:31:52 -0500" MODIFIED_BY="[Empty name]">
<P>Anakinra 100 mg daily (n = 1116) vs. placebo (n = 283) for 6 months. 15 excluded from analysis after not receiving any doses of study drug.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-21 21:51:07 -0400" MODIFIED_BY="[Empty name]">
<P>Outcome Data: none; Safety Data: withdrawals, infections, serious infections, adverse effects, serious adverse events, deaths, injection site reactions</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>no outcome data reported; only partial intention-to-treat analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-09 20:31:53 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Genovese-2004">
<CHAR_METHODS MODIFIED="2008-10-21 21:51:28 -0400" MODIFIED_BY="[Empty name]">
<P>A randomized, double blinded, placebo-controlled trial comparing anakinra to placebo in the setting of treatment with etanercept and methotrexate.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>244 patients with active RA and on methotrexate for at least 16 weeks though other DMARD therapy discontinued at least 4 weeks prior to the study.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-09 20:31:53 -0500" MODIFIED_BY="[Empty name]">
<P>Etanercept 25 mg 2 doses/week + placebo + methotrexate (n = 80) vs. etanercept 25 mg 1 dose/week + anakinra 100 mg daily + methotrexate ( n = 81) vs. etanercept 25 mg 2 doses/week + anakinra 100 mg daily + methotrexate (n = 81). 2 excluded from analysis after not receiving any doses of study drug.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-10-21 21:52:16 -0400" MODIFIED_BY="[Empty name]">
<P>Outcome Data: ACR20, ACR50, ACR70, change in HAQ, change in ESR, change in CRP; Safety Data: withdrawals, infections, serious infections, adverse events, serious adverse effects, injection site reactions</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2008-11-09 20:31:53 -0500" MODIFIED_BY="[Empty name]">
<P>Etanercept 25 mg 1 dose/week group without control arm; full intention-to-treat analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>CRP: C-reactive protein</P>
<P>DMARD: Disease-modifying anti-rheumatic drugs </P>
<P>ESR: Erythrocyte sedimentation rate</P>
<P>HAQ: </P>
<P>NSAID: Non steroidal anti-inflammatory drugs</P>
<P>RA: Rheumatoid arthritis</P>
<P>TNF: Tumor necrosing factor</P>
<P>vs: versus</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2008-11-11 22:50:58 -0500" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-AMGEN-FDA-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>FDA document review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bresnihan-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review, anakinra studies</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-11 22:50:58 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bresnihan-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-11 22:50:58 -0500" MODIFIED_BY="[Empty name]">
<P>Review, anakinra studies</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bresnihan-2002b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review, anakinra studies</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bresnihan-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Extension of Bresnihan 1998 trial (24wk); no placebo/control arm; same as Nuki</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Burls-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Editorial, of Genovese, 2004</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Calabrese-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case report</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-21 21:53:38 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Campion-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-21 21:53:38 -0400" MODIFIED_BY="[Empty name]">
<P>No placebo/control arm to study, randomized</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-21 21:53:42 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Choy-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-21 21:53:42 -0400" MODIFIED_BY="[Empty name]">
<P>Meta-analysis, DMARD combination and safety</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-21 21:53:49 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cohen-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-21 21:53:49 -0400" MODIFIED_BY="[Empty name]">
<P>Reevaluation of Cohen, 2002 study with emphasis on functional outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cohen-2004b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Meta-analysis, Bresnihan 1998, Cohen 2001, Cohen 2002</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-21 21:54:07 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-La-Mata-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-21 21:54:07 -0400" MODIFIED_BY="[Empty name]">
<P>Review - anakinra studies in RA</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dinarello-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Editorial, IL-1 overview</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-21 21:54:12 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dougados-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-21 21:54:12 -0400" MODIFIED_BY="[Empty name]">
<P>Not anakinra (IX 207-887 = organic compound)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-21 21:54:28 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Drevlow-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-21 21:54:28 -0400" MODIFIED_BY="[Empty name]">
<P>Randomized, double blinded; though only individual data with 28 days on 12 patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-21 21:54:34 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fleischmann-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-21 21:54:34 -0400" MODIFIED_BY="[Empty name]">
<P>Review, safety of anakinra from Fleischmann 2003 study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-21 21:54:45 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fleischmann-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-21 21:54:45 -0400" MODIFIED_BY="[Empty name]">
<P>36 month extension of Fleischmann, 2003; open label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-21 21:54:51 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garces-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-21 21:54:51 -0400" MODIFIED_BY="[Empty name]">
<P>Review - anakinra studies</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Garrood-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review of DMARDs</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Genant-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review of post-hoc analysis/validation of Gentant radiograph evaluation from Bresnihan, 1998</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-21 21:55:08 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Haraoui-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-21 21:55:08 -0400" MODIFIED_BY="[Empty name]">
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jiang-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Reevaluation of Bresnihan, 1998 (with Genant radiograph validation and analysis)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-21 21:55:25 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jones-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-21 21:55:25 -0400" MODIFIED_BY="[Empty name]">
<P>Meta-analysis, radiographic changes in RA</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Loft-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review, anakinra studies</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-National-Horizon-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-21 21:55:31 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nixon-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-21 21:55:31 -0400" MODIFIED_BY="[Empty name]">
<P>Meta-analysis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-09 20:32:01 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nuki-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-09 20:32:01 -0500" MODIFIED_BY="[Empty name]">
<P>Extension (24 wk) of Bresnihan, 1998 trial: no placebo/control arm; same as Bresnihan, 2004</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-21 21:55:55 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Paget-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-21 21:55:55 -0400" MODIFIED_BY="[Empty name]">
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-21 21:56:00 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rau-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-21 21:56:00 -0400" MODIFIED_BY="[Empty name]">
<P>Same study as Bresnihan 1998</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-21 21:56:03 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rau-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-21 21:56:03 -0400" MODIFIED_BY="[Empty name]">
<P>Case report</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Riente-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review, anakinra studies</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-21 21:56:10 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schiff-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-21 21:56:10 -0400" MODIFIED_BY="[Empty name]">
<P>Reevaluation of Fleischmann, 2003; emphasis on evaluation of comorbid conditions</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-21 21:56:22 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schwetz-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-21 21:56:22 -0400" MODIFIED_BY="[Empty name]">
<P>Not anakinra (xigris)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Strand-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review, radiographic analysis following RA treatments</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Strand-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review of DMARD therapy on radiographic changes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tesser-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Reevaluation of Fleischmann, 2003 study, with emphasis on concomitant medications used</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-21 21:56:37 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tomoo-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-21 21:56:37 -0400" MODIFIED_BY="[Empty name]">
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-09 20:32:01 -0500" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Watt-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-09 20:32:01 -0500" MODIFIED_BY="[Empty name]">
<P>Re-evaluation of Bresnihan, 1998 study with emphasis on radiographic changes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-10-21 21:56:45 -0400" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zundorf-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-10-21 21:56:45 -0400" MODIFIED_BY="[Empty name]">
<P>Review of Biologics for RA</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Bresnihan-1998">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Cohen-2002">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Cohen-2004">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Fleischman-2003">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Genovese-2004">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-11-12 14:05:48 -0500" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-11-12 14:05:38 -0500" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-11-12 14:05:38 -0500" MODIFIED_BY="[Empty name]">Clinical Relevance table: ACR outcome data for Anakinra 50-150 mg daily versus placebo after six months</TITLE>
<TABLE COLS="9" ROWS="4">
<TR>
<TD>
<P>
<B>Outcome</B>
</P>
</TD>
<TD>
<P># patients (# trials)&#8224;</P>
</TD>
<TD>
<P>Control event rate</P>
</TD>
<TD>
<P>Anakinra event rate</P>
</TD>
<TD>
<P>Wt absolute RD (95% CI)</P>
</TD>
<TD>
<P>Wt Rel % change (95% CI)</P>
</TD>
<TD>
<P>NNTB (95% CI)</P>
</TD>
<TD>
<P>statsistical significance</P>
</TD>
<TD>
<P>quality of evidence</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>ACR20 </B>
</P>
</TD>
<TD>
<P>1003 (3)</P>
</TD>
<TD>
<P>23.4%</P>
<P>23 out of 100</P>
</TD>
<TD>
<P>38.3%</P>
<P>38 out of 100</P>
</TD>
<TD>
<P>15% (9,20)</P>
<P>15 more out of 100</P>
</TD>
<TD>
<P>61% improvement</P>
<P>(32%, 98%)</P>
</TD>
<TD>
<P>8</P>
<P>(5, 14)</P>
</TD>
<TD>
<P>statistically significant</P>
</TD>
<TD>
<P>silver</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>ACR50</B>
</P>
</TD>
<TD>
<P>654 (2)</P>
</TD>
<TD>
<P>7.4%</P>
<P>7 out of 100</P>
</TD>
<TD>
<P>18.3%</P>
<P>18 out of 100</P>
</TD>
<TD>
<P>11% (6, 16)</P>
<P>11 more out of 100</P>
</TD>
<TD>
<P>151% improvement</P>
<P>(56%, 303%)</P>
</TD>
<TD>
<P>9</P>
<P>(5, 25)</P>
</TD>
<TD>
<P>statistically significant</P>
</TD>
<TD>
<P>silver</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>ACR70</B>
</P>
</TD>
<TD>
<P>654 (2)</P>
</TD>
<TD>
<P>1.7%</P>
<P>2 out of 100</P>
</TD>
<TD>
<P>6.8%</P>
<P>7 out of 100 </P>
</TD>
<TD>
<P>5% (2, 8)</P>
<P>5 more out of 100</P>
</TD>
<TD>
<P>271% improvement</P>
<P>(44%, 857%)</P>
</TD>
<TD>
<P>22</P>
<P>(7, 134)</P>
</TD>
<TD>
<P>statistically significant</P>
</TD>
<TD>
<P>silver</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>Wt = weighted</P>
<P>RD = risk difference</P>
<P>CI = confidence interval</P>
<P>NNTB = number needed to treat to benefit</P>
<P>&#8224; Note: data excludes outcome data from <LINK REF="STD-Genovese-2004" TYPE="STUDY">Genovese 2004</LINK>
</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2008-11-12 14:05:48 -0500" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2008-11-12 14:05:48 -0500" MODIFIED_BY="[Empty name]">Summary of ACR outcome data for Anakinra 50-150 mg daily versus placebo after six months</TITLE>
<TABLE COLS="10" ROWS="9">
<TR>
<TH>
<P/>
</TH>
<TH>
<P>ACR 20</P>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P>ACR 50</P>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
<TH>
<P>ACR70</P>
</TH>
<TH>
<P/>
</TH>
<TH>
<P/>
</TH>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P>
<B>Anakinra</B>
</P>
</TD>
<TD>
<P>
<B>Placebo</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>
<B>Anakinra</B>
</P>
</TD>
<TD>
<P>
<B>Placebo</B>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>
<B>Anakinra</B>
</P>
</TD>
<TD>
<P>
<B>Placebo</B>
</P>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Study</B>
</P>
</TD>
<TD>
<P>n/N (%)</P>
</TD>
<TD>
<P>n/N (%)</P>
</TD>
<TD>
<P>ARD (%), NNTB</P>
</TD>
<TD>
<P>n/N</P>
</TD>
<TD>
<P>n/N</P>
</TD>
<TD>
<P>ARD (%), NNTB</P>
</TD>
<TD>
<P>n/N</P>
</TD>
<TD>
<P>n/N</P>
</TD>
<TD>
<P>ARD (%), NNTB</P>
</TD>
</TR>
<TR>
<TD>
<P>Bresnihan 1998</P>
</TD>
<TD>
<P>88/230 (38)</P>
</TD>
<TD>
<P>32/119 (27)</P>
</TD>
<TD>
<P>11, 9.1</P>
</TD>
<TD>
<P>no data</P>
</TD>
<TD>
<P>no data</P>
</TD>
<TD>
<P>no data</P>
</TD>
<TD>
<P>no data</P>
</TD>
<TD>
<P>no data</P>
</TD>
<TD>
<P>no data</P>
</TD>
</TR>
<TR>
<TD>
<P>Cohen 2002</P>
</TD>
<TD>
<P>41/105 (39)</P>
</TD>
<TD>
<P>11/48 (23)</P>
</TD>
<TD>
<P>16, 6.3</P>
</TD>
<TD>
<P>22/105 (21)</P>
</TD>
<TD>
<P>2/48 (4)</P>
</TD>
<TD>
<P>17, 5.9</P>
</TD>
<TD>
<P>9/105 (9)</P>
</TD>
<TD>
<P>0/48 (0)</P>
</TD>
<TD>
<P>9, 11.1</P>
</TD>
</TR>
<TR>
<TD>
<P>Cohen 2004</P>
</TD>
<TD>
<P>95/250 (38)</P>
</TD>
<TD>
<P>55/251 (22)</P>
</TD>
<TD>
<P>16, 6.3</P>
</TD>
<TD>
<P>43/250 (17)</P>
</TD>
<TD>
<P>20/251 (8)</P>
</TD>
<TD>
<P>9, 11.1</P>
</TD>
<TD>
<P>15/250 (6)</P>
</TD>
<TD>
<P>5/251 (2)</P>
</TD>
<TD>
<P>4, 25</P>
</TD>
</TR>
<TR>
<TD>
<P>Fleischman 2003</P>
</TD>
<TD>
<P>no data</P>
</TD>
<TD>
<P>no data</P>
</TD>
<TD>
<P>no data</P>
</TD>
<TD>
<P>no data</P>
</TD>
<TD>
<P>no data</P>
</TD>
<TD>
<P>no data</P>
</TD>
<TD>
<P>no data</P>
</TD>
<TD>
<P>no data</P>
</TD>
<TD>
<P>no data</P>
</TD>
</TR>
<TR>
<TD>
<P>Genovese 2004</P>
</TD>
<TD>
<P>50/81 (62)</P>
</TD>
<TD>
<P>54/80 (68)</P>
</TD>
<TD>
<P>-4, NA</P>
</TD>
<TD>
<P>25/81 (31)</P>
</TD>
<TD>
<P>33/80 (41)</P>
</TD>
<TD>
<P>-7, NA</P>
</TD>
<TD>
<P>11/81 (14)</P>
</TD>
<TD>
<P>17/80 (21)</P>
</TD>
<TD>
<P>-7, NA</P>
</TD>
</TR>
<TR>
<TD>
<P>Totals (excluding Genovese)</P>
</TD>
<TD>
<P>224/585 (38)</P>
</TD>
<TD>
<P>98/418 (23)</P>
</TD>
<TD>
<P>15, 8</P>
</TD>
<TD>
<P>65/355 (18)</P>
</TD>
<TD>
<P>22/299 (7)</P>
</TD>
<TD>
<P>11, 9</P>
</TD>
<TD>
<P>24/355 (7)</P>
</TD>
<TD>
<P>5/299 (2)</P>
</TD>
<TD>
<P>5, 22</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>NNTB: number needed to treat to benefit</P>
<P>ARD: absolute risk difference [n/N (Anakinra) - n/N (placebo)]</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-11-09 20:52:05 -0500" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2008-11-09 20:51:57 -0500" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Anakinra (0 to 50 mg/day)</NAME>
<DICH_OUTCOME CHI2="0.2751770399561271" CI_END="1.8899156799120387" CI_START="1.0131577427719636" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3837567359507312" ESTIMABLE="YES" EVENTS_1="93" EVENTS_2="43" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.2764424282124967" LOG_CI_START="0.005677067751287942" LOG_EFFECT_SIZE="0.1410597479818923" METHOD="MH" NO="1" P_CHI2="0.599879979263103" P_Q="0.0" P_Z="0.04113644548558968" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="283" TOTAL_2="167" WEIGHT="100.0" Z="2.042152107211028">
<NAME>ACR20</NAME>
<GROUP_LABEL_1>Anakinra</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors Anakinra</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.127269108931727" CI_START="1.0140825875966946" DF="0.0" EFFECT_SIZE="1.46875" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="32" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="0.32782243354698054" LOG_CI_START="0.006073325684642512" LOG_EFFECT_SIZE="0.16694787961581148" NO="1" P_CHI2="1.0" P_Z="0.04195598987642425" STUDIES="1" TAU2="0.0" TOTAL_1="119" TOTAL_2="119" WEIGHT="65.28098537336413" Z="2.033956417261107">
<NAME>Anakinra</NAME>
<DICH_DATA CI_END="2.127269108931727" CI_START="1.0140825875966946" EFFECT_SIZE="1.46875" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="32" LOG_CI_END="0.32782243354698054" LOG_CI_START="0.006073325684642512" LOG_EFFECT_SIZE="0.16694787961581148" ORDER="16200" O_E="0.0" SE="0.18899701864210777" STUDY_ID="STD-Bresnihan-1998" TOTAL_1="119" TOTAL_2="119" VAR="0.03571987305560523" WEIGHT="65.28098537336413"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.1725673644302836" CI_START="0.6895278631393331" DF="0.0" EFFECT_SIZE="1.2239467849223946" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="11" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.3369732514253191" LOG_CI_START="-0.16144817972284248" LOG_EFFECT_SIZE="0.08776253585123835" NO="2" P_CHI2="1.0" P_Z="0.4900528518722529" STUDIES="1" TAU2="0.0" TOTAL_1="164" TOTAL_2="48" WEIGHT="34.719014626635875" Z="0.6902247724945844">
<NAME>Anakinra + Methotrexate</NAME>
<DICH_DATA CI_END="2.1725673644302836" CI_START="0.6895278631393331" EFFECT_SIZE="1.2239467849223946" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="11" LOG_CI_END="0.3369732514253191" LOG_CI_START="-0.16144817972284248" LOG_EFFECT_SIZE="0.08776253585123835" ORDER="16201" O_E="0.0" SE="0.2927752158823052" STUDY_ID="STD-Cohen-2002" TOTAL_1="164" TOTAL_2="48" VAR="0.08571732703493043" WEIGHT="34.719014626635875"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.544876185236913E-32" CI_END="13.767790423259296" CI_START="0.8228604955770505" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.365853658536585" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="2" I2="100.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="1.1388642464308658" LOG_CI_START="-0.08467378706786381" LOG_EFFECT_SIZE="0.5270952296815009" METHOD="MH" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.09127902672982156" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="164" TOTAL_2="48" WEIGHT="100.0" Z="1.6886890939458195">
<NAME>ACR50</NAME>
<GROUP_LABEL_1>Anakinra</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors Anakinra</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="9.544876185236913E-32" CI_END="13.767790423259296" CI_START="0.8228604955770505" DF="0.0" EFFECT_SIZE="3.365853658536585" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="2" I2="100.0" ID="CMP-001.02.01" LOG_CI_END="1.1388642464308658" LOG_CI_START="-0.08467378706786381" LOG_EFFECT_SIZE="0.5270952296815009" NO="1" P_CHI2="0.0" P_Z="0.09127902672982156" STUDIES="1" TAU2="0.0" TOTAL_1="164" TOTAL_2="48" WEIGHT="100.0" Z="1.6886890939458195">
<NAME>Anakinra + Methotrexate</NAME>
<DICH_DATA CI_END="13.767790423259296" CI_START="0.8228604955770508" EFFECT_SIZE="3.3658536585365852" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="2" LOG_CI_END="1.1388642464308658" LOG_CI_START="-0.08467378706786369" LOG_EFFECT_SIZE="0.527095229681501" ORDER="16202" O_E="0.0" SE="0.7187122974880993" STUDY_ID="STD-Cohen-2002" TOTAL_1="164" TOTAL_2="48" VAR="0.5165473665606221" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="76.61715924392335" CI_START="0.25898865740294796" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="4.454545454545454" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="1.8843260454862678" LOG_CI_START="-0.5867192557456904" LOG_EFFECT_SIZE="0.6488033948702886" METHOD="MH" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.3033737864596453" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="164" TOTAL_2="48" WEIGHT="100.0" Z="1.0292253940946399">
<NAME>ACR70</NAME>
<GROUP_LABEL_1>Anakinra</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors Anakinra</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="76.61715924392335" CI_START="0.25898865740294796" DF="0.0" EFFECT_SIZE="4.454545454545454" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="1.8843260454862678" LOG_CI_START="-0.5867192557456904" LOG_EFFECT_SIZE="0.6488033948702886" NO="1" P_CHI2="1.0" P_Z="0.3033737864596453" STUDIES="1" TAU2="0.0" TOTAL_1="164" TOTAL_2="48" WEIGHT="100.0" Z="1.0292253940946399">
<NAME>Anakinra + Methotrexate</NAME>
<DICH_DATA CI_END="76.61715924392335" CI_START="0.25898865740294796" EFFECT_SIZE="4.454545454545454" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="1.8843260454862678" LOG_CI_START="-0.5867192557456904" LOG_EFFECT_SIZE="0.6488033948702886" ORDER="16203" O_E="0.0" SE="1.4515042418151665" STUDY_ID="STD-Cohen-2002" TOTAL_1="164" TOTAL_2="48" VAR="2.1068645640074215" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8326686172921445" CI_END="1.1840645947266768" CI_START="0.6166366688840593" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8544809228039042" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="53" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.07337539526540202" LOG_CI_START="-0.20997065310854604" LOG_EFFECT_SIZE="-0.06829762892157201" METHOD="MH" NO="4" P_CHI2="0.3615020729776828" P_Q="0.0" P_Z="0.3447313782957385" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="333" TOTAL_2="195" WEIGHT="100.0" Z="0.9448580185533305">
<NAME>Withdrawals</NAME>
<GROUP_LABEL_1>Anakinra</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors Anakinra</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1376641338740394" CI_START="0.5024924408406591" DF="0.0" EFFECT_SIZE="0.7560870502046972" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="39" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.05601406668606144" LOG_CI_START="-0.29887046709330894" LOG_EFFECT_SIZE="-0.1214282002036238" NO="1" P_CHI2="1.0" P_Z="0.1798384586488231" STUDIES="1" TAU2="0.0" TOTAL_1="119" TOTAL_2="121" WEIGHT="65.02124877410918" Z="1.3412525847327115">
<NAME>Anakinra</NAME>
<DICH_DATA CI_END="1.1376641338740394" CI_START="0.5024924408406591" EFFECT_SIZE="0.7560870502046972" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="39" LOG_CI_END="0.05601406668606144" LOG_CI_START="-0.29887046709330894" LOG_EFFECT_SIZE="-0.1214282002036238" ORDER="16204" O_E="0.0" SE="0.20846093184877623" STUDY_ID="STD-Bresnihan-1998" TOTAL_1="119" TOTAL_2="121" VAR="0.043455960107260126" WEIGHT="65.02124877410918"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.787381678271988" CI_START="0.6020895649696052" DF="0.0" EFFECT_SIZE="1.0373831775700935" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="14" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="0.2522173018440959" LOG_CI_START="-0.22033889964120032" LOG_EFFECT_SIZE="0.015939201101447795" NO="2" P_CHI2="1.0" P_Z="0.8948117230099325" STUDIES="1" TAU2="0.0" TOTAL_1="214" TOTAL_2="74" WEIGHT="34.97875122589082" Z="0.13221817850654488">
<NAME>Anakinra + Methotrexate</NAME>
<DICH_DATA CI_END="1.787381678271988" CI_START="0.6020895649696052" EFFECT_SIZE="1.0373831775700935" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="14" LOG_CI_END="0.2522173018440959" LOG_CI_START="-0.22033889964120032" LOG_EFFECT_SIZE="0.015939201101447795" ORDER="16205" O_E="0.0" SE="0.2775818519433863" STUDY_ID="STD-Cohen-2002" TOTAL_1="214" TOTAL_2="74" VAR="0.07705168452832004" WEIGHT="34.97875122589082"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.003850092885261988" CI_START="-0.16385009288526198" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.08" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2008-10-21 22:27:43 -0400" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.061488049280353604" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="119" TOTAL_2="119" UNITS="" WEIGHT="100.0" Z="1.8699695297626076">
<NAME>change in pain VAS score</NAME>
<GROUP_LABEL_1>Anakinra</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors Anakinra</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.003850092885261988" CI_START="-0.16385009288526198" DF="0.0" EFFECT_SIZE="-0.08" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.01" NO="1" P_CHI2="1.0" P_Z="0.061488049280353604" STUDIES="1" TAU2="0.0" TOTAL_1="119" TOTAL_2="119" WEIGHT="100.0" Z="1.8699695297626076">
<NAME>Anakinra</NAME>
<CONT_DATA CI_END="0.003850092885261988" CI_START="-0.16385009288526198" EFFECT_SIZE="-0.08" ESTIMABLE="YES" MEAN_1="-0.13" MEAN_2="-0.05" ORDER="16208" SD_1="0.33" SD_2="0.33" SE="0.04278144575444285" STUDY_ID="STD-Bresnihan-1998" TOTAL_1="119" TOTAL_2="119" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.07395552641329445" CI_START="-0.3260444735867056" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.2" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2008-10-21 22:27:43 -0400" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.001871150640839919" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="116" TOTAL_2="114" UNITS="" WEIGHT="100.0" Z="3.1099562380921073">
<NAME>change in HAQ score</NAME>
<GROUP_LABEL_1>Anakinra</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors Anakinra</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.07395552641329445" CI_START="-0.3260444735867056" DF="0.0" EFFECT_SIZE="-0.2" ESTIMABLE="YES" I2="0.0" ID="CMP-001.06.01" NO="1" P_CHI2="1.0" P_Z="0.001871150640839919" STUDIES="1" TAU2="0.0" TOTAL_1="116" TOTAL_2="114" WEIGHT="100.0" Z="3.1099562380921073">
<NAME>Anakinra</NAME>
<CONT_DATA CI_END="-0.07395552641329445" CI_START="-0.3260444735867056" EFFECT_SIZE="-0.2" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="0.0" ORDER="16209" SD_1="0.54" SD_2="0.43" SE="0.06430958659492128" STUDY_ID="STD-Bresnihan-1998" TOTAL_1="116" TOTAL_2="114" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-4.331377127267566" CI_START="-15.668622872732435" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-10.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" MODIFIED="2008-10-21 22:27:43 -0400" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="5.450779473180863E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="115" TOTAL_2="113" UNITS="" WEIGHT="100.0" Z="3.4575663764262683">
<NAME>change in ESR</NAME>
<GROUP_LABEL_1>Anakinra</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors Anakinra</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-4.331377127267566" CI_START="-15.668622872732435" DF="0.0" EFFECT_SIZE="-10.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.07.01" NO="1" P_CHI2="1.0" P_Z="5.450779473180863E-4" STUDIES="1" TAU2="0.0" TOTAL_1="115" TOTAL_2="113" WEIGHT="100.0" Z="3.4575663764262683">
<NAME>Anakinra</NAME>
<CONT_DATA CI_END="-4.331377127267566" CI_START="-15.668622872732435" EFFECT_SIZE="-10.0" ESTIMABLE="YES" MEAN_1="-9.1" MEAN_2="0.9" ORDER="16210" SD_1="22.2" SD_2="21.47" SE="2.8922076718989773" STUDY_ID="STD-Bresnihan-1998" TOTAL_1="115" TOTAL_2="113" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.16416975304255477" CI_START="-1.6358302469574453" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.9" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.08" MODIFIED="2008-10-21 22:27:43 -0400" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.01651873924550252" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="119" TOTAL_2="118" UNITS="" WEIGHT="100.0" Z="2.397247997591574">
<NAME>change in CRP</NAME>
<GROUP_LABEL_1>Anakinra</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors Anakinra</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.16416975304255477" CI_START="-1.6358302469574453" DF="0.0" EFFECT_SIZE="-0.9" ESTIMABLE="YES" I2="0.0" ID="CMP-001.08.01" NO="1" P_CHI2="1.0" P_Z="0.01651873924550252" STUDIES="1" TAU2="0.0" TOTAL_1="119" TOTAL_2="118" WEIGHT="100.0" Z="2.397247997591574">
<NAME>Anakinra</NAME>
<CONT_DATA CI_END="-0.16416975304255477" CI_START="-1.6358302469574453" EFFECT_SIZE="-0.9" ESTIMABLE="YES" MEAN_1="-1.3" MEAN_2="-0.4" ORDER="16211" SD_1="2.73" SD_2="3.04" SE="0.37543049400987993" STUDY_ID="STD-Bresnihan-1998" TOTAL_1="119" TOTAL_2="118" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.1304925883029444" CI_START="-5.469507411697056" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.8000000000000003" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.09" MODIFIED="2008-10-21 22:27:43 -0400" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Q="1.0" P_Z="0.039804477686509174" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="89" TOTAL_2="83" UNITS="" WEIGHT="100.0" Z="2.055772212006481">
<NAME>change in Larsen score</NAME>
<GROUP_LABEL_1>Anakinra</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors Anakinra</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.1304925883029444" CI_START="-5.469507411697056" DF="0.0" EFFECT_SIZE="-2.8000000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-001.09.01" NO="1" P_CHI2="1.0" P_Z="0.039804477686509174" STUDIES="1" TAU2="0.0" TOTAL_1="89" TOTAL_2="83" WEIGHT="100.0" Z="2.055772212006481">
<NAME>Anakinra</NAME>
<CONT_DATA CI_END="-0.1304925883029444" CI_START="-5.469507411697056" EFFECT_SIZE="-2.8000000000000003" ESTIMABLE="YES" MEAN_1="3.6" MEAN_2="6.4" ORDER="16212" SD_1="7.45" SD_2="10.11" SE="1.3620186048079401" STUDY_ID="STD-Bresnihan-1998" TOTAL_1="89" TOTAL_2="83" WEIGHT="100.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2008-11-09 20:52:05 -0500" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Anakinra (51 to 150 mg/day)</NAME>
<DICH_OUTCOME CHI2="0.8156062697449494" CI_END="1.9753002055091635" CI_START="1.3171942911204122" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6130263959234044" ESTIMABLE="YES" EVENTS_1="224" EVENTS_2="98" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.29563310891852534" LOG_CI_START="0.11964983975906567" LOG_EFFECT_SIZE="0.2076414743387955" METHOD="MH" MODIFIED="2008-11-09 19:17:26 -0500" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6651100635981652" P_Q="0.0" P_Z="3.744238267425879E-6" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="585" TOTAL_2="418" WEIGHT="100.0" Z="4.625096616793485">
<NAME>ACR20</NAME>
<GROUP_LABEL_1>Anakinra</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors Anakinra</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9963922324502603" CI_START="1.0140462584545975" DF="0.0" EFFECT_SIZE="1.4228260869565217" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="32" I2="0.0" ID="CMP-002.01.01" LOG_CI_END="0.3002458714472643" LOG_CI_START="0.006057766963136788" LOG_EFFECT_SIZE="0.15315181920520052" NO="1" P_CHI2="1.0" P_Z="0.04128253687232178" STUDIES="1" TAU2="0.0" TOTAL_1="230" TOTAL_2="119" WEIGHT="37.60291404779733" Z="2.0406810828422066">
<NAME>Anakinra</NAME>
<DICH_DATA CI_END="1.9963922324502603" CI_START="1.0140462584545975" EFFECT_SIZE="1.4228260869565217" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="32" LOG_CI_END="0.3002458714472643" LOG_CI_START="0.006057766963136788" LOG_EFFECT_SIZE="0.15315181920520052" ORDER="16213" O_E="0.0" SE="0.1728075488285799" STUDY_ID="STD-Bresnihan-1998" TOTAL_1="230" TOTAL_2="119" VAR="0.02986244893214203" WEIGHT="37.60291404779733"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0029436946822434954" CI_END="2.2255374532056624" CI_START="1.3411454244083145" DF="1.0" EFFECT_SIZE="1.7276485094532705" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="66" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.3474349073508179" LOG_CI_START="0.12747587225412624" LOG_EFFECT_SIZE="0.23745538980247202" NO="2" P_CHI2="0.956731368208571" P_Z="2.3189704998318236E-5" STUDIES="2" TAU2="0.0" TOTAL_1="355" TOTAL_2="299" WEIGHT="62.397085952202666" Z="4.231733529319931">
<NAME>Anakinra + Methotrexate</NAME>
<DICH_DATA CI_END="3.016646838927435" CI_START="0.9624135962513176" EFFECT_SIZE="1.7038961038961038" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="11" LOG_CI_END="0.47952446997525255" LOG_CI_START="-0.01663825024093351" LOG_EFFECT_SIZE="0.23144310986715955" ORDER="16214" O_E="0.0" SE="0.29144843790006336" STUDY_ID="STD-Cohen-2002" TOTAL_1="105" TOTAL_2="48" VAR="0.08494219195438708" WEIGHT="13.46045275477485"/>
<DICH_DATA CI_END="2.299494560509435" CI_START="1.3078467895336676" EFFECT_SIZE="1.7341818181818183" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="55" LOG_CI_END="0.361632386580841" LOG_CI_START="0.11655687062636787" LOG_EFFECT_SIZE="0.23909462860360445" ORDER="16215" O_E="0.0" SE="0.1439585712150268" STUDY_ID="STD-Cohen-2004" TOTAL_1="250" TOTAL_2="251" VAR="0.020724070226271943" WEIGHT="48.93663319742782"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.2825114734578995" CI_END="4.026311359129938" CI_START="1.559232489695145" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.5055848588271794" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="22" I2="22.02798799890607" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.6049073563259768" LOG_CI_START="0.19291087558898606" LOG_EFFECT_SIZE="0.3989091159574814" METHOD="MH" MODIFIED="2008-11-09 19:27:16 -0500" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.2574326994059737" P_Q="0.0" P_Z="1.474004712649276E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="355" TOTAL_2="299" WEIGHT="100.0" Z="3.795408635446524">
<NAME>ACR50</NAME>
<GROUP_LABEL_1>Anakinra</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors Anakinra</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.2825114734578995" CI_END="4.026311359129938" CI_START="1.559232489695145" DF="1.0" EFFECT_SIZE="2.5055848588271794" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="22" I2="22.02798799890607" ID="CMP-002.02.01" LOG_CI_END="0.6049073563259768" LOG_CI_START="0.19291087558898606" LOG_EFFECT_SIZE="0.3989091159574814" NO="1" P_CHI2="0.2574326994059737" P_Z="1.474004712649276E-4" STUDIES="2" TAU2="0.0" TOTAL_1="355" TOTAL_2="299" WEIGHT="100.0" Z="3.795408635446524">
<NAME>Anakinra + Methotrexate</NAME>
<DICH_DATA CI_END="20.52836730886724" CI_START="1.2317847898854755" EFFECT_SIZE="5.0285714285714285" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="2" LOG_CI_END="1.3123544098213376" LOG_CI_START="0.09053483710641082" LOG_EFFECT_SIZE="0.7014446234638742" ORDER="16216" O_E="0.0" SE="0.7177028651171755" STUDY_ID="STD-Cohen-2002" TOTAL_1="105" TOTAL_2="48" VAR="0.5150974025974026" WEIGHT="12.09018512772779"/>
<DICH_DATA CI_END="3.5615578913013666" CI_START="1.308290950816872" EFFECT_SIZE="2.1586" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="20" LOG_CI_END="0.5516400079725713" LOG_CI_START="0.11670433747664029" LOG_EFFECT_SIZE="0.33417217272460586" ORDER="16217" O_E="0.0" SE="0.2554833658156015" STUDY_ID="STD-Cohen-2004" TOTAL_1="250" TOTAL_2="251" VAR="0.06527175020846845" WEIGHT="87.90981487227221"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5252725323557446" CI_END="9.567973164465647" CI_START="1.436681782065098" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.7075777451963887" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.9808199485694158" LOG_CI_START="0.15736058469832956" LOG_EFFECT_SIZE="0.5690902666338726" METHOD="MH" MODIFIED="2008-11-09 19:30:49 -0500" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.46860126617156883" P_Q="0.0" P_Z="0.006747610503814017" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="355" TOTAL_2="299" WEIGHT="100.0" Z="2.7090503198875613">
<NAME>ACR70</NAME>
<GROUP_LABEL_1>Anakinra</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors Anakinra</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.5252725323557446" CI_END="9.567973164465647" CI_START="1.436681782065098" DF="1.0" EFFECT_SIZE="3.7075777451963887" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="5" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="0.9808199485694158" LOG_CI_START="0.15736058469832956" LOG_EFFECT_SIZE="0.5690902666338726" NO="1" P_CHI2="0.46860126617156883" P_Z="0.006747610503814017" STUDIES="2" TAU2="0.0" TOTAL_1="355" TOTAL_2="299" WEIGHT="100.0" Z="2.7090503198875613">
<NAME>Anakinra + Methotrexate</NAME>
<DICH_DATA CI_END="147.88091771480083" CI_START="0.5216455349776168" EFFECT_SIZE="8.783018867924529" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" LOG_CI_END="2.1699121370406234" LOG_CI_START="-0.2826245056074789" LOG_EFFECT_SIZE="0.9436438157165724" ORDER="16218" O_E="0.0" SE="1.440632164143672" STUDY_ID="STD-Cohen-2002" TOTAL_1="105" TOTAL_2="48" VAR="2.0754210323652797" WEIGHT="12.05294526175313"/>
<DICH_DATA CI_END="8.161750317865678" CI_START="1.1115439270595564" EFFECT_SIZE="3.012" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" LOG_CI_END="0.9117833048170898" LOG_CI_START="0.045926630240236126" LOG_EFFECT_SIZE="0.47885496752866297" ORDER="16219" O_E="0.0" SE="0.5086084967061076" STUDY_ID="STD-Cohen-2004" TOTAL_1="250" TOTAL_2="251" VAR="0.25868260292164674" WEIGHT="87.94705473824688"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.9956039981791025" CI_END="1.2702966764522052" CI_START="0.8568399389492496" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0432837230105443" ESTIMABLE="YES" EVENTS_1="331" EVENTS_2="106" I2="49.944989520696986" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.10390516182141445" LOG_CI_START="-0.06710029840750584" LOG_EFFECT_SIZE="0.01840243170695428" METHOD="MH" NO="4" P_CHI2="0.13563328228570093" P_Q="0.0" P_Z="0.6731449524674906" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1479" TOTAL_2="478" WEIGHT="100.0" Z="0.4218356925598162">
<NAME>Withdrawals</NAME>
<GROUP_LABEL_1>Anakinra</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors Anakinra</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.2463443309536393" CI_END="1.2473998465850529" CI_START="0.8187988262678397" DF="1.0" EFFECT_SIZE="1.0106282849151436" ESTIMABLE="YES" EVENTS_1="299" EVENTS_2="92" I2="69.19612037253479" ID="CMP-002.04.01" LOG_CI_END="0.09600568630219869" LOG_CI_START="-0.08682278856176179" LOG_EFFECT_SIZE="0.004591448870218443" NO="1" P_CHI2="0.07158300075063795" P_Z="0.921580682152447" STUDIES="2" TAU2="0.0" TOTAL_1="1348" TOTAL_2="404" WEIGHT="88.35973290531938" Z="0.09844281017146075">
<NAME>Anakinra</NAME>
<DICH_DATA CI_END="1.0910561628653843" CI_START="0.5514097451019033" EFFECT_SIZE="0.7756410256410257" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="39" LOG_CI_END="0.037847106770501404" LOG_CI_START="-0.25852556284652434" LOG_EFFECT_SIZE="-0.1103392280380115" ORDER="16221" O_E="0.0" SE="0.1740907732014161" STUDY_ID="STD-Bresnihan-1998" TOTAL_1="232" TOTAL_2="121" VAR="0.030307597313866903" WEIGHT="33.3499634197877"/>
<DICH_DATA CI_END="1.5063065383543042" CI_START="0.882700691019953" EFFECT_SIZE="1.1530905525123418" ESTIMABLE="YES" EVENTS_1="241" EVENTS_2="53" LOG_CI_END="0.1779133612198357" LOG_CI_START="-0.054186533426216564" LOG_EFFECT_SIZE="0.061863413896809584" ORDER="16220" O_E="0.0" SE="0.13633662702809904" STUDY_ID="STD-Fleischman-2003" TOTAL_1="1116" TOTAL_2="283" VAR="0.018587675869398988" WEIGHT="55.00976948553168"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.2596024582151553" CI_START="0.7377898817531228" DF="0.0" EFFECT_SIZE="1.2911668484187568" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="14" I2="0.0" ID="CMP-002.04.02" LOG_CI_END="0.3540320385322913" LOG_CI_START="-0.1320673050985315" LOG_EFFECT_SIZE="0.11098236671687987" NO="2" P_CHI2="1.0" P_Z="0.3708047254216402" STUDIES="1" TAU2="0.0" TOTAL_1="131" TOTAL_2="74" WEIGHT="11.640267094680617" Z="0.8949670248857695">
<NAME>Anakinra + Methotrexate</NAME>
<DICH_DATA CI_END="2.2596024582151553" CI_START="0.7377898817531228" EFFECT_SIZE="1.2911668484187568" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="14" LOG_CI_END="0.3540320385322913" LOG_CI_START="-0.1320673050985315" LOG_EFFECT_SIZE="0.11098236671687987" ORDER="16222" O_E="0.0" SE="0.28553716067930346" STUDY_ID="STD-Cohen-2002" TOTAL_1="131" TOTAL_2="74" VAR="0.08153147012879837" WEIGHT="11.640267094680617"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.6314236525508825" CI_END="1.446845353525248" CI_START="0.8037578550653657" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0783845872232893" ESTIMABLE="YES" EVENTS_1="543" EVENTS_2="188" I2="72.46259055184726" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.16042211391114297" LOG_CI_START="-0.09487476971951185" LOG_EFFECT_SIZE="0.03277367209581558" METHOD="MH" NO="5" P_CHI2="0.05669848653476395" P_Q="0.0" P_Z="0.6148097826685313" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.03331791859791532" TOTALS="YES" TOTAL_1="1366" TOTAL_2="534" WEIGHT="100.0" Z="0.503219749770661">
<NAME>Infections</NAME>
<GROUP_LABEL_1>Anakinra</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors Anakinra</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1020842989101172" CI_START="0.8160844583711262" DF="0.0" EFFECT_SIZE="0.948363784713116" ESTIMABLE="YES" EVENTS_1="460" EVENTS_2="123" I2="0.0" ID="CMP-002.05.01" LOG_CI_END="0.04221481516121097" LOG_CI_START="-0.08826489283139811" LOG_EFFECT_SIZE="-0.023025038835093544" NO="1" P_CHI2="1.0" P_Z="0.4891080379713413" STUDIES="1" TAU2="0.0" TOTAL_1="1116" TOTAL_2="283" WEIGHT="57.380671681849506" Z="0.691728201322702">
<NAME>Anakinra</NAME>
<DICH_DATA CI_END="1.1020842989101172" CI_START="0.8160844583711262" EFFECT_SIZE="0.948363784713116" ESTIMABLE="YES" EVENTS_1="460" EVENTS_2="123" LOG_CI_END="0.04221481516121097" LOG_CI_START="-0.08826489283139811" LOG_EFFECT_SIZE="-0.023025038835093544" ORDER="16223" O_E="0.0" SE="0.07664442635982983" STUDY_ID="STD-Fleischman-2003" TOTAL_1="1116" TOTAL_2="283" VAR="0.005874368092027379" WEIGHT="57.380671681849506"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6850234771816432" CI_START="0.9754183935784176" DF="0.0" EFFECT_SIZE="1.2820307692307693" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="65" I2="0.0" ID="CMP-002.05.02" LOG_CI_END="0.2266059562099736" LOG_CI_START="-0.010809059125535852" LOG_EFFECT_SIZE="0.10789844854221887" NO="2" P_CHI2="1.0" P_Z="0.07483128857739095" STUDIES="1" TAU2="0.0" TOTAL_1="250" TOTAL_2="251" WEIGHT="42.61932831815049" Z="1.7814970365850094">
<NAME>Anakinra + Methotrexate</NAME>
<DICH_DATA CI_END="1.6850234771816432" CI_START="0.9754183935784176" EFFECT_SIZE="1.2820307692307693" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="65" LOG_CI_END="0.2266059562099736" LOG_CI_START="-0.010809059125535852" LOG_EFFECT_SIZE="0.10789844854221887" ORDER="16224" O_E="0.0" SE="0.13945875523135792" STUDY_ID="STD-Cohen-2004" TOTAL_1="250" TOTAL_2="251" VAR="0.019448744410679803" WEIGHT="42.61932831815049"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.6827675157243542" CI_END="12.199591565569339" CI_START="0.8127998989065239" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="3.148940582353951" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="3" I2="40.57408461622544" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="1.0863452910199352" LOG_CI_START="-0.0900163590763242" LOG_EFFECT_SIZE="0.4981644659718054" METHOD="MH" NO="6" P_CHI2="0.19455720041861368" P_Q="0.0" P_Z="0.09691300163314559" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1366" TOTAL_2="534" WEIGHT="100.0" Z="1.6600072122420388">
<NAME>Serious Infections</NAME>
<GROUP_LABEL_1>Anakinra</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors Anakinra</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="43.00427228320546" CI_START="0.7910219792648814" DF="0.0" EFFECT_SIZE="5.832437275985663" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="1" I2="0.0" ID="CMP-002.06.01" LOG_CI_END="1.6335116029482817" LOG_CI_START="-0.10181144906763544" LOG_EFFECT_SIZE="0.7658500769403231" NO="1" P_CHI2="1.0" P_Z="0.08363354349915579" STUDIES="1" TAU2="0.0" TOTAL_1="1116" TOTAL_2="283" WEIGHT="44.4230805901085" Z="1.7299817075748667">
<NAME>Anakinra</NAME>
<DICH_DATA CI_END="43.004272283205495" CI_START="0.791021979264881" EFFECT_SIZE="5.832437275985663" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="1" LOG_CI_END="1.6335116029482821" LOG_CI_START="-0.10181144906763562" LOG_EFFECT_SIZE="0.7658500769403231" ORDER="16225" O_E="0.0" SE="1.019337350741795" STUDY_ID="STD-Fleischman-2003" TOTAL_1="1116" TOTAL_2="283" VAR="1.0390486346173013" WEIGHT="44.4230805901085"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.07180737418783" CI_START="0.14254008157508205" DF="0.0" EFFECT_SIZE="1.004" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" I2="0.0" ID="CMP-002.06.02" LOG_CI_END="0.8495304226121114" LOG_CI_START="-0.8460629969941103" LOG_EFFECT_SIZE="0.0017337128090005314" NO="2" P_CHI2="1.0" P_Z="0.9968020444658369" STUDIES="1" TAU2="0.0" TOTAL_1="250" TOTAL_2="251" WEIGHT="55.576919409891495" Z="0.004008053612246211">
<NAME>Anakinra + Methotrexate</NAME>
<DICH_DATA CI_END="7.07180737418783" CI_START="0.14254008157508205" EFFECT_SIZE="1.004" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8495304226121114" LOG_CI_START="-0.8460629969941103" LOG_EFFECT_SIZE="0.0017337128090005314" ORDER="16226" O_E="0.0" SE="0.9959999679994874" STUDY_ID="STD-Cohen-2004" TOTAL_1="250" TOTAL_2="251" VAR="0.9920159362549801" WEIGHT="55.576919409891495"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.394046364902214" CI_END="1.1730876320798107" CI_START="0.9385689192934746" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0492967126021548" ESTIMABLE="YES" EVENTS_1="1252" EVENTS_2="464" I2="86.47560549867846" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="0.06933045602614604" LOG_CI_START="-0.02753383154567544" LOG_EFFECT_SIZE="0.02089831224023531" METHOD="MH" NO="7" P_CHI2="0.0065440461861879795" P_Q="0.0" P_Z="0.3977100467576671" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.005633123774124793" TOTALS="YES" TOTAL_1="1366" TOTAL_2="534" WEIGHT="100.00000000000001" Z="0.8457180733025758">
<NAME>Adverse Events</NAME>
<GROUP_LABEL_1>Anakinra</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors Anakinra</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0364458954851337" CI_START="0.9606334794898752" DF="0.0" EFFECT_SIZE="0.9978199371043271" ESTIMABLE="YES" EVENTS_1="1027" EVENTS_2="261" I2="0.0" ID="CMP-002.07.01" LOG_CI_END="0.015546635995201142" LOG_CI_START="-0.01744228163174606" LOG_EFFECT_SIZE="-9.478228182724822E-4" NO="1" P_CHI2="1.0" P_Z="0.9103273754936877" STUDIES="1" TAU2="0.0" TOTAL_1="1116" TOTAL_2="283" WEIGHT="53.87998699581825" Z="0.11262561618704621">
<NAME>Anakinra</NAME>
<DICH_DATA CI_END="1.0364458954851337" CI_START="0.9606334794898752" EFFECT_SIZE="0.9978199371043271" ESTIMABLE="YES" EVENTS_1="1027" EVENTS_2="261" LOG_CI_END="0.015546635995201142" LOG_CI_START="-0.01744228163174606" LOG_EFFECT_SIZE="-9.478228182724822E-4" ORDER="16227" O_E="0.0" SE="0.019377853511844657" STUDY_ID="STD-Fleischman-2003" TOTAL_1="1116" TOTAL_2="283" VAR="3.7550120672651035E-4" WEIGHT="53.87998699581825"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1970579731448365" CI_START="1.03448739285676" DF="0.0" EFFECT_SIZE="1.112807881773399" ESTIMABLE="YES" EVENTS_1="225" EVENTS_2="203" I2="0.0" ID="CMP-002.07.02" LOG_CI_END="0.07811518366223691" LOG_CI_START="0.014725202352063321" LOG_EFFECT_SIZE="0.04642019300715011" NO="2" P_CHI2="1.0" P_Z="0.004097644798451459" STUDIES="1" TAU2="0.0" TOTAL_1="250" TOTAL_2="251" WEIGHT="46.120013004181764" Z="2.8705452997131697">
<NAME>Anakinra + Methotrexate</NAME>
<DICH_DATA CI_END="1.1970579731448365" CI_START="1.03448739285676" EFFECT_SIZE="1.112807881773399" ESTIMABLE="YES" EVENTS_1="225" EVENTS_2="203" LOG_CI_END="0.07811518366223691" LOG_CI_START="0.014725202352063321" LOG_EFFECT_SIZE="0.04642019300715011" ORDER="16228" O_E="0.0" SE="0.037235588807064145" STUDY_ID="STD-Cohen-2004" TOTAL_1="250" TOTAL_2="251" VAR="0.0013864890738087606" WEIGHT="46.120013004181764"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2064430841823337" CI_END="1.5565275633050835" CI_START="0.6950866620347788" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0401545790616211" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="30" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="0.19215681566120116" LOG_CI_START="-0.1579610450542693" LOG_EFFECT_SIZE="0.017097885303465923" METHOD="MH" NO="8" P_CHI2="0.6495696903773129" P_Q="0.0" P_Z="0.8481900232189079" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1366" TOTAL_2="534" WEIGHT="100.0" Z="0.19142833409360632">
<NAME>Serious Adverse Events</NAME>
<GROUP_LABEL_1>Anakinra</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors Anakinra</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.3409857625056317E-31" CI_END="1.5542341633953825" CI_START="0.6322365102916783" DF="0.0" EFFECT_SIZE="0.9912838057999347" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="22" I2="100.0" ID="CMP-002.08.01" LOG_CI_END="0.1915164508929924" LOG_CI_START="-0.19912042820480894" LOG_EFFECT_SIZE="-0.0038019886559082844" NO="1" P_CHI2="0.0" P_Z="0.9695666068579598" STUDIES="1" TAU2="0.0" TOTAL_1="1116" TOTAL_2="283" WEIGHT="81.46842160758197" Z="0.038151855259648614">
<NAME>Anakinra</NAME>
<DICH_DATA CI_END="1.5542341633953827" CI_START="0.6322365102916783" EFFECT_SIZE="0.9912838057999348" ESTIMABLE="YES" EVENTS_1="86" EVENTS_2="22" LOG_CI_END="0.19151645089299243" LOG_CI_START="-0.19912042820480894" LOG_EFFECT_SIZE="-0.003801988655908236" ORDER="16229" O_E="0.0" SE="0.2294620364657861" STUDY_ID="STD-Fleischman-2003" TOTAL_1="1116" TOTAL_2="283" VAR="0.05265282617902575" WEIGHT="81.46842160758197"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.127344345900868" CI_START="0.5036301813276323" DF="0.0" EFFECT_SIZE="1.255" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" I2="0.0" ID="CMP-002.08.02" LOG_CI_END="0.495175703210031" LOG_CI_START="-0.29788825157591725" LOG_EFFECT_SIZE="0.0986437258170569" NO="2" P_CHI2="1.0" P_Z="0.6258525685524723" STUDIES="1" TAU2="0.0" TOTAL_1="250" TOTAL_2="251" WEIGHT="18.531578392418027" Z="0.4875726572504694">
<NAME>Anakinra + Methotrexate</NAME>
<DICH_DATA CI_END="3.127344345900868" CI_START="0.5036301813276323" EFFECT_SIZE="1.255" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.495175703210031" LOG_CI_START="-0.29788825157591725" LOG_EFFECT_SIZE="0.0986437258170569" ORDER="16230" O_E="0.0" SE="0.4658496927711556" STUDY_ID="STD-Cohen-2004" TOTAL_1="250" TOTAL_2="251" VAR="0.21701593625498009" WEIGHT="18.531578392418027"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.595486946192167" CI_END="2.768827440351549" CI_START="2.174820150229928" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.4539155873391616" ESTIMABLE="YES" EVENTS_1="1235" EVENTS_2="204" I2="34.718561163886925" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="0.4422958903651693" LOG_CI_START="0.3374233481907758" LOG_EFFECT_SIZE="0.3898596192779725" METHOD="MH" NO="9" P_CHI2="0.20392963726700375" P_Q="0.0" P_Z="4.221961893119893E-48" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1729" TOTAL_2="729" WEIGHT="100.0" Z="14.57218061026264">
<NAME>Injection site reactions</NAME>
<GROUP_LABEL_1>Anakinra</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors Anakinra</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.473512885096236" CI_END="2.786209055669489" CI_START="2.064392911458646" DF="1.0" EFFECT_SIZE="2.398297359454407" ESTIMABLE="YES" EVENTS_1="989" EVENTS_2="123" I2="71.21070129635363" ID="CMP-002.09.01" LOG_CI_END="0.4450136994237051" LOG_CI_START="0.3147923591560618" LOG_EFFECT_SIZE="0.37990302928988345" NO="1" P_CHI2="0.062358866349372155" P_Z="2.767929798225596E-30" STUDIES="2" TAU2="0.0" TOTAL_1="1348" TOTAL_2="404" WEIGHT="68.41141798705078" Z="11.43585611230036">
<NAME>Anakinra</NAME>
<DICH_DATA CI_END="4.277492036273592" CI_START="2.2639618991609325" EFFECT_SIZE="3.1119252873563217" ESTIMABLE="YES" EVENTS_1="179" EVENTS_2="30" LOG_CI_END="0.6311892096554164" LOG_CI_START="0.35486911371614593" LOG_EFFECT_SIZE="0.49302916168578115" ORDER="16232" O_E="0.0" SE="0.16231179216126201" STUDY_ID="STD-Bresnihan-1998" TOTAL_1="232" TOTAL_2="121" VAR="0.02634511787460072" WEIGHT="14.364121773316755"/>
<DICH_DATA CI_END="2.6189258484772466" CI_START="1.8626249685338436" EFFECT_SIZE="2.208636836628512" ESTIMABLE="YES" EVENTS_1="810" EVENTS_2="93" LOG_CI_END="0.41812320210867854" LOG_CI_START="0.2701254203862114" LOG_EFFECT_SIZE="0.3441243112474449" ORDER="16231" O_E="0.0" SE="0.08693462958461197" STUDY_ID="STD-Fleischman-2003" TOTAL_1="1116" TOTAL_2="283" VAR="0.00755762982101369" WEIGHT="54.04729621373403"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.7519684764031023" CI_END="3.152528241429022" CI_START="2.1022399299100614" DF="1.0" EFFECT_SIZE="2.5743680291095203" ESTIMABLE="YES" EVENTS_1="246" EVENTS_2="81" I2="0.0" ID="CMP-002.09.02" LOG_CI_END="0.49865898582143886" LOG_CI_START="0.32268228081189" LOG_EFFECT_SIZE="0.4106706333166644" NO="2" P_CHI2="0.3858537475974705" P_Z="5.81059717813973E-20" STUDIES="2" TAU2="0.0" TOTAL_1="381" TOTAL_2="325" WEIGHT="31.588582012949217" Z="9.147797724309491">
<NAME>Anakinra + Methotrexate</NAME>
<DICH_DATA CI_END="3.2800517986254487" CI_START="1.5196995724472848" EFFECT_SIZE="2.232642675390767" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="21" LOG_CI_END="0.5158807021505736" LOG_CI_START="0.18175774128415953" LOG_EFFECT_SIZE="0.34881922171736657" ORDER="16233" O_E="0.0" SE="0.19626548114826228" STUDY_ID="STD-Cohen-2002" TOTAL_1="131" TOTAL_2="74" VAR="0.038520139090358896" WEIGHT="9.776452023011789"/>
<DICH_DATA CI_END="3.4624591690048154" CI_START="2.1485995130399456" EFFECT_SIZE="2.727533333333333" ESTIMABLE="YES" EVENTS_1="163" EVENTS_2="60" LOG_CI_END="0.5393846606918682" LOG_CI_START="0.33215547296676107" LOG_EFFECT_SIZE="0.43577006682931463" ORDER="16234" O_E="0.0" SE="0.12172745067075101" STUDY_ID="STD-Cohen-2004" TOTAL_1="250" TOTAL_2="251" VAR="0.01481757224680012" WEIGHT="21.81212998993743"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="9.039965464929848" CI_START="0.11381452576584954" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.014336917562724" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.10" LOG_CI_END="0.9561667713582119" LOG_CI_START="-0.9438023068568266" LOG_EFFECT_SIZE="0.006182232250692644" METHOD="MH" NO="10" P_CHI2="1.0" P_Q="0.0" P_Z="0.9898233425537435" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1116" TOTAL_2="283" WEIGHT="100.0" Z="0.012754894481549223">
<NAME>Deaths</NAME>
<GROUP_LABEL_1>Anakinra</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors Anakinra</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.039965464929848" CI_START="0.11381452576584954" DF="0.0" EFFECT_SIZE="1.014336917562724" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" ID="CMP-002.10.01" LOG_CI_END="0.9561667713582119" LOG_CI_START="-0.9438023068568266" LOG_EFFECT_SIZE="0.006182232250692644" NO="1" P_CHI2="1.0" P_Z="0.9898233425537435" STUDIES="1" TAU2="0.0" TOTAL_1="1116" TOTAL_2="283" WEIGHT="100.0" Z="0.012754894481549223">
<NAME>Anakinra</NAME>
<DICH_DATA CI_END="9.039965464929848" CI_START="0.11381452576584954" EFFECT_SIZE="1.014336917562724" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="0.9561667713582119" LOG_CI_START="-0.9438023068568266" LOG_EFFECT_SIZE="0.006182232250692644" ORDER="16235" O_E="0.0" SE="1.1160512415421329" STUDY_ID="STD-Fleischman-2003" TOTAL_1="1116" TOTAL_2="283" VAR="1.2455703737477362" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.6923056687617117" CI_END="-0.03611032523294698" CI_START="-0.153889674767053" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.095" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.11" NO="11" P_CHI2="0.40538164383572006" P_Q="0.40538164383572006" P_Z="0.0015680448501713964" Q="0.6923056687617117" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="230" TOTAL_2="238" UNITS="" WEIGHT="100.0" Z="3.161786497681194">
<NAME>change in pain VAS score</NAME>
<GROUP_LABEL_1>Anakinra</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors Anakinra</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.013282576739307037" CI_START="-0.153282576739307" DF="0.0" EFFECT_SIZE="-0.06999999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-002.11.01" NO="1" P_CHI2="1.0" P_Z="0.0994813753072929" STUDIES="1" TAU2="0.0" TOTAL_1="115" TOTAL_2="119" WEIGHT="50.0" Z="1.647373127602216">
<NAME>Anakinra 75</NAME>
<CONT_DATA CI_END="0.013282576739307037" CI_START="-0.153282576739307" EFFECT_SIZE="-0.06999999999999999" ESTIMABLE="YES" MEAN_1="-0.12" MEAN_2="-0.05" ORDER="16236" SD_1="0.32" SD_2="0.33" SE="0.04249189137975461" STUDY_ID="STD-Bresnihan-1998" TOTAL_1="115" TOTAL_2="119" WEIGHT="50.0"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.0666657745097685E-31" CI_END="-0.036717423260692994" CI_START="-0.20328257673930705" DF="0.0" EFFECT_SIZE="-0.12000000000000002" ESTIMABLE="YES" I2="100.0" ID="CMP-002.11.02" NO="2" P_CHI2="0.0" P_Z="0.004741829100126167" STUDIES="1" TAU2="0.0" TOTAL_1="115" TOTAL_2="119" WEIGHT="50.0" Z="2.8240682187466573">
<NAME>Anakinra 150</NAME>
<CONT_DATA CI_END="-0.03671742326069298" CI_START="-0.20328257673930705" EFFECT_SIZE="-0.12000000000000001" ESTIMABLE="YES" MEAN_1="-0.17" MEAN_2="-0.05" ORDER="16237" SD_1="0.32" SD_2="0.33" SE="0.04249189137975461" STUDY_ID="STD-Bresnihan-1998" TOTAL_1="115" TOTAL_2="119" WEIGHT="50.0"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.510286541282729" CI_END="-0.08591457150004836" CI_START="-0.29659261783493973" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.19125359466749403" ESTIMABLE="YES" I2="63.70424686600011" I2_Q="63.70424686600011" ID="CMP-002.12" NO="12" P_CHI2="0.0635999469255003" P_Q="0.0635999469255003" P_Z="3.729620311329769E-4" Q="5.510286541282729" RANDOM="YES" SCALE="4.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.005474110730256162" TOTALS="YES" TOTAL_1="472" TOTAL_2="479" UNITS="" WEIGHT="100.0" Z="3.5585118049391125">
<NAME>change in HAQ score</NAME>
<GROUP_LABEL_1>Anakinra</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors Anakinra</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.08918089391399368" CI_START="-0.3108191060860063" DF="0.0" EFFECT_SIZE="-0.2" ESTIMABLE="YES" I2="0.0" ID="CMP-002.12.01" NO="1" P_CHI2="1.0" P_Z="4.0434557696151764E-4" STUDIES="1" TAU2="0.0" TOTAL_1="112" TOTAL_2="114" WEIGHT="33.31280280198048" Z="3.537231175676391">
<NAME>Anakinra 75</NAME>
<CONT_DATA CI_END="-0.08918089391399368" CI_START="-0.3108191060860063" EFFECT_SIZE="-0.2" ESTIMABLE="YES" MEAN_1="-0.2" MEAN_2="0.0" ORDER="16238" SD_1="0.42" SD_2="0.43" SE="0.05654139920944124" STUDY_ID="STD-Bresnihan-1998" TOTAL_1="112" TOTAL_2="114" WEIGHT="33.31280280198048"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.1582563634471339" CI_START="-0.4417436365528661" DF="0.0" EFFECT_SIZE="-0.3" ESTIMABLE="YES" I2="0.0" ID="CMP-002.12.02" NO="2" P_CHI2="1.0" P_Z="3.3501451129183885E-5" STUDIES="1" TAU2="0.0" TOTAL_1="110" TOTAL_2="114" WEIGHT="26.985301129321893" Z="4.148258148736815">
<NAME>Anakinra 150</NAME>
<CONT_DATA CI_END="-0.1582563634471339" CI_START="-0.4417436365528661" EFFECT_SIZE="-0.3" ESTIMABLE="YES" MEAN_1="-0.3" MEAN_2="0.0" ORDER="16239" SD_1="0.63" SD_2="0.43" SE="0.07231951080270954" STUDY_ID="STD-Bresnihan-1998" TOTAL_1="110" TOTAL_2="114" WEIGHT="26.985301129321893"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.02681047705233633" CI_START="-0.19318952294766364" DF="0.0" EFFECT_SIZE="-0.10999999999999999" ESTIMABLE="YES" I2="0.0" ID="CMP-002.12.03" NO="3" P_CHI2="1.0" P_Z="0.009552386262847616" STUDIES="1" TAU2="0.0" TOTAL_1="250" TOTAL_2="251" WEIGHT="39.70189606869762" Z="2.591624890493027">
<NAME>Anakinra + Methotrexate</NAME>
<CONT_DATA CI_END="-0.02681047705233633" CI_START="-0.19318952294766364" EFFECT_SIZE="-0.10999999999999999" ESTIMABLE="YES" MEAN_1="-0.29" MEAN_2="-0.18" ORDER="16240" SD_1="0.47" SD_2="0.48" SE="0.0424444140830403" STUDY_ID="STD-Cohen-2004" TOTAL_1="250" TOTAL_2="251" WEIGHT="39.70189606869762"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.3063989397518844" CI_END="-7.3321177020346955" CI_START="-12.747519039361185" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-10.03981837069794" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.13" NO="13" P_CHI2="0.857958583602124" P_Q="0.857958583602124" P_Z="3.6673436268355583E-13" Q="0.3063989397518844" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="472" TOTAL_2="477" UNITS="" WEIGHT="99.99999999999999" Z="7.267303452565965">
<NAME>change in ESR</NAME>
<GROUP_LABEL_1>Anakinra</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors Anakinra</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-3.1460721351186773" CI_START="-14.453927864881324" DF="0.0" EFFECT_SIZE="-8.8" ESTIMABLE="YES" I2="0.0" ID="CMP-002.13.01" NO="1" P_CHI2="1.0" P_Z="0.0022841007593078595" STUDIES="1" TAU2="0.0" TOTAL_1="111" TOTAL_2="113" WEIGHT="22.935107382887143" Z="3.0505665222728324">
<NAME>Anakinra 75</NAME>
<CONT_DATA CI_END="-3.1460721351186773" CI_START="-14.453927864881324" EFFECT_SIZE="-8.8" ESTIMABLE="YES" MEAN_1="-7.9" MEAN_2="0.9" ORDER="16241" SD_1="21.7" SD_2="21.47" SE="2.8847100811437274" STUDY_ID="STD-Bresnihan-1998" TOTAL_1="111" TOTAL_2="113" WEIGHT="22.935107382887143"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-4.449914019913581" CI_START="-17.95008598008642" DF="0.0" EFFECT_SIZE="-11.200000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-002.13.02" NO="2" P_CHI2="1.0" P_Z="0.0011457708786064683" STUDIES="1" TAU2="0.0" TOTAL_1="111" TOTAL_2="113" WEIGHT="16.090987405835936" Z="3.2520469652695545">
<NAME>Anakinra 150</NAME>
<CONT_DATA CI_END="-4.449914019913581" CI_START="-17.95008598008642" EFFECT_SIZE="-11.200000000000001" ESTIMABLE="YES" MEAN_1="-10.3" MEAN_2="0.9" ORDER="16242" SD_1="29.39" SD_2="21.47" SE="3.443984702438533" STUDY_ID="STD-Bresnihan-1998" TOTAL_1="111" TOTAL_2="113" WEIGHT="16.090987405835936"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-6.7324027762810426" CI_START="-13.667597223718957" DF="0.0" EFFECT_SIZE="-10.2" ESTIMABLE="YES" I2="0.0" ID="CMP-002.13.03" NO="3" P_CHI2="1.0" P_Z="8.152743915297693E-9" STUDIES="1" TAU2="0.0" TOTAL_1="250" TOTAL_2="251" WEIGHT="60.97390521127691" Z="5.76526953752367">
<NAME>Anakinra + Methotrexate</NAME>
<CONT_DATA CI_END="-6.7324027762810426" CI_START="-13.667597223718957" EFFECT_SIZE="-10.2" ESTIMABLE="YES" MEAN_1="-16.2" MEAN_2="-6.0" ORDER="16243" SD_1="18.97" SD_2="20.6" SE="1.7692147667359814" STUDY_ID="STD-Cohen-2004" TOTAL_1="250" TOTAL_2="251" WEIGHT="60.97390521127691"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.05778631213525498" CI_START="-1.2577863121352548" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.6" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.14" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.07381121988000564" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="227" TOTAL_2="236" UNITS="" WEIGHT="100.0" Z="1.7877817902696431">
<NAME>change in CRP</NAME>
<GROUP_LABEL_1>Anakinra</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors Anakinra</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.21795475586743918" CI_START="-1.4179547558674392" DF="0.0" EFFECT_SIZE="-0.6" ESTIMABLE="YES" I2="0.0" ID="CMP-002.14.01" NO="1" P_CHI2="1.0" P_Z="0.15051751409445896" STUDIES="1" TAU2="0.0" TOTAL_1="115" TOTAL_2="118" WEIGHT="64.67122691210507" Z="1.43770591501349">
<NAME>Anakinra 75</NAME>
<CONT_DATA CI_END="0.21795475586743918" CI_START="-1.4179547558674392" EFFECT_SIZE="-0.6" ESTIMABLE="YES" MEAN_1="-1.0" MEAN_2="-0.4" ORDER="16244" SD_1="3.32" SD_2="3.04" SE="0.4173315235990875" STUDY_ID="STD-Bresnihan-1998" TOTAL_1="115" TOTAL_2="118" WEIGHT="64.67122691210507"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.5066761596464998" CI_START="-1.7066761596464999" DF="0.0" EFFECT_SIZE="-0.6" ESTIMABLE="YES" I2="0.0" ID="CMP-002.14.02" NO="2" P_CHI2="1.0" P_Z="0.2879534396448359" STUDIES="1" TAU2="0.0" TOTAL_1="112" TOTAL_2="118" WEIGHT="35.32877308789493" Z="1.062621960790833">
<NAME>Anakinra 150</NAME>
<CONT_DATA CI_END="0.5066761596464998" CI_START="-1.7066761596464999" EFFECT_SIZE="-0.6" ESTIMABLE="YES" MEAN_1="-1.0" MEAN_2="-0.4" ORDER="16245" SD_1="5.19" SD_2="3.04" SE="0.5646410691093409" STUDY_ID="STD-Bresnihan-1998" TOTAL_1="112" TOTAL_2="118" WEIGHT="35.32877308789493"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.002194079088389266" CI_END="-0.35964624144307544" CI_START="-4.533191323535352" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.4464187824892134" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.15" NO="15" P_CHI2="0.96263996522844" P_Q="0.96263996522844" P_Z="0.021575719129642963" Q="0.002194079088389266" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="175" TOTAL_2="166" UNITS="" WEIGHT="100.0" Z="2.2977553185444055">
<NAME>change in Larsen score</NAME>
<GROUP_LABEL_1>Anakinra</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors Anakinra</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors Placebo</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="8.075699359784037E-32" CI_END="0.5628677199886449" CI_START="-5.562867719988645" DF="0.0" EFFECT_SIZE="-2.5" ESTIMABLE="YES" I2="100.0" ID="CMP-002.15.01" NO="1" P_CHI2="0.0" P_Z="0.10964772752793371" STUDIES="1" TAU2="0.0" TOTAL_1="89" TOTAL_2="83" WEIGHT="46.418782489213044" Z="1.599778511286247">
<NAME>Anakinra 75</NAME>
<CONT_DATA CI_END="0.5628677199886445" CI_START="-5.562867719988645" EFFECT_SIZE="-2.5000000000000004" ESTIMABLE="YES" MEAN_1="3.9" MEAN_2="6.4" ORDER="16246" SD_1="10.38" SD_2="10.11" SE="1.5627163275183393" STUDY_ID="STD-Bresnihan-1998" TOTAL_1="89" TOTAL_2="83" WEIGHT="46.418782489213044"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.4508136168229089" CI_START="-5.25081361682291" DF="0.0" EFFECT_SIZE="-2.4000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-002.15.02" NO="2" P_CHI2="1.0" P_Z="0.09893783549295113" STUDIES="1" TAU2="0.0" TOTAL_1="86" TOTAL_2="83" WEIGHT="53.58121751078696" Z="1.6500249385431272">
<NAME>Anakinra 150</NAME>
<CONT_DATA CI_END="0.4508136168229089" CI_START="-5.25081361682291" EFFECT_SIZE="-2.4000000000000004" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="6.4" ORDER="16247" SD_1="8.72" SD_2="10.11" SE="1.4545234704870922" STUDY_ID="STD-Bresnihan-1998" TOTAL_1="86" TOTAL_2="83" WEIGHT="53.58121751078696"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.140950461862271E-30" CI_END="1.1500401170632724" CI_START="0.7271925736387724" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9144947416552356" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="54" I2="100.0" I2_Q="0.0" ID="CMP-002.16" LOG_CI_END="0.06071299019302698" LOG_CI_START="-0.13835056494033857" LOG_EFFECT_SIZE="-0.038818787373655815" METHOD="MH" NO="16" P_CHI2="0.0" P_Q="0.0" P_Z="0.44462092812162235" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="81" TOTAL_2="80" WEIGHT="100.0" Z="0.7644134068128182">
<NAME>ACR20 (Genovese 2004)</NAME>
<GROUP_LABEL_1>Anakinra</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors Anakinra</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.140950461862271E-30" CI_END="1.1500401170632724" CI_START="0.7271925736387724" DF="0.0" EFFECT_SIZE="0.9144947416552356" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="54" I2="100.0" ID="CMP-002.16.01" LOG_CI_END="0.06071299019302698" LOG_CI_START="-0.13835056494033857" LOG_EFFECT_SIZE="-0.038818787373655815" NO="1" P_CHI2="0.0" P_Z="0.44462092812162235" STUDIES="1" TAU2="0.0" TOTAL_1="81" TOTAL_2="80" WEIGHT="100.0" Z="0.7644134068128182">
<NAME>Anakinra + Etanercept BW</NAME>
<DICH_DATA CI_END="1.1500401170632721" CI_START="0.7271925736387723" EFFECT_SIZE="0.9144947416552355" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="54" LOG_CI_END="0.06071299019302689" LOG_CI_START="-0.13835056494033862" LOG_EFFECT_SIZE="-0.03881878737365587" ORDER="16248" O_E="0.0" SE="0.11693091766582883" STUDY_ID="STD-Genovese-2004" TOTAL_1="81" TOTAL_2="80" VAR="0.013672839506172842" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1363534026820874" CI_START="0.49266153661393225" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7482229704451927" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="33" I2="0.0" I2_Q="0.0" ID="CMP-002.17" LOG_CI_END="0.05551341673256517" LOG_CI_START="-0.30745134291767723" LOG_EFFECT_SIZE="-0.125968963092556" METHOD="MH" NO="17" P_CHI2="1.0" P_Q="0.0" P_Z="0.17369291996696368" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="81" TOTAL_2="80" WEIGHT="100.0" Z="1.3604330683186765">
<NAME>ACR50 (Genovese 2004)</NAME>
<GROUP_LABEL_1>Anakinra</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors Anakinra</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1363534026820874" CI_START="0.49266153661393225" DF="0.0" EFFECT_SIZE="0.7482229704451927" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="33" I2="0.0" ID="CMP-002.17.01" LOG_CI_END="0.05551341673256517" LOG_CI_START="-0.30745134291767723" LOG_EFFECT_SIZE="-0.125968963092556" NO="1" P_CHI2="1.0" P_Z="0.17369291996696368" STUDIES="1" TAU2="0.0" TOTAL_1="81" TOTAL_2="80" WEIGHT="100.0" Z="1.3604330683186765">
<NAME>Anakinra + etanercept BW</NAME>
<DICH_DATA CI_END="1.1363534026820876" CI_START="0.4926615366139322" EFFECT_SIZE="0.7482229704451927" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="33" LOG_CI_END="0.05551341673256526" LOG_CI_START="-0.3074513429176773" LOG_EFFECT_SIZE="-0.125968963092556" ORDER="16249" O_E="0.0" SE="0.21320729652308956" STUDY_ID="STD-Genovese-2004" TOTAL_1="81" TOTAL_2="80" VAR="0.045457351290684636" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2774908403384853" CI_START="0.3196978156006137" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6390704429920117" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="17" I2="0.0" I2_Q="0.0" ID="CMP-002.18" LOG_CI_END="0.10635779490873618" LOG_CI_START="-0.4952603311222461" LOG_EFFECT_SIZE="-0.19445126810675503" METHOD="MH" NO="18" P_CHI2="1.0" P_Q="0.0" P_Z="0.20516434985788767" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="81" TOTAL_2="80" WEIGHT="100.0" Z="1.2669747327983765">
<NAME>ACR 70 (Genovese 2004)</NAME>
<GROUP_LABEL_1>Anakinra</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors Anakinra</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2774908403384853" CI_START="0.3196978156006137" DF="0.0" EFFECT_SIZE="0.6390704429920117" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="17" I2="0.0" ID="CMP-002.18.01" LOG_CI_END="0.10635779490873618" LOG_CI_START="-0.4952603311222461" LOG_EFFECT_SIZE="-0.19445126810675503" NO="1" P_CHI2="1.0" P_Z="0.20516434985788767" STUDIES="1" TAU2="0.0" TOTAL_1="81" TOTAL_2="80" WEIGHT="100.0" Z="1.2669747327983765">
<NAME>Anakinra + etanercept BW</NAME>
<DICH_DATA CI_END="1.2774908403384853" CI_START="0.3196978156006137" EFFECT_SIZE="0.6390704429920117" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="17" LOG_CI_END="0.10635779490873618" LOG_CI_START="-0.4952603311222461" LOG_EFFECT_SIZE="-0.19445126810675503" ORDER="16250" O_E="0.0" SE="0.3533934652883524" STUDY_ID="STD-Genovese-2004" TOTAL_1="81" TOTAL_2="80" VAR="0.12488694130850993" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.767962375335617" CI_START="1.130174052820506" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.962962962962963" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-002.19" LOG_CI_END="0.8903071133696063" LOG_CI_START="0.053145332296306094" LOG_EFFECT_SIZE="0.4717262228329563" METHOD="MH" NO="19" P_CHI2="1.0" P_Q="0.0" P_Z="0.02718773444224613" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="81" TOTAL_2="80" WEIGHT="100.0" Z="2.2088117929376834">
<NAME>Withdrawals (Genovese 2004)</NAME>
<GROUP_LABEL_1>Anakinra</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors Anakinra</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.767962375335617" CI_START="1.130174052820506" DF="0.0" EFFECT_SIZE="2.962962962962963" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" I2="0.0" ID="CMP-002.19.01" LOG_CI_END="0.8903071133696063" LOG_CI_START="0.053145332296306094" LOG_EFFECT_SIZE="0.4717262228329563" NO="1" P_CHI2="1.0" P_Z="0.02718773444224613" STUDIES="1" TAU2="0.0" TOTAL_1="81" TOTAL_2="80" WEIGHT="100.0" Z="2.2088117929376834">
<NAME>Anakinra + etanercept BW</NAME>
<DICH_DATA CI_END="7.767962375335617" CI_START="1.130174052820506" EFFECT_SIZE="2.962962962962963" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="5" LOG_CI_END="0.8903071133696063" LOG_CI_START="0.053145332296306094" LOG_EFFECT_SIZE="0.4717262228329563" ORDER="16251" O_E="0.0" SE="0.4917529742201068" STUDY_ID="STD-Genovese-2004" TOTAL_1="81" TOTAL_2="80" VAR="0.24182098765432097" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.6718984249738438" CI_START="0.8227488504639691" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1728395061728396" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-002.20" LOG_CI_END="0.22320988864523839" LOG_CI_START="-0.08473271582484224" LOG_EFFECT_SIZE="0.06923858641019806" METHOD="MH" NO="20" P_CHI2="1.0" P_Q="0.0" P_Z="0.37811953526529996" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="81" TOTAL_2="80" WEIGHT="100.0" Z="0.8813664217588806">
<NAME>Infections (Genovese 2004)</NAME>
<GROUP_LABEL_1>Anakinra</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors Anakinra</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.6718984249738438" CI_START="0.8227488504639691" DF="0.0" EFFECT_SIZE="1.1728395061728396" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="32" I2="0.0" ID="CMP-002.20.01" LOG_CI_END="0.22320988864523839" LOG_CI_START="-0.08473271582484224" LOG_EFFECT_SIZE="0.06923858641019806" NO="1" P_CHI2="1.0" P_Z="0.37811953526529996" STUDIES="1" TAU2="0.0" TOTAL_1="81" TOTAL_2="80" WEIGHT="100.0" Z="0.8813664217588806">
<NAME>Anakinra + etanercept BW</NAME>
<DICH_DATA CI_END="1.6718984249738438" CI_START="0.8227488504639691" EFFECT_SIZE="1.1728395061728396" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="32" LOG_CI_END="0.22320988864523839" LOG_CI_START="-0.08473271582484224" LOG_EFFECT_SIZE="0.06923858641019806" ORDER="16252" O_E="0.0" SE="0.18088701020620174" STUDY_ID="STD-Genovese-2004" TOTAL_1="81" TOTAL_2="80" VAR="0.032720110461338534" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="224.2330815018726" CI_START="0.7354096974670095" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="12.841463414634147" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.21" LOG_CI_END="2.3506996852164095" LOG_CI_START="-0.13347064761286934" LOG_EFFECT_SIZE="1.1086145188017698" METHOD="MH" NO="21" P_CHI2="1.0" P_Q="0.0" P_Z="0.0802301425416033" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="81" TOTAL_2="80" WEIGHT="100.0" Z="1.7493522894744253">
<NAME>Serious Infections (Genovese 2004)</NAME>
<GROUP_LABEL_1>Anakinra</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors Anakinra</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="224.2330815018726" CI_START="0.7354096974670095" DF="0.0" EFFECT_SIZE="12.841463414634147" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" ID="CMP-002.21.01" LOG_CI_END="2.3506996852164095" LOG_CI_START="-0.13347064761286934" LOG_EFFECT_SIZE="1.1086145188017698" NO="1" P_CHI2="1.0" P_Z="0.0802301425416033" STUDIES="1" TAU2="0.0" TOTAL_1="81" TOTAL_2="80" WEIGHT="100.0" Z="1.7493522894744253">
<NAME>Anakinra + etanercept BW</NAME>
<DICH_DATA CI_END="224.2330815018726" CI_START="0.7354096974670095" EFFECT_SIZE="12.841463414634147" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.3506996852164095" LOG_CI_START="-0.13347064761286934" LOG_EFFECT_SIZE="1.1086145188017698" ORDER="16253" O_E="0.0" SE="1.4592139503453867" STUDY_ID="STD-Genovese-2004" TOTAL_1="81" TOTAL_2="80" VAR="2.1293053528825885" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1429335389788546" CI_START="0.950935697440147" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0425240054869684" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="72" I2="0.0" I2_Q="0.0" ID="CMP-002.22" LOG_CI_END="0.058020977119750274" LOG_CI_START="-0.021848849194116816" LOG_EFFECT_SIZE="0.018086063962816725" METHOD="MH" NO="22" P_CHI2="1.0" P_Q="0.0" P_Z="0.3747316414488031" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="81" TOTAL_2="80" WEIGHT="100.0" Z="0.8876452003265226">
<NAME>Adverse Events (Genovese 2004)</NAME>
<GROUP_LABEL_1>Anakinra</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors Anakinra</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1429335389788546" CI_START="0.950935697440147" DF="0.0" EFFECT_SIZE="1.0425240054869684" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="72" I2="0.0" ID="CMP-002.22.01" LOG_CI_END="0.058020977119750274" LOG_CI_START="-0.021848849194116816" LOG_EFFECT_SIZE="0.018086063962816725" NO="1" P_CHI2="1.0" P_Z="0.3747316414488031" STUDIES="1" TAU2="0.0" TOTAL_1="81" TOTAL_2="80" WEIGHT="100.0" Z="0.8876452003265226">
<NAME>Anakinra + etanercept BW</NAME>
<DICH_DATA CI_END="1.1429335389788546" CI_START="0.950935697440147" EFFECT_SIZE="1.0425240054869684" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="72" LOG_CI_END="0.058020977119750274" LOG_CI_START="-0.021848849194116816" LOG_EFFECT_SIZE="0.018086063962816725" ORDER="16254" O_E="0.0" SE="0.04691593133878207" STUDY_ID="STD-Genovese-2004" TOTAL_1="81" TOTAL_2="80" VAR="0.0022011046133853136" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="25.637544342678048" CI_START="1.3697332946628393" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="5.925925925925926" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-002.23" LOG_CI_END="1.4088764245324923" LOG_CI_START="0.13663601246138257" LOG_EFFECT_SIZE="0.7727562184969374" METHOD="MH" NO="23" P_CHI2="1.0" P_Q="0.0" P_Z="0.0172677643443943" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="81" TOTAL_2="80" WEIGHT="100.0" Z="2.380956213484449">
<NAME>Serious Adverse Events (Genovese 2004)</NAME>
<GROUP_LABEL_1>Anakinra</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors Anakinra</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="25.637544342678048" CI_START="1.3697332946628393" DF="0.0" EFFECT_SIZE="5.925925925925926" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="2" I2="0.0" ID="CMP-002.23.01" LOG_CI_END="1.4088764245324923" LOG_CI_START="0.13663601246138257" LOG_EFFECT_SIZE="0.7727562184969374" NO="1" P_CHI2="1.0" P_Z="0.0172677643443943" STUDIES="1" TAU2="0.0" TOTAL_1="81" TOTAL_2="80" WEIGHT="100.0" Z="2.380956213484449">
<NAME>Anakinra + etanercept BW</NAME>
<DICH_DATA CI_END="25.637544342678048" CI_START="1.3697332946628393" EFFECT_SIZE="5.925925925925926" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="2" LOG_CI_END="1.4088764245324923" LOG_CI_START="0.13663601246138257" LOG_EFFECT_SIZE="0.7727562184969374" ORDER="16255" O_E="0.0" SE="0.7473203157421775" STUDY_ID="STD-Genovese-2004" TOTAL_1="81" TOTAL_2="80" VAR="0.5584876543209878" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.382621104442132" CI_START="1.2989867064969614" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7592592592592593" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-002.24" LOG_CI_END="0.3770549842964181" LOG_CI_START="0.11360470663534045" LOG_EFFECT_SIZE="0.24532984546587927" METHOD="MH" NO="24" P_CHI2="1.0" P_Q="0.0" P_Z="2.6192345824758127E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="81" TOTAL_2="80" WEIGHT="100.0" Z="3.65031053081285">
<NAME>Injection Site Reactions (Genovese 2004)</NAME>
<GROUP_LABEL_1>Anakinra</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors Anakinra</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.382621104442132" CI_START="1.2989867064969614" DF="0.0" EFFECT_SIZE="1.7592592592592593" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="32" I2="0.0" ID="CMP-002.24.01" LOG_CI_END="0.3770549842964181" LOG_CI_START="0.11360470663534045" LOG_EFFECT_SIZE="0.24532984546587927" NO="1" P_CHI2="1.0" P_Z="2.6192345824758127E-4" STUDIES="1" TAU2="0.0" TOTAL_1="81" TOTAL_2="80" WEIGHT="100.0" Z="3.65031053081285">
<NAME>Anakinra + etanercept BW</NAME>
<DICH_DATA CI_END="2.382621104442132" CI_START="1.2989867064969614" EFFECT_SIZE="1.7592592592592593" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="32" LOG_CI_END="0.3770549842964181" LOG_CI_START="0.11360470663534045" LOG_EFFECT_SIZE="0.24532984546587927" ORDER="16256" O_E="0.0" SE="0.15475199719802368" STUDY_ID="STD-Genovese-2004" TOTAL_1="81" TOTAL_2="80" VAR="0.023948180636777127" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.571925782449267" CI_END="1.982266479844409" CI_START="0.942106921189872" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3665675871701706" ESTIMABLE="YES" EVENTS_1="274" EVENTS_2="152" I2="80.7345601185614" I2_Q="0.0" ID="CMP-002.25" LOG_CI_END="0.29716203710519296" LOG_CI_START="-0.025899805649103744" LOG_EFFECT_SIZE="0.13563111572804465" METHOD="MH" NO="25" P_CHI2="0.0013877433971005715" P_Q="0.0" P_Z="0.09982469141002824" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.11123589082441156" TOTALS="YES" TOTAL_1="666" TOTAL_2="498" WEIGHT="100.0" Z="1.6457041149989906">
<NAME>ACR20 (including Genovese 2004)</NAME>
<GROUP_LABEL_1>Anakinra</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Anakinra</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Placebo</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.9963922324502603" CI_START="1.0140462584545975" DF="0.0" EFFECT_SIZE="1.4228260869565217" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="32" I2="0.0" ID="CMP-002.25.01" LOG_CI_END="0.3002458714472643" LOG_CI_START="0.006057766963136788" LOG_EFFECT_SIZE="0.15315181920520052" NO="1" P_CHI2="1.0" P_Z="0.04128253687232178" STUDIES="1" TAU2="0.0" TOTAL_1="230" TOTAL_2="119" WEIGHT="25.522583442060956" Z="2.0406810828422066">
<NAME>Anakinra</NAME>
<DICH_DATA CI_END="1.9963922324502603" CI_START="1.0140462584545975" EFFECT_SIZE="1.4228260869565217" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="32" LOG_CI_END="0.3002458714472643" LOG_CI_START="0.006057766963136788" LOG_EFFECT_SIZE="0.15315181920520052" ORDER="16257" O_E="0.0" SE="0.1728075488285799" STUDY_ID="STD-Bresnihan-1998" TOTAL_1="230" TOTAL_2="119" VAR="0.02986244893214203" WEIGHT="25.522583442060956"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0029436946822434954" CI_END="2.225666039968706" CI_START="1.3419239684096895" DF="1.0" EFFECT_SIZE="1.7281998161987764" ESTIMABLE="YES" EVENTS_1="136" EVENTS_2="66" I2="0.0" ID="CMP-002.25.02" LOG_CI_END="0.34745999922618903" LOG_CI_START="0.1277279099942687" LOG_EFFECT_SIZE="0.23759395461022886" NO="2" P_CHI2="0.956731368208571" P_Z="2.2494190671959313E-5" STUDIES="2" TAU2="0.0" TOTAL_1="355" TOTAL_2="299" WEIGHT="45.64681248053023" Z="4.23857612794085">
<NAME>Anakinra + Methotrexate</NAME>
<DICH_DATA CI_END="3.016646838927435" CI_START="0.9624135962513176" EFFECT_SIZE="1.7038961038961038" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="11" LOG_CI_END="0.47952446997525255" LOG_CI_START="-0.01663825024093351" LOG_EFFECT_SIZE="0.23144310986715955" ORDER="16258" O_E="0.0" SE="0.29144843790006336" STUDY_ID="STD-Cohen-2002" TOTAL_1="105" TOTAL_2="48" VAR="0.08494219195438708" WEIGHT="18.356760851993062"/>
<DICH_DATA CI_END="2.299494560509435" CI_START="1.3078467895336676" EFFECT_SIZE="1.7341818181818183" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="55" LOG_CI_END="0.361632386580841" LOG_CI_START="0.11655687062636787" LOG_EFFECT_SIZE="0.23909462860360445" ORDER="16259" O_E="0.0" SE="0.1439585712150268" STUDY_ID="STD-Cohen-2004" TOTAL_1="250" TOTAL_2="251" VAR="0.020724070226271943" WEIGHT="27.290051628537164"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.140950461862271E-30" CI_END="1.1500401170632721" CI_START="0.7271925736387723" DF="0.0" EFFECT_SIZE="0.9144947416552355" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="54" I2="100.0" ID="CMP-002.25.03" LOG_CI_END="0.06071299019302689" LOG_CI_START="-0.13835056494033862" LOG_EFFECT_SIZE="-0.03881878737365587" NO="3" P_CHI2="0.0" P_Z="0.4446209281216218" STUDIES="1" TAU2="0.0" TOTAL_1="81" TOTAL_2="80" WEIGHT="28.83060407740882" Z="0.7644134068128192">
<NAME>Anakinra + Etanercept BW</NAME>
<DICH_DATA CI_END="1.1500401170632721" CI_START="0.7271925736387723" EFFECT_SIZE="0.9144947416552355" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="54" LOG_CI_END="0.06071299019302689" LOG_CI_START="-0.13835056494033862" LOG_EFFECT_SIZE="-0.03881878737365587" ORDER="16260" O_E="0.0" SE="0.11693091766582883" STUDY_ID="STD-Genovese-2004" TOTAL_1="81" TOTAL_2="80" VAR="0.013672839506172842" WEIGHT="28.83060407740882"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.113480400974664" CI_END="2.2063061886715833" CI_START="1.2978661420234259" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.6921850079744818" ESTIMABLE="YES" EVENTS_1="143" EVENTS_2="51" I2="52.68468070303209" I2_Q="0.0" ID="CMP-002.26" LOG_CI_END="0.3436657831825627" LOG_CI_START="0.11322990295868578" LOG_EFFECT_SIZE="0.22844784307062424" METHOD="MH" MODIFIED="2008-10-21 22:25:39 -0400" MODIFIED_BY="[Empty name]" NO="26" P_CHI2="0.1460069752152049" P_Q="0.0" P_Z="1.0186352553231237E-4" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="333" TOTAL_2="195" WEIGHT="100.0" Z="3.886109613913221">
<NAME>Injection site reactions</NAME>
<GROUP_LABEL_1>Anakinra</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors Anakinra</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.9085272366444745" CI_START="1.4218823853937699" DF="0.0" EFFECT_SIZE="2.033613445378151" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="30" I2="0.0" ID="CMP-002.26.01" LOG_CI_END="0.46367313506545627" LOG_CI_START="0.15286367411034477" LOG_EFFECT_SIZE="0.3082684045879005" MODIFIED="2008-10-21 22:25:39 -0400" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="1.0112352396447597E-4" STUDIES="1" TAU2="0.0" TOTAL_1="119" TOTAL_2="121" WEIGHT="48.803827751196174" Z="3.8878801739639934">
<NAME>Anakinra</NAME>
<DICH_DATA CI_END="2.9085272366444745" CI_START="1.4218823853937699" EFFECT_SIZE="2.033613445378151" ESTIMABLE="YES" EVENTS_1="60" EVENTS_2="30" LOG_CI_END="0.46367313506545627" LOG_CI_START="0.15286367411034477" LOG_EFFECT_SIZE="0.3082684045879005" ORDER="62" O_E="0.0" SE="0.1825710158966774" STUDY_ID="STD-Bresnihan-1998" TOTAL_1="119" TOTAL_2="121" VAR="0.033332175845544834" WEIGHT="48.803827751196174"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.037227953156164" CI_START="0.9168828753491123" DF="0.0" EFFECT_SIZE="1.3667111704494883" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="21" I2="0.0" ID="CMP-002.26.02" LOG_CI_END="0.3090396265745247" LOG_CI_START="-0.037686138526644666" LOG_EFFECT_SIZE="0.13567674402394" MODIFIED="2008-10-21 22:25:39 -0400" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.1250539632295473" STUDIES="1" TAU2="0.0" TOTAL_1="214" TOTAL_2="74" WEIGHT="51.196172248803826" Z="1.533901189887002">
<NAME>Anakinra + Methotrexate</NAME>
<DICH_DATA CI_END="2.037227953156164" CI_START="0.9168828753491123" EFFECT_SIZE="1.3667111704494883" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="21" LOG_CI_END="0.3090396265745247" LOG_CI_START="-0.037686138526644666" LOG_EFFECT_SIZE="0.13567674402394" ORDER="63" O_E="0.0" SE="0.2036684307406446" STUDY_ID="STD-Cohen-2002" TOTAL_1="214" TOTAL_2="74" VAR="0.041480829680356754" WEIGHT="51.196172248803826"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2008-10-29 05:56:06 -0400" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Anakinra Cochrane Review Screening Process.jpg" FILE_TYPE="JPG" ID="FIG-01" MODIFIED="2008-10-29 05:56:06 -0400" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Article Screening Process for the Anakinra Cochrane Review</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-11-09 20:52:33 -0500" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2008-11-09 20:52:33 -0500" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-11-09 20:52:33 -0500" MODIFIED_BY="[Empty name]">Search Strategy<I> The Cochrane Library </I>
</TITLE>
<APPENDIX_BODY MODIFIED="2008-10-29 11:23:49 -0400" MODIFIED_BY="[Empty name]">
<TABLE COLS="1" ROWS="2">
<TR>
<TH>
<P/>
</TH>
</TR>
<TR>
<TD>
<P>
<I>The Cochrane Library </I>2008, Issue 1<BR/>
<BR/>CENTRAL (39 trials); HTA (6 trials); NHS EED (1 trial)<BR/>
<BR/>#1 MeSH descriptor Arthritis, Rheumatoid explode all trees in MeSH products<BR/>#2 felty near/2 syndrome in All Fields in all products<BR/>#3 caplan near/2 syndrome in All Fields in all products<BR/>#4 rheumatoid nodule in All Fields in all products<BR/>#5 sjogren* near/2 syndrome in All Fields in all products<BR/>#6 sicca near/2 syndrome in All Fields in all products<BR/>#7 still* next disease in All Fields in all products<BR/>#8 bechterew* next disease in All Fields in all products<BR/>#9 arthritis near/2 rheumat* in All Fields in all products<BR/>#10 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9)<BR/>#11 MeSH descriptor Interleukin 1 Receptor Antagonist Protein, this term only<BR/>#12 anakinra:ti,ab<BR/>#13 kineret:ti,ab<BR/>#14 interleukin-1:ti,ab<BR/>#15 IL-1ra:ti,ab<BR/>#16 Il-a:ti,ab<BR/>#17 (#11 OR #12 OR #13 OR #14 OR #15 OR #16)<BR/>#18 (#10 AND #17)<BR/>
</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2008-11-09 20:33:47 -0500" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2008-11-09 20:33:47 -0500" MODIFIED_BY="[Empty name]">Search strategy: Ovid MEDLINE(R)</TITLE>
<APPENDIX_BODY MODIFIED="2008-10-28 19:01:43 -0400" MODIFIED_BY="[Empty name]">
<TABLE COLS="1" ROWS="2">
<TR>
<TH>
<P/>
</TH>
</TR>
<TR>
<TD>
<P>Ovid MEDLINE(R) 1950 to January Week 4 2008<BR/>&amp; Ovid MEDLINE(R) In-Process &amp; Other Non-Indexed Citations February 05, 2008 (416 trials)<BR/>
<BR/>1 exp arthritis, rheumatoid/<BR/>2 (felty$ adj2 syndrome).tw.<BR/>3 (caplan$ adj2 syndrome).tw.<BR/>4 rheumatoid nodule.tw.<BR/>5 (sjogren$ adj2 syndrome).tw.<BR/>6 (sicca adj2 syndrome).tw.<BR/>7 still$ disease.tw.<BR/>8 bechterew$ disease.tw.<BR/>9 (arthritis adj2 rheumat$).tw.<BR/>10 or/1-9<BR/>11 Interleukin 1 Receptor Antagonist Protein/<BR/>12 anakinra.tw.<BR/>13 kineret.tw.<BR/>14 interleukin-1.tw.<BR/>15 IL-1ra.tw.<BR/>16 Il-a.tw.<BR/>17 or/11-16<BR/>18 10 and 17<BR/>19 clinical trial.pt.<BR/>20 randomized.ab.<BR/>21 placebo.ab.<BR/>22 dt.fs.<BR/>23 clinical trial/<BR/>24 randomly.ab.<BR/>25 trial.ti.<BR/>26 groups.ab.<BR/>27 or/19-26<BR/>28 animals/<BR/>29 humans/<BR/>30 28 and 29<BR/>31 28 not 30<BR/>32 27 not 31<BR/>33 18 and 32<BR/>
</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2008-11-09 20:33:39 -0500" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2008-11-09 20:33:39 -0500" MODIFIED_BY="[Empty name]">Search strategy: EMBASE</TITLE>
<APPENDIX_BODY MODIFIED="2008-07-31 10:34:26 -0400" MODIFIED_BY="[Empty name]">
<TABLE COLS="1" ROWS="2">
<TR>
<TH>
<P/>
</TH>
</TR>
<TR>
<TD>
<P>EMBASE 1980 to 2008 Week 05 (186 trials)<BR/>
<BR/>1 exp arthritis, rheumatoid/<BR/>2 (felty$ adj2 syndrome).tw.<BR/>3 (caplan$ adj2 syndrome).tw.<BR/>4 rheumatoid nodule.tw.<BR/>5 (sjogren$ adj2 syndrome).tw.<BR/>6 (sicca adj2 syndrome).tw.<BR/>7 still$ disease.tw.<BR/>8 bechterew$ disease.tw.<BR/>9 (arthritis adj2 rheumat$).tw.<BR/>10 or/1-9<BR/>11 Recombinant Interleukin 1 Receptor Blocking Agent/<BR/>12 anakinra.tw.<BR/>13 kineret.tw.<BR/>14 interleukin-1.tw.<BR/>15 IL-1ra.tw.<BR/>16 Il-a.tw.<BR/>17 or/11-16<BR/>18 10 and 17<BR/>19 random$.ti,ab.<BR/>20 factorial$.ti,ab.<BR/>21 (crossover$ or cross over$ or cross-over$).ti,ab.<BR/>22 placebo$.ti,ab.<BR/>23 (doubl$ adj blind$).ti,ab.<BR/>24 (singl$ adj blind$).ti,ab.<BR/>25 assign$.ti,ab.<BR/>26 allocat$.ti,ab.<BR/>27 volunteer$.ti,ab.<BR/>28 crossover procedure.sh.<BR/>29 double blind procedure.sh.<BR/>30 randomized controlled trial.sh.<BR/>31 single blind procedure.sh.<BR/>32 or/19-31<BR/>33 exp animal/ or nonhuman/ or exp animal experiment/<BR/>34 exp human/<BR/>35 33 and 34<BR/>36 33 not 35<BR/>37 32 not 36<BR/>38 18 and 37<BR/>
</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2008-11-09 20:33:22 -0500" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2008-11-09 20:33:22 -0500" MODIFIED_BY="[Empty name]">Search Strategy CINAHL</TITLE>
<APPENDIX_BODY MODIFIED="2008-07-31 10:35:17 -0400" MODIFIED_BY="[Empty name]">
<TABLE COLS="1" ROWS="2">
<TR>
<TH>
<P/>
</TH>
</TR>
<TR>
<TD>
<P>CINAHL 1982 to 11/2007 (70 trials)<BR/>
<BR/>#18 ((sjogren* near2 (syndrome in ti,ab)) or (rheumatoid nodule in ti,ab) or (caplan* near2 (syndrome in ti,ab)) or (felty* near2 (syndrome in ti,ab)) or (explode "Arthritis-Rheumatoid" / all TOPICAL SUBHEADINGS / all AGE SUBHEADINGS in DE) or (arthritis near2 (rheumat* in ti,ab)) or (bechterew* disease in ti,ab) or (still* disease in ti,ab) or (sicca near2 (syndrome in ti,ab))) and ((kineret in ti,ab) or (anakinra in ti,ab) or ("Interleukin-1" / all TOPICAL SUBHEADINGS / all AGE SUBHEADINGS in DE) or (Il-a in ti,ab) or (IL-1ra in ti,ab) or (interleukin-1 in ti,ab))<BR/>#17 (kineret in ti,ab) or (anakinra in ti,ab) or ("Interleukin-1" / all TOPICAL SUBHEADINGS / all AGE SUBHEADINGS in DE) or (Il-a in ti,ab) or (IL-1ra in ti,ab) or (interleukin-1 in ti,ab)<BR/>#16 Il-a in ti,ab<BR/>#15 IL-1ra in ti,ab<BR/>#14 interleukin-1 in ti,ab<BR/>#13 kineret in ti,ab<BR/>#12 anakinra in ti,ab<BR/>#11 "Interleukin-1" / all TOPICAL SUBHEADINGS / all AGE SUBHEADINGS in DE<BR/>#10 (sjogren* near2 (syndrome in ti,ab)) or (rheumatoid nodule in ti,ab) or (caplan* near2 (syndrome in ti,ab)) or (felty* near2 (syndrome in ti,ab)) or (explode "Arthritis-Rheumatoid" / all TOPICAL SUBHEADINGS / all AGE SUBHEADINGS in DE) or (arthritis near2 (rheumat* in ti,ab)) or (bechterew* disease in ti,ab) or (still* disease in ti,ab) or (sicca near2 (syndrome in ti,ab))<BR/>#9 arthritis near2 (rheumat* in ti,ab)<BR/>#8 bechterew* disease in ti,ab<BR/>#7 still* disease in ti,ab<BR/>#6 sicca near2 (syndrome in ti,ab)<BR/>#5 sjogren* near2 (syndrome in ti,ab)<BR/>#4 rheumatoid nodule in ti,ab<BR/>#3 caplan* near2 (syndrome in ti,ab)<BR/>#2 felty* near2 (syndrome in ti,ab)<BR/>#1 explode "Arthritis-Rheumatoid" / all TOPICAL SUBHEADINGS / all AGE SUBHEADINGS in DE<BR/>
</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2008-10-28 19:07:01 -0400" MODIFIED_BY="[Empty name]"/>
</COCHRANE_REVIEW>